ACCESS DB # 195658

FOR OFFICIAL USE ONLY *PLEASE PRINT CLEARLY*

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: SABIHA QAZI Examiner #: 74141 Date: 7/14/06
Art Unit: 1616 Phone Number: 2-0622 Serial Number: 10/692,563
Location (Bldg/Room#): 4A45 (Mailbox #): 20622 Results Format Preferred (circle): ~~PAPER~~ DISK
****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Substituted Tetracycline Compounds.

Inventors (please provide full names): DRAPER, MICHAEL et al.

Earliest Priority Date: CIP of 10/128990 4/24/01.

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.* cls. 1-85 87

Please search for the tetracycline compds of cl 1, 67 - 69, formula (1) and their use for treating or preventing malaria

Copy of cls enclosed.

Thanks

****

STAFF USE ONLY

Searcher: Sabiha Qazi
Searcher Phone #:
Searcher Location:
Date Searcher Picked Up: 7/20/06
Date Completed: 8/1/06
Searcher Prep & Review Time: 120
Online Time: 50

Type of Search

___ NA Sequence (#)
___ AA Sequence (#)
___ Structure (#)
___ Bibliographic
___ Litigation
___ Fulltext
___ Other

Vendors and cost where applicable

✓ STN ___ Dialog
___ Questel/Orbit ___ Lexis/Nexis
___ Westlaw ___ WWW/Internet
___ In-house sequence systems
___ Commercial ___ Oligomer ___ Score/Length
___ Interference ___ SPDI ___ Encode/Transl
___ Other (specify)

THIS PAGE LEFT BLANK

```
=> d his nofile

     (FILE 'HOME' ENTERED AT 09:23:05 ON 01 AUG 2006)

     FILE 'REGISTRY' ENTERED AT 09:23:25 ON 01 AUG 2006
               ACTIVATE QAZI563/A
              ---------
L1             STR
L2          8027 SEA SSS FUL L1
              ---------

     FILE 'CAPLUS' ENTERED AT 09:23:57 ON 01 AUG 2006
               ACTIVATE QAZI563RL/A
              ---------
L3             STR
L4   (       8027)SEA SSS FUL L3
L5          8858 SEA ABB=ON  PLU=ON  L4 (L) (BAC OR DMA OR PAC OR PKT OR
               THU)/RL
              ---------

     FILE 'REGISTRY' ENTERED AT 09:24:08 ON 01 AUG 2006
L6             1 SEA ABB=ON  PLU=ON  OXYTETRACYCLINE/CN
               D RN
L7             1 SEA ABB=ON  PLU=ON  DEMECLOCYCLINE/CN
               D RN
L8             1 SEA ABB=ON  PLU=ON  DOXYCYCLINE/CN
               D RN
L9             0 SEA ABB=ON  PLU=ON  CHLOROTETRACYCLINE/CN
L10            0 SEA ABB=ON  PLU=ON  CHLOROTETRACYCLINE/CN
               E CCHLOROTETRACYCLINE/CN
               E CHLOROTETRACYCLINE/CN
L11            1 SEA ABB=ON  PLU=ON  MINOCYCLINE/CN
               D RN
L12            1 SEA ABB=ON  PLU=ON  TETRACYCLINE/CN
               D RN
L13          236 SEA ABB=ON  PLU=ON  79-57-2/CRN
L14          237 SEA ABB=ON  PLU=ON  (L13 OR L6)
L15           31 SEA ABB=ON  PLU=ON  127-33-3/CRN
L16           32 SEA ABB=ON  PLU=ON  (L15 OR L7)
L17          108 SEA ABB=ON  PLU=ON  564-25-0/CRN
L18          109 SEA ABB=ON  PLU=ON  (L17 OR L8)
L19           34 SEA ABB=ON  PLU=ON  10118-90-8/CRN
L20           35 SEA ABB=ON  PLU=ON  (L19 OR L11)
L21          441 SEA ABB=ON  PLU=ON  60-54-8/CRN
L22          442 SEA ABB=ON  PLU=ON  (L21 OR L12)
               E CHLOROTETRACYCLINE/CN
L23            1 SEA ABB=ON  PLU=ON  "CHLOROTETRACYCLINE BISULFATE"/CN
               D RN
               D SCAN
               E CHLOROTETRACYCLINE/CN
L24            1 SEA ABB=ON  PLU=ON  "CHLOROTETRACYCLINE CALCIUM SALT"/CN
               D SCAN
               D RN
               E CHLOROTETRACYCLINE/CN
L25            1 SEA ABB=ON  PLU=ON  "CHLOROTETRACYCLINE SULFADIMETHOXIMEPROPANE
               SULFONATE"/CN
               D SCAN
               D RN
```

```
     FILE 'STNGUIDE' ENTERED AT 09:34:41 ON 01 AUG 2006

     FILE 'REGISTRY' ENTERED AT 09:35:20 ON 01 AUG 2006
L26         7175 SEA ABB=ON  PLU=ON  L2 NOT (L14 OR L16 OR L18 OR L20 OR L22)
L27            1 SEA ABB=ON  PLU=ON  27823-62-7/CRN
L28            2 SEA ABB=ON  PLU=ON  (L27 OR L23)
L29            1 SEA ABB=ON  PLU=ON  5892-31-9/CRN
L30            2 SEA ABB=ON  PLU=ON  (L29 OR L24)
L31            0 SEA ABB=ON  PLU=ON  34514-33-5/CRN
L32         7170 SEA ABB=ON  PLU=ON  L26 NOT (L28 OR L30 OR L25)
                 SAVE L32 QAZI563PRO/A TEMP

     FILE 'CAPLUS' ENTERED AT 09:38:32 ON 01 AUG 2006
L33         1313 SEA ABB=ON  PLU=ON  L32 (L) (BAC OR DMA OR PAC OR PKT OR
                 THU)/RL

     FILE 'HCAPLUS' ENTERED AT 09:39:13 ON 01 AUG 2006
                 E MALARIA/CT
                 E E3+ALL
L34         9105 SEA ABB=ON  PLU=ON  MALARIA+PFT/CT
                 E MALARIA/CT
                 E E4+ALL
L35         7394 SEA ABB=ON  PLU=ON  ("MALARIA (L) ANTIMALARIALS"/CT OR
                 ANTIMALARIALS+PFT/CT)
                 E ANTIMALARIA/CT
                 E E7+ALL
L36         7394 SEA ABB=ON  PLU=ON  ANTIMALARIALS+PFT/CT
                 E ARGUE/CT
                 E MARSH FEVER/CT
L37        56457 SEA ABB=ON  PLU=ON  (?MALARIA? OR ARGUE? OR MARSH FEVER?)/OBI,B
                 I
L38           23 SEA ABB=ON  PLU=ON  L33 AND (L34 OR L35 OR L36)
L39           25 SEA ABB=ON  PLU=ON  L33 AND L37
L40           25 SEA ABB=ON  PLU=ON  (L38 OR L39)

     FILE 'STNGUIDE' ENTERED AT 09:42:49 ON 01 AUG 2006

     FILE 'HCAPLUS' ENTERED AT 09:44:22 ON 01 AUG 2006
L41            5 SEA ABB=ON  PLU=ON  L40 NOT (PY>2001 OR AY>2001 OR PRY>2001)
                 E US2003-692563/APPS
L42            1 SEA ABB=ON  PLU=ON  US2003-692563/AP
L43           25 SEA ABB=ON  PLU=ON  (L40 OR L42)
                 E DRAPER M/AU
                 E DRAPER M?/AU
                 E DRAPER M/AU
                 E DRAPER M?/AU
L44          132 SEA ABB=ON  PLU=ON  DRAPER M?/AU
                 E NELSON M/AU
L45         1631 SEA ABB=ON  PLU=ON  NELSON M?/AU
L46            8 SEA ABB=ON  PLU=ON  L44 AND L45
L47           25 SEA ABB=ON  PLU=ON  (L43 OR L41 OR L42 OR L40 OR L38 OR L39)

     FILE 'STNGUIDE' ENTERED AT 09:46:50 ON 01 AUG 2006

     FILE 'REGISTRY' ENTERED AT 09:48:39 ON 01 AUG 2006

     FILE 'HCAPLUS' ENTERED AT 09:54:20 ON 01 AUG 2006

     FILE 'REGISTRY' ENTERED AT 09:56:19 ON 01 AUG 2006
```

```
L48             1 SEA ABB=ON  PLU=ON  57-62-5
                  D SCAN
L49           143 SEA ABB=ON  PLU=ON  57-62-5/CRN
L50           144 SEA ABB=ON  PLU=ON  (L49 OR L48)
L51          7033 SEA ABB=ON  PLU=ON  L32 NOT L50

     FILE 'HCAPLUS' ENTERED AT 09:57:10 ON 01 AUG 2006
L52           782 SEA ABB=ON  PLU=ON  L51 (L) (BAC OR DMA OR PAC OR PKT OR
                  THU)/RL
L53            20 SEA ABB=ON  PLU=ON  L52 AND (L34 OR L35 OR L36 OR L37)
L54             3 SEA ABB=ON  PLU=ON  L53 NOT (PY>2001 OR AY>2001 OR PRY>2001)
                  D SCAN
L55             5 SEA ABB=ON  PLU=ON  L47 NOT L53
                  D SCAN
L56             2 SEA ABB=ON  PLU=ON  L55 NOT (PY>2001 OR AY>2001 OR PRY>2001)
                  D KWIC
                  D KWIC 2

     FILE 'REGISTRY' ENTERED AT 10:02:02 ON 01 AUG 2006
L57             1 SEA ABB=ON  PLU=ON  64-72-2
                  D SCAN
L58            18 SEA ABB=ON  PLU=ON  64-72-2/CRN
L59            19 SEA ABB=ON  PLU=ON  (L57 OR L58)
L60          7033 SEA ABB=ON  PLU=ON  L51 NOT L59

     FILE 'STNGUIDE' ENTERED AT 10:03:34 ON 01 AUG 2006

=> file hcaplus
FILE 'HCAPLUS' ENTERED AT 10:04:03 ON 01 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 1 Aug 2006  VOL 145 ISS 6
FILE LAST UPDATED: 31 Jul 2006  (20060731/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d que l46
L44           132 SEA FILE=HCAPLUS ABB=ON  PLU=ON  DRAPER M?/AU
L45          1631 SEA FILE=HCAPLUS ABB=ON  PLU=ON  NELSON M?/AU
L46             8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L44 AND L45

=> d ibib abs l46 tot
```

L46 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1036703 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 141:420412
TITLE: Substituted tetracycline compounds for the treatment of malaria
INVENTOR(S): ***Draper, Michael; Nelson, Mark L.***
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 590 pp., Cont.-in-part of U.S. Ser. No. 128,990, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004242548	A1	20041202	US 2003-692563		20031024
US 2004092490	A1	20040513	US 2002-128990		20020424
PRIORITY APPLN. INFO.:			US 2001-286193P	P	20010424
			US 2002-128990	B2	20020424
			US 2002-421259P	P	20021024

OTHER SOURCE(S): MARPAT 141:420412
AB The invention provides a method for treating or preventing malaria in a subject. The method includes administering an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented. In one aspect, the invention relates to pharmaceutical compns. which include an effective amount of a tetracycline compound to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used to in combination with one or more antimalarial compds. or can be used to treat or prevent malaria which is resistant to one or more other antimalarial compds. Preparation of e.g. sancycline derivs. is described.

L46 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:633439 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 141:167771
TITLE: Tetracycline compounds having target therapeutic activities
INVENTOR(S): Levy, Stuart B.; ***Draper, Michael***; ***Nelson, Mark L.***; Jones, Graham
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 277 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064728	A2	20040805	WO 2004-US1036	20040116
WO 2004064728	A3	20041216		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC,

LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

PRIORITY APPLN. INFO.: US 2003-441141P P 20030116

OTHER SOURCE(S): MARPAT 141:167771

AB Methods and compds. for treating diseases, e.g. inflammation process-associated states, with tetracycline compds. having a target therapeutic activity are described. Preparation of selected tetracycline compds. is described.

L46 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:371069 HCAPLUS <<LOGINID::20060801>>

DOCUMENT NUMBER: 140:386006

TITLE: Substituted tetracycline compounds for the treatment of malaria

INVENTOR(S): ***Draper, Michael; Nelson, Mark L.***

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038001	A2	20040506	WO 2003-US33927	20031024
WO 2004038001	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502464	AA	20040506	CA 2003-2502464	20031024
AU 2003287218	A1	20040513	AU 2003-287218	20031024
EP 1556007	A2	20050727	EP 2003-781398	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503898	T2	20060202	JP 2004-547165	20031024

PRIORITY APPLN. INFO.: US 2002-421259P P 20021024
WO 2003-US33927 W 20031024

OTHER SOURCE(S): MARPAT 140:386006

AB The invention provides a method for treating or preventing malaria in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented. In one aspect, the invention relates to pharmaceutical compns. which include an effective amount of a tetracycline compound to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used to in combination with one or more antimalarial compds. or can be used to treat or prevent malaria which is resistant to one or more other antimalarial compds. Compound preparation is described.

L46 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:371068 HCAPLUS <<LOGINID::20060801>>

DOCUMENT NUMBER: 140:386057
TITLE: Methods of using substituted tetracycline compounds to modulate RNA, and therapeutic use
INVENTOR(S): Levy, Stuart B.; ***Draper, Michael***; Jones, Graham; ***Nelson, Mark L.***
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038000	A2	20040506	WO 2003-US33926	20031024
WO 2004038000	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2503446	AA	20040506	CA 2003-2503446	20031024
AU 2003287217	A1	20040513	AU 2003-287217	20031024
US 2004214800	A1	20041028	US 2003-692764	20031024
EP 1562608	A2	20050817	EP 2003-781397	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503897	T2	20060202	JP 2004-547164	20031024
PRIORITY APPLN. INFO.:			US 2002-421248P P	20021024
			WO 2003-US33926 W	20031024

OTHER SOURCE(S): MARPAT 140:386057
AB A method for modulating RNA with tetracycline compds. is described. The invention also discloses a method for treating a subject for a disorder treatable by modulation of RNA or by modulation of RNA in combination with a second agent. Compound preparation is also described.

L46 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:57866 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 138:117673
TITLE: Tetracycline compounds having target therapeutic activities
INVENTOR(S): Levy, Stuart B.; ***Draper, Michael***; ***Nelson, Mark L.***; Jones, Graham
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003005971	A2	20030123	WO 2002-US22451		20020715
WO 2003005971	A3	20031127			
WO 2003005971	C1	20040506			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002318238	A1	20030129	AU 2002-318238		20020715
US 2004063674	A1	20040401	US 2002-196010		20020715
EP 1408987	A2	20040421	EP 2002-748169		20020715

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

JP 2004537544	T2	20041216	JP 2003-511780		20020715
PRIORITY APPLN. INFO.:			US 2001-305546P	P	20010713
			US 2002-395741P	P	20020712
			WO 2002-US22451	W	20020715

OTHER SOURCE(S): MARPAT 138:117673

AB Methods and compds. for treating a variety of diseases with tetracycline compds. having a target therapeutic activity are described, as is compound preparation

L46 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:832571 HCAPLUS <<LOGINID::20060801>>

DOCUMENT NUMBER: 137:333118

TITLE: Substituted tetracycline compounds for the treatment of malaria

INVENTOR(S): ***Draper, Michael; Nelson, Mark L.***; Frechette, Roger

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085303	A2	20021031	WO 2002-US12935	20020424
WO 2002085303	A3	20030515		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2444899	AA	20021031	CA 2002-2444899	20020424
EP 1399414	A2	20040324	EP 2002-723955	20020424

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004529927 T2 20040930 JP 2002-582879 20020424
PRIORITY APPLN. INFO.: US 2001-286193P P 20010424
WO 2002-US12935 W 20020424
OTHER SOURCE(S): MARPAT 137:333118
AB The invention provides a method for treating or preventing malaria in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented. In one aspect, the invention provides pharmaceutical compns. which include an effective amount of a tetracycline compound to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used in combination with one or more antimalarial compds. or can be used to treat or prevent malaria which is resistant to one or more other antimalarial compds. Compound preparation is described.

L46 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:716035 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 137:244598
TITLE: Substituted tetracycline compounds as synergistic antifungal agents
INVENTOR(S): ***Draper, Michael; Nelson, Mark L.***
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072031	A2	20020919	WO 2002-US7829	20020314
WO 2002072031	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440757	AA	20020919	CA 2002-2440757	20020314
US 2003166585	A1	20030904	US 2002-97634	20020314
US 7045507	B2	20060516		
EP 1381372	A2	20040121	EP 2002-750617	20020314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005504722	T2	20050217	JP 2002-570991	20020314
US 2005070510	A1	20050331	US 2004-943571	20040916

PRIORITY APPLN. INFO.: US 2001-275899P P 20010314
US 2002-97634 A1 20020314
WO 2002-US7829 W 20020314
OTHER SOURCE(S): MARPAT 137:244598
AB Methods and compns. for treating for the synergistic treatment of fungal associated disorders are discussed. The method includes administering the antifungal agent with an effective amount of a substituted tetracycline compound, such that the antifungal activity of the antifungal agent is

increased. Examples of antifungal agents include polyenes such as amphotericin B.

L46 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:716027 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 137:244597
TITLE: Substituted tetracycline compounds as antifungal agents
INVENTOR(S): ***Draper, Michael; Nelson, Mark L.***
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072022	A2	20020919	WO 2002-US7502	20020314
WO 2002072022	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457234	AA	20020919	CA 2002-2457234	20020314
US 2003100017	A1	20030529	US 2002-97457	20020314
US 6841546	B2	20050111		
EP 1379255	A2	20040114	EP 2002-721365	20020314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004530661	T2	20041007	JP 2002-570982	20020314
US 2005020545	A1	20050127	US 2004-921580	20040818
PRIORITY APPLN. INFO.:			US 2001-275948P	P 20010314
			US 2002-97457	A3 20020314
			WO 2002-US7502	W 20020314

OTHER SOURCE(S): MARPAT 137:244597
AB Methods and compns. for treating fungal associated disorders in subjects are discussed. The method includes contacting the fungus with an effective amount of a substituted tetracycline compound, such that the growth of said fungus is inhibited.

=> d que l61
L1 STR



G1

G2 H,O,S,N,X,Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

L2	8027	SEA FILE=REGISTRY SSS FUL L1	
L6	1	SEA FILE=REGISTRY ABB=ON PLU=ON	OXYTETRACYCLINE/CN
L7	1	SEA FILE=REGISTRY ABB=ON PLU=ON	DEMECLOCYCLINE/CN
L8	1	SEA FILE=REGISTRY ABB=ON PLU=ON	DOXYCYCLINE/CN
L11	1	SEA FILE=REGISTRY ABB=ON PLU=ON	MINOCYCLINE/CN
L12	1	SEA FILE=REGISTRY ABB=ON PLU=ON	TETRACYCLINE/CN
L13	236	SEA FILE=REGISTRY ABB=ON PLU=ON	79-57-2/CRN
L14	237	SEA FILE=REGISTRY ABB=ON PLU=ON	(L13 OR L6)
L15	31	SEA FILE=REGISTRY ABB=ON PLU=ON	127-33-3/CRN
L16	32	SEA FILE=REGISTRY ABB=ON PLU=ON	(L15 OR L7)
L17	108	SEA FILE=REGISTRY ABB=ON PLU=ON	564-25-0/CRN
L18	109	SEA FILE=REGISTRY ABB=ON PLU=ON	(L17 OR L8)
L19	34	SEA FILE=REGISTRY ABB=ON PLU=ON	10118-90-8/CRN
L20	35	SEA FILE=REGISTRY ABB=ON PLU=ON	(L19 OR L11)
L21	441	SEA FILE=REGISTRY ABB=ON PLU=ON	60-54-8/CRN
L22	442	SEA FILE=REGISTRY ABB=ON PLU=ON	(L21 OR L12)
L23	1	SEA FILE=REGISTRY ABB=ON PLU=ON	"CHLOROTETRACYCLINE BISULFATE "/CN
L24	1	SEA FILE=REGISTRY ABB=ON PLU=ON	"CHLOROTETRACYCLINE CALCIUM SALT"/CN
L25	1	SEA FILE=REGISTRY ABB=ON PLU=ON	"CHLOROTETRACYCLINE SULFADIMETHOXIMEPROPANESULFONATE"/CN
L26	7175	SEA FILE=REGISTRY ABB=ON PLU=ON	L2 NOT (L14 OR L16 OR L18 OR L20 OR L22)
L27	1	SEA FILE=REGISTRY ABB=ON PLU=ON	27823-62-7/CRN
L28	2	SEA FILE=REGISTRY ABB=ON PLU=ON	(L27 OR L23)
L29	1	SEA FILE=REGISTRY ABB=ON PLU=ON	5892-31-9/CRN
L30	2	SEA FILE=REGISTRY ABB=ON PLU=ON	(L29 OR L24)
L32	7170	SEA FILE=REGISTRY ABB=ON PLU=ON	L26 NOT (L28 OR L30 OR L25)
L34	9105	SEA FILE=HCAPLUS ABB=ON PLU=ON	MALARIA+PFT/CT
L35	7394	SEA FILE=HCAPLUS ABB=ON PLU=ON	("MALARIA (L) ANTIMALARIALS"/CT OR ANTIMALARIALS+PFT/CT)
L36	7394	SEA FILE=HCAPLUS ABB=ON PLU=ON	ANTIMALARIALS+PFT/CT
L37	56457	SEA FILE=HCAPLUS ABB=ON PLU=ON	(?MALARIA? OR ARGUE? OR MARSH FEVER?)/OBI,BI
L42	1	SEA FILE=HCAPLUS ABB=ON PLU=ON	US2003-692563/AP
L48	1	SEA FILE=REGISTRY ABB=ON PLU=ON	57-62-5
L49	143	SEA FILE=REGISTRY ABB=ON PLU=ON	57-62-5/CRN
L50	144	SEA FILE=REGISTRY ABB=ON PLU=ON	(L49 OR L48)

```
L51         7033 SEA FILE=REGISTRY ABB=ON  PLU=ON  L32 NOT L50
L52          782 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 (L) (BAC OR DMA OR PAC OR
                 PKT OR THU)/RL
L53           20 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L52 AND (L34 OR L35 OR L36 OR
                 L37)
L61           20 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L53 OR L42)


=> d ibib abs hitind hitstr l61 tot

L61  ANSWER 1 OF 20  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2006:410014  HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER:          144:450548
TITLE:                    Preparation of substituted tetracycline compounds for
                          the treatment of bacterial infections and neoplasms
INVENTOR(S):              Abato, Paul; Assefa, Haregewein; Berniac, Joel;
                          Bhatia, Beena; Bowser, Todd; Chen, Jackson; Grier,
                          Mark; Honeyman, Laura; Ismail, Mohamed Y.; Nelson,
                          Mark; Kwasi, Ohemeng; Pan, Jingwen
PATENT ASSIGNEE(S):       Paratek Pharmaceuticals, Inc., USA
SOURCE:                   PCT Int. Appl., 126 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2006047756         A2    20060504    WO 2005-US39014         20051025
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
             NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
             SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
             YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     US 2006166945         A1    20060727    US 2005-258622          20051025
PRIORITY APPLN. INFO.:                       US 2004-622027P      P  20041025
                                             US 2004-622749P      P  20041027
OTHER SOURCE(S):          MARPAT 144:450548
GI
```



I



II

AB Tetracycline compds., e.g. of formula I [R = alkoxyiminomethyl, alkoxycarbonyl, (substituted) H2NCO, alkynyl, alkyl, heteroaryl, etc.; R1 = H, alkenyl] are prepared The tetracycline compds. can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compds. such as blocking tetracycline efflux and modulation of gene expression. Thus, II was prepared from 9-iodominocycline, and was found to be active against S. aureus and S. pneumoniae.

CC 26-6 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 30, 63

IT Antibacterial agents
Antimalarials
Antitumor agents
Antiviral agents
Human
Malaria
Multiple sclerosis
Neoplasm
Parasiticides
(preparation of substituted tetracyclines for treatment of bacterial infections and neoplasms)

IT ***885334-84-9P 885335-05-7P***
RL: ***PAC (Pharmacological activity)***; RCT (Reactant); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted tetracyclines for treatment of bacterial infections and neoplasms)

IT ***53108-38-6P*** 182004-72-4P ***330627-23-1P***
389139-66-6P 460072-59-7P 460072-61-1P
460073-33-0P 488817-82-9P 488819-08-5P
488820-48-0P 835884-28-1P 835884-75-8P
885334-85-0P 885334-86-1P 885334-87-2P
885334-88-3P 885334-89-4P 885334-90-7P
885334-91-8P 885334-92-9P 885334-93-0P
885334-94-1P 885334-95-2P 885334-96-3P
885334-97-4P 885334-98-5P 885334-99-6P
885335-00-2P 885335-01-3P 885335-02-4P
885335-03-5P 885335-04-6P 885335-06-8P

885335-07-9P 885335-08-0P 885335-09-1P
885335-10-4P 885335-11-5P 885335-15-9P
885335-16-0P 885335-17-1P 885335-18-2P
885335-19-3P 885335-20-6P 885335-21-7P
885335-22-8P 885335-23-9P 885335-24-0P
885335-25-1P 885335-26-2P 885335-27-3P
885335-28-4P 885335-29-5P 885335-30-8P
885335-31-9P 885335-32-0P 885335-33-1P
885335-34-2P 885335-35-3P 885335-36-4P
885335-37-5P 885335-38-6P 885335-39-7P
885335-40-0P 885335-41-1P 885335-42-2P
885335-43-3P 885335-44-4P 885335-45-5P
885335-46-6P 885335-47-7P 885335-48-8P
885335-49-9P 885335-50-2P 885335-51-3P
885335-52-4P 885335-53-5P 885335-54-6P
885335-55-7P 885335-56-8P 885335-57-9P
885335-58-0P 885335-59-1P 885335-60-4P
885335-61-5P 885335-62-6P 885335-63-7P
885335-64-8P 885335-65-9P 885335-66-0P
885335-67-1P 885335-68-2P 885335-69-3P
885335-70-6P 885335-71-7P 885335-72-8P
885335-73-9P 885335-74-0P 885335-75-1P
885335-76-2P 885335-77-3P 885335-78-4P
885335-79-5P 885335-80-8P 885335-81-9P
885335-82-0P 885335-83-1P 885335-84-2P
885335-85-3P 885335-86-4P 885335-87-5P
885335-88-6P 885335-89-7P 885335-90-0P
885335-91-1P 885335-92-2P 885335-93-3P
885335-94-4P 885335-95-5P 885335-96-6P
885335-97-7P 885335-98-8P 885335-99-9P
885336-00-5P 885336-01-6P 885336-02-7P
885336-03-8P 885336-04-9P 885336-05-0P
885336-06-1P 885336-07-2P 885336-08-3P
885336-09-4P 885336-10-7P 885336-11-8P
885336-12-9P 885336-13-0P 885336-14-1P
885336-15-2P 885336-16-3P 885336-17-4P
885336-18-5P 885336-19-6P 885336-20-9P
885336-21-0P 885336-22-1P 885336-23-2P
885336-24-3P 885336-25-4P 885336-26-5P
885336-27-6P 885336-28-7P 885336-29-8P
885336-30-1P 885336-31-2P 885336-32-3P
885336-33-4P 885336-34-5P 885336-35-6P
885336-36-7P 885336-37-8P 885336-38-9P
885336-39-0P 885336-40-3P 885336-41-4P
885336-42-5P 885336-43-6P 885336-44-7P
885336-45-8P 885336-46-9P 885336-47-0P
885336-48-1P 885336-49-2P 885336-50-5P
885336-51-6P 885336-52-7P 885336-53-8P
885336-54-9P 885336-55-0P 885336-56-1P
885336-57-2P 885336-58-3P 885336-59-4P
885336-60-7P 885336-61-8P 885336-62-9P
885336-63-0P 885336-64-1P 885336-65-2P
885336-66-3P 885336-67-4P 885336-68-5P
885336-69-6P 885336-70-9P 885336-71-0P
885336-72-1P 885336-73-2P 885336-74-3P
885336-75-4P 885336-76-5P 885336-77-6P
885336-78-7P 885336-79-8P 885336-80-1P
885336-81-2P 885336-82-3P 885336-83-4P
885336-84-5P 885336-85-6P 885336-86-7P

885336-87-8P 885336-88-9P 885336-89-0P
885336-90-3P 885336-91-4P 885336-92-5P
885336-93-6P 885336-94-7P 885336-95-8P
885336-96-9P 885336-97-0P 885336-98-1P
885336-99-2P 885337-00-8P 885337-01-9P
885337-02-0P 885337-03-1P 885337-04-2P
885337-05-3P 885337-06-4P 885337-07-5P
885337-08-6P 885337-09-7P 885337-10-0P
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted tetracyclines for treatment of bacterial infections and neoplasms)

IT ***885337-11-1P 885337-12-2P 885337-13-3P***
885337-14-4P 885337-15-5P 885337-16-6P
885337-17-7P 885337-18-8P 885337-19-9P
885337-20-2P 885337-21-3P 885337-22-4P
885337-23-5P 885337-24-6P 885337-25-7P
885337-26-8P 885337-27-9P 885337-28-0P
885337-29-1P 885337-30-4P 885337-31-5P
885337-32-6P 885337-33-7P 885337-34-8P
885337-35-9P 885532-37-6P
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted tetracyclines for treatment of bacterial infections and neoplasms)

IT ***885334-84-9P 885335-05-7P***
RL: ***PAC (Pharmacological activity)***; RCT (Reactant); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted tetracyclines for treatment of bacterial infections and neoplasms)

RN 885334-84-9 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1,2,3,6-tetrahydro-4-pyridinyl)-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885335-05-7 HCAPLUS
CN 2-Naphthacenecarbothioic acid, 9-(aminocarbonyl)-4,7-bis(dimethylamino)-

5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-, S-(4-methylphenyl) ester, (5aR,6aS,7S,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT *53108-38-6P 330627-23-1P 389139-66-6P*
460072-59-7P 460072-61-1P 460073-33-0P
488817-82-9P 488819-08-5P 488820-48-0P
835884-28-1P 835884-75-8P 885334-85-0P
885334-86-1P 885334-87-2P 885334-88-3P
885334-89-4P 885334-90-7P 885334-91-8P
885334-92-9P 885334-93-0P 885334-94-1P
885334-95-2P 885334-96-3P 885334-97-4P
885334-98-5P 885334-99-6P 885335-00-2P
885335-01-3P 885335-02-4P 885335-03-5P
885335-04-6P 885335-06-8P 885335-07-9P
885335-08-0P 885335-09-1P 885335-10-4P
885335-11-5P 885335-15-9P 885335-16-0P
885335-17-1P 885335-18-2P 885335-19-3P
885335-20-6P 885335-21-7P 885335-22-8P
885335-23-9P 885335-24-0P 885335-25-1P
885335-26-2P 885335-27-3P 885335-28-4P
885335-29-5P 885335-30-8P 885335-31-9P
885335-32-0P 885335-33-1P 885335-34-2P
885335-35-3P 885335-36-4P 885335-37-5P
885335-38-6P 885335-39-7P 885335-40-0P
885335-41-1P 885335-42-2P 885335-43-3P
885335-44-4P 885335-45-5P 885335-46-6P
885335-47-7P 885335-48-8P 885335-49-9P
885335-50-2P 885335-51-3P 885335-52-4P
885335-53-5P 885335-54-6P 885335-55-7P
885335-56-8P 885335-57-9P 885335-58-0P
885335-59-1P 885335-60-4P 885335-61-5P
885335-62-6P 885335-63-7P 885335-64-8P
885335-65-9P 885335-66-0P 885335-67-1P
885335-68-2P 885335-69-3P 885335-70-6P
885335-71-7P 885335-72-8P 885335-73-9P
885335-74-0P 885335-75-1P 885335-76-2P
885335-77-3P 885335-78-4P 885335-79-5P
885335-80-8P 885335-81-9P 885335-82-0P
885335-83-1P 885335-84-2P 885335-85-3P
885335-86-4P 885335-87-5P 885335-88-6P
885335-89-7P 885335-90-0P 885335-91-1P

885335-92-2P 885335-93-3P 885335-94-4P
885335-95-5P 885335-96-6P 885335-97-7P
885335-98-8P 885335-99-9P 885336-00-5P
885336-01-6P 885336-02-7P 885336-03-8P
885336-04-9P 885336-05-0P 885336-06-1P
885336-07-2P 885336-08-3P 885336-09-4P
885336-10-7P 885336-11-8P 885336-12-9P
885336-13-0P 885336-14-1P 885336-15-2P
885336-16-3P 885336-17-4P 885336-18-5P
885336-19-6P 885336-20-9P 885336-21-0P
885336-22-1P 885336-23-2P 885336-24-3P
885336-25-4P 885336-26-5P 885336-27-6P
885336-28-7P 885336-29-8P 885336-30-1P
885336-31-2P 885336-32-3P 885336-33-4P
885336-34-5P 885336-35-6P 885336-36-7P
885336-37-8P 885336-38-9P 885336-39-0P
885336-40-3P 885336-41-4P 885336-42-5P
885336-43-6P 885336-44-7P 885336-45-8P
885336-46-9P 885336-47-0P 885336-48-1P
885336-49-2P 885336-50-5P 885336-51-6P
885336-52-7P 885336-53-8P 885336-54-9P
885336-55-0P 885336-56-1P 885336-57-2P
885336-58-3P 885336-59-4P 885336-60-7P
885336-61-8P 885336-62-9P 885336-63-0P
885336-64-1P 885336-65-2P 885336-66-3P
885336-67-4P 885336-68-5P 885336-69-6P
885336-70-9P 885336-71-0P 885336-72-1P
885336-73-2P 885336-74-3P 885336-75-4P
885336-76-5P 885336-77-6P 885336-78-7P
885336-79-8P 885336-80-1P 885336-81-2P
885336-82-3P 885336-83-4P 885336-84-5P
885336-85-6P 885336-86-7P 885336-87-8P
885336-88-9P 885336-89-0P 885336-90-3P
885336-91-4P 885336-92-5P 885336-93-6P
885336-94-7P 885336-95-8P 885336-96-9P
885336-97-0P 885336-98-1P 885336-99-2P
885337-00-8P 885337-01-9P 885337-02-0P
885337-03-1P 885337-04-2P 885337-05-3P
885337-06-4P 885337-07-5P 885337-08-6P
885337-09-7P 885337-10-0P 885337-11-1P
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted tetracyclines for treatment of bacterial infections and neoplasms)

RN 53108-38-6 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-(aminomethyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330627-23-1 HCAPLUS
CN 2-Naphthacenecarboxylic acid, 9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-, (5R,5aR,6S,6aR,7S,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 389139-66-6 HCAPLUS
CN 2-Propynoic acid, 3-[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460072-59-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-9-[4-methoxy-3-(1-pyrrolidinylmethyl)phenyl]-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

[The remaining compounds were deleted to save paper]

L61 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:979619 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 143:286216
TITLE: Preparation of tetracyclines for therapeutic use as calpain inhibitors
INVENTOR(S): Angusti, Angela; Hou, Sheng T.; Jiang, Xiuxian Susan; Komatsu, Hiroto; Konishi, Yasuo; Kubo, Takahiro; Lertvorachon, Jittiwud; Roman, Gheorghe
PATENT ASSIGNEE(S): National Research Council of Canada, Can.
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082860	A1	20050909	WO 2005-CA279	20050225
WO 2005082860	C1	20051208		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-547780P P 20040227
US 2004-590345P P 20040723

OTHER SOURCE(S): MARPAT 143:286216
GI



I

AB Tetracyclines, such as I, were prepared for use in pharmaceutical compns. as calpain inhibitors, particularly inhibitors of calpains 1 and 2, as demonstrated in enzymic assays as well as at the cellular and animal levels. These tetracyclines were claimed for use in the treatment of a wide range of conditions implicated by or associated with calpain activity or activation, including cellular protection from apoptosis and necrosis, particularly neuro protection, prevention of cell motility (e.g. anti-metastasis of cancer) and treatment of certain infectious diseases (e.g. ***malaria*** and AIDS). Some of these tetracyclines are particularly useful as calpain inhibitors since they are also antioxidants, in that oxidative stress is often associated with conditions where calpain is activated. These tetracyclines are also claimed for use in the treatment of traumatic brain injury, traumatic spinal cord injury, stroke, Wallerian degeneration, Alzheimer's disease, Parkinson's disease, Huntington's disease, damages of motorneurons from exocitotoxic cell death, axonal degeneration, peripheral neuropathy, inflammation, severe hemorrhage, muscular dystrophy, Duchenne muscular dystrophy, rheumatoid arthritis, diabetic retinopathy, acoustic trauma, virus-induced myocardial injury, acute myocardial infarction, testicular torsion, liver ischemia, kidney ischemia, inflammatory bowel disease, liver transplantation, prostate cancer, lung cancer, renal cancer, platelet secretion, platelet aggregation, platelet spreading, HIV-1 replication, replication of severe acute respiratory syndrome-associated coronavirus, invasion of erythrocytes by P. falciparum, prion propagation in Creutzfeldt Jacob disease, human acute lymphoblastic leukemia, non-Hodgkin's lymphoma cells, tumor cell, cataractogenesis and combinations thereof. Thus, tetracycline derivative I was prepared via a cyclocondensation reaction of tetracycline hydrochloride with hydrazine hydrate in EtOH. The prepared tetracyclines were assayed for inhibition of calpains 1 and 2 as well as undergoing a number of other pharmacol. evaluations. Condition is a neurol. condition or disease.

IC ICM C07D231-12
ICS C07C235-40; C07C237-26; C07D221-18; A61K031-65; A61P039-06; A61P009-10; A61P025-00

CC 26-6 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 63

ST tetracycline deriv prepn calpain inhibitor; neurol disorder treatment tetracycline deriv prepn; AIDS treatment tetracycline deriv prepn; cancer treatment tetracycline deriv prepn; bacterial infection treatment tetracycline deriv prepn; ***malaria*** treatment tetracycline deriv prepn; neurodegeneration treatment tetracycline deriv prepn; cardiovascular disease treatment tetracycline deriv prepn; brain injury treatment tetracycline deriv prepn; antioxidant tetracycline deriv prepn; ***antimalarial*** agent tetracycline deriv prepn; antibacterial agent tetracycline deriv prepn; NMDA receptor agonist tetracycline deriv prepn

IT Anti-AIDS agents
Antibacterial agents
Antimalarials
Antioxidants
Human
(preparation of tetracyclines for therapeutic use as calpain inhibitors)

IT AIDS (disease)
Cardiovascular system, disease
Malaria
Neoplasm
Nervous system, disease
(treatment; preparation of tetracyclines for therapeutic use as calpain inhibitors)

IT ***5585-59-1P***, 7-Nitrosancycline
RL: ***PAC (Pharmacological activity)***; RCT (Reactant); SPN

(Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetracyclines for therapeutic use as calpain inhibitors)

IT 57-62-5, Chlortetracycline 60-54-8, Tetracycline 564-25-0, Doxycycline ***808-26-4***, Sancycline 10118-90-8, Minocycline
RL: ***PAC (Pharmacological activity)***; RCT (Reactant); ***THU (Therapeutic use)***; BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of tetracyclines for therapeutic use as calpain inhibitors)

IT ***2444-65-7P***, 4-De(dimethylamino)tetracycline ***4632-89-7P*** ***5679-00-5P***, 7-Aminosancycline ***15866-90-7P***, 4-De(dimethylamino)sancycline ***179471-97-7P*** ***180002-76-0P*** 182004-72-4P ***511268-95-4P***, 7,9-Dibromosancycline 860428-45-1P 860428-49-5P 860428-60-0P 864073-39-2P, 12-Aminotetracycline 864073-40-5P, 12-Aminochlortetracycline 864073-41-6P, 12-Aminodemeclocycline 864073-42-7P, 12-Aminominocycline 864073-43-8P, 12-Aminodoxycycline 864073-49-4P
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetracyclines for therapeutic use as calpain inhibitors)

IT 79-57-2, Oxytetracycline 127-33-3, Demeclocycline ***751-97-3***, Rolitetracycline ***2013-58-3***, Meclocycline ***4656-99-9***, 7-Chlorosancycline ***31642-30-5***, 7-Bromosancycline ***113164-67-3***, 7-Iodosancycline ***263760-96-9***, 7-Phenylsancycline ***864073-38-1***, 7-(2-Thienyl)sancycline 864073-44-9 864073-45-0 864073-46-1 864073-47-2
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(preparation of tetracyclines for therapeutic use as calpain inhibitors)

IT ***5585-59-1P***, 7-Nitrosancycline
RL: ***PAC (Pharmacological activity)***; RCT (Reactant); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetracyclines for therapeutic use as calpain inhibitors)

RN 5585-59-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT ***808-26-4***, Sancycline
RL: ***PAC (Pharmacological activity)***; RCT (Reactant); ***THU (Therapeutic use)***; BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of tetracyclines for therapeutic use as calpain inhibitors)

RN 808-26-4 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT ***2444-65-7P***, 4-De(dimethylamino)tetracycline ***4632-89-7P*** ***5679-00-5P***, 7-Aminosancycline ***15866-90-7P***, 4-De(dimethylamino)sancycline ***179471-97-7P*** ***180002-76-0P*** ***511268-95-4P***, 7,9-Dibromosancycline
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetracyclines for therapeutic use as calpain inhibitors)

RN 2444-65-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4632-89-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-chloro-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 5679-00-5 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-amino-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15866-90-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

[The remaining compounds were deleted to save paper]

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:99455 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 142:197754
TITLE: Preparation of substituted tetracycline analogs for use in antibiotic pharmaceutical compositions

INVENTOR(S): Nelson, Mark L.; Ohemeng, Kwasi; Amoo, Victor; Kim, Oak; Abato, Paul; Assefa, Haregewein; Berniac, Joel; Bhatia, Beena; Bowser, Todd; Chen, Jackson; Grier, Mark; Hohos, Aaron; Honeyman, Laura; Ismail, Mohamed Y.; Mechiche, Rachid; Nihlawi, Mohammed; Sizensky, Emmanuelle

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009943	A2	20050203	WO 2004-US20249	20040625
WO 2005009943	A3	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259659	A1	20050203	AU 2004-259659	20040625
CA 2531728	AA	20050203	CA 2004-2531728	20040625
US 2005143352	A1	20050630	US 2004-877928	20040625
EP 1648859	A2	20060426	EP 2004-756012	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.:

US 2003-486017P	P	20030709
US 2003-525287P	P	20031125
US 2003-530123P	P	20031216
WO 2004-US20249	W	20040625

OTHER SOURCE(S): CASREACT 142:197754; MARPAT 142:197754

GI



I

AB Novel tetracycline analogs, such as I [R5 = R6 = H; R5 = OH, R6 = Me; R7 = H, Et, CH2NH2, NR9aR9b, perhaloalkenyl, substituted-Ph, -pyridinyl, -pyrazinyl, -furanyl, pyrazolyl; R8 = H, OH, SH, halogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfonyl, alkylsulfinyl, etc.; R9 =

H, CH2NR9aR9b; R9a, R9b = H, alkyl, alkenyl; NR9aR9b = nitrogen linked heterocyclyl], were prepared for therapeutic uses, such as treating bacterial infections, viral infections, parasitic infections, especially ***malaria***, and neoplasms, as well as other known applications for tetracycline compds. such as blocking tetracycline efflux and modulation of gene expression. Thus, I [R5 = R6 = R8 = H, R7 = 6-fluoropyridin-2-yl, R9 = CH2N(Me)CH2CH:CH2] was prepared via aromatic coupling of 7-iodosancycline I [R5 = R6 = R8 = R9 = H, R7 = iodo] with 6-fluoropyridin-3-ylboronic acid using Pd(dppf)2Cl2 and Na2CO3 in DMF and H2O, formylation of the coupled product I [R5 = R6 = R8 = R9 = H, R7 = 6-fluoropyridin-2-yl], and finally, amination of the resulting formyl deriv, I [R5 = R6 = R8 = H, R7 = 6-fluoropyridin-2-yl, R9 = CHO] with MeNHCH2CH:CH2. The prepared tetracycline analogs were assayed in vitro for min. inhibitory concentration of common bacteria, such as E. coli, S.aureus, and Enterococcus sp.

IC ICM C07C237-26
ICS A61K031-65

CC 26-6 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 63

ST bacterial infection treatment tetracycline analog prepn; viral infection treatment tetracycline analog prepn; parasitic infection treatment tetracycline analog prepn; ***malaria*** treatment tetracycline analog prepn; neoplasm treatment tetracycline analog prepn; gene expression modulation tetracycline analog prepn; tetracycline antibiotic virucide parasiticide antibacterial agent synthesis; drug delivery system tetracycline analog antibiotic prepn

IT Antibacterial agents
Antibiotics
Antimalarials
Antitumor agents
Antiviral agents
Drug delivery systems
Parasiticides
(preparation of substituted tetracycline analogs for therapeutic uses as antibiotics)

IT Infection
Malaria
Neoplasm
(treatment; preparation of substituted tetracycline analogs for therapeutic uses as antibiotics)

IT ***53108-41-1P 389624-58-2P 459809-97-3P***
460070-02-4P 460072-19-9P 460073-17-0P
460074-13-9P 488818-73-1P 685831-48-5P
685832-85-3P 685832-95-5P 685832-96-6P
685832-99-9P 685833-00-5P 685833-02-7P
685833-03-8P 685833-05-0P 685833-06-1P
685833-07-2P 685833-09-4P 685833-10-7P
685833-11-8P 685833-12-9P 685833-13-0P
685833-15-2P 685833-16-3P 685833-18-5P
685833-19-6P 685833-21-0P 685833-23-2P
685833-26-5P 685833-27-6P 685833-29-8P
685833-30-1P 685833-31-2P 685833-32-3P
685833-33-4P 685833-35-6P 685833-36-7P
685833-39-0P 685833-40-3P 685833-42-5P
685833-43-6P 685833-44-7P 685833-48-1P
685833-51-6P 685833-52-7P 685833-53-8P
685833-54-9P 685833-55-0P 731030-17-4P
731030-18-5P 731030-19-6P 731030-20-9P
731030-21-0P 731030-23-2P 731030-24-3P
731030-25-4P 731030-26-5P 731030-27-6P

731030-28-7P 731030-30-1P 731030-31-2P
731030-33-4P 731030-34-5P 731030-37-8P
731030-38-9P 731030-39-0P 731030-40-3P
731030-41-4P 731030-43-6P 731030-44-7P
731030-45-8P 731030-47-0P 731030-48-1P
731030-51-6P 731030-53-8P 731030-56-1P
731030-57-2P 731030-58-3P 732993-66-7P
835883-69-7P 835883-70-0P 835883-71-1P
835883-72-2P 835883-73-3P 835883-74-4P
835883-75-5P 835883-76-6P 835883-77-7P
835883-78-8P 835883-79-9P 835883-80-2P
835883-81-3P 835883-84-6P 835883-85-7P
835883-86-8P 835883-87-9P 835883-88-0P
835883-89-1P 835883-90-4P 835883-91-5P
835883-92-6P 835883-93-7P 835883-94-8P
835883-95-9P 835883-96-0P 835883-97-1P
835883-98-2P 835883-99-3P 835884-00-9P
835884-01-0P 835884-02-1P 835884-03-2P
835884-04-3P 835884-05-4P 835884-06-5P
835884-07-6P 835884-09-8P 835884-10-1P
835884-11-2P 835884-12-3P 835884-13-4P
835884-14-5P 835884-15-6P 835884-16-7P
835884-17-8P 835884-18-9P 835884-19-0P
835884-20-3P 835884-21-4P 835884-22-5P
835884-23-6P 835884-24-7P 835884-25-8P
835884-26-9P 835884-27-0P 835884-28-1P
835884-29-2P 835884-30-5P 835884-31-6P
835884-32-7P 835884-33-8P 835884-34-9P
835884-35-0P 835884-36-1P 835884-37-2P
835884-38-3P 835884-39-4P 835884-40-7P
835884-41-8P 835884-42-9P 835884-43-0P
835884-44-1P 835884-45-2P 835884-46-3P
835884-47-4P 835884-48-5P 835884-49-6P
835884-50-9P 835884-51-0P 835884-52-1P
835884-53-2P 835884-54-3P 835884-55-4P
835884-56-5P 835884-57-6P 835884-58-7P
835884-59-8P 835884-60-1P 835884-61-2P
835884-62-3P 835884-63-4P 835884-64-5P
835884-65-6P 835884-66-7P 835884-67-8P
835884-68-9P 835884-69-0P 835884-70-3P
835884-71-4P 835884-72-5P 835884-73-6P
835884-74-7P 835884-75-8P 835884-76-9P
835884-78-1P 835885-52-4P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of substituted tetracycline analogs for therapeutic uses as antibiotics)

IT 10118-92-0P 731030-59-4P
RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted tetracycline analogs for therapeutic uses as antibiotics)

IT 60-54-8DP, Tetracycline, analogs 488815-54-9P
685833-04-9P 685833-08-3P 685833-14-1P
685833-41-4P 685833-45-8P 731030-22-1P
731030-35-6P 731030-42-5P 731030-50-5P
731030-54-9P 731030-55-0P 731030-61-8P

835883-40-4P 835883-41-5P 835883-45-9P
835883-46-0P 835883-47-1P 835883-48-2P
835883-50-6P
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted tetracycline analogs for therapeutic uses as antibiotics)

IT ***53108-41-1P 389624-58-2P 459809-97-3P***
460070-02-4P 460072-19-9P 460073-17-0P
460074-13-9P 488818-73-1P 685831-48-5P
685832-85-3P 685832-95-5P 685832-96-6P
685832-99-9P 685833-00-5P 685833-02-7P
685833-03-8P 685833-05-0P 685833-06-1P
685833-07-2P 685833-09-4P 685833-10-7P
685833-11-8P 685833-12-9P 685833-13-0P
685833-15-2P 685833-16-3P 685833-18-5P
685833-19-6P 685833-21-0P 685833-23-2P
685833-26-5P 685833-27-6P 685833-29-8P
685833-30-1P 685833-31-2P 685833-32-3P
685833-33-4P 685833-35-6P 685833-36-7P
685833-39-0P 685833-40-3P 685833-42-5P
685833-43-6P 685833-44-7P 685833-48-1P
685833-51-6P 685833-52-7P 685833-53-8P
685833-54-9P 685833-55-0P 731030-17-4P
731030-18-5P 731030-19-6P 731030-20-9P
731030-21-0P 731030-23-2P 731030-24-3P
731030-25-4P 731030-26-5P 731030-27-6P
731030-28-7P 731030-30-1P 731030-31-2P
731030-33-4P 731030-34-5P 731030-37-8P
731030-38-9P 731030-39-0P 731030-40-3P
731030-41-4P 731030-43-6P 731030-44-7P
731030-45-8P 731030-47-0P 731030-48-1P
731030-51-6P 731030-53-8P 731030-56-1P
731030-57-2P 731030-58-3P 732993-66-7P
835883-69-7P 835883-70-0P 835883-71-1P
835883-72-2P 835883-73-3P 835883-74-4P
835883-75-5P 835883-76-6P 835883-77-7P
835883-78-8P 835883-79-9P 835883-80-2P
835883-81-3P 835883-84-6P 835883-85-7P
835883-86-8P 835883-87-9P 835883-88-0P
835883-89-1P 835883-90-4P 835883-91-5P
835883-92-6P 835883-93-7P 835883-94-8P
835883-95-9P 835883-96-0P 835883-97-1P
835883-98-2P 835883-99-3P 835884-00-9P
835884-01-0P 835884-03-2P 835884-04-3P
835884-05-4P 835884-06-5P 835884-07-6P
835884-09-8P 835884-10-1P 835884-11-2P
835884-12-3P 835884-13-4P 835884-14-5P
835884-15-6P 835884-16-7P 835884-17-8P
835884-18-9P 835884-19-0P 835884-20-3P
835884-21-4P 835884-22-5P 835884-23-6P
835884-24-7P 835884-25-8P 835884-26-9P
835884-27-0P 835884-28-1P 835884-29-2P
835884-30-5P 835884-31-6P 835884-32-7P
835884-33-8P 835884-34-9P 835884-35-0P
835884-36-1P 835884-37-2P 835884-38-3P
835884-39-4P 835884-40-7P 835884-41-8P
835884-42-9P 835884-43-0P 835884-44-1P

835884-45-2P 835884-46-3P 835884-47-4P
835884-48-5P 835884-49-6P 835884-50-9P
835884-51-0P 835884-52-1P 835884-53-2P
835884-54-3P 835884-55-4P 835884-56-5P
835884-57-6P 835884-58-7P 835884-59-8P
835884-60-1P 835884-61-2P 835884-62-3P
835884-63-4P 835884-64-5P 835884-65-6P
835884-66-7P 835884-67-8P 835884-68-9P
835884-69-0P 835884-70-3P 835884-71-4P
835884-72-5P 835884-73-6P 835884-74-7P
835884-75-8P 835884-76-9P 835885-52-4P
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of substituted tetracycline analogs for therapeutic uses as antibiotics)

RN 53108-41-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(dimethylamino)methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4α,4aα,5aα,12aα)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 389624-58-2 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[3-(1-piperidinylmethyl)phenyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 459809-97-3 HCAPLUS
CN 2-Naphthacenecarboxamide, 9-(aminomethyl)-4-(dimethylamino)-7-[4-(dimethylamino)phenyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460070-02-4 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[4-[(dimethylamino)methyl]phenyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460072-19-9 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[4-[[(1-methylethyl)amino]methyl]phenyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460073-17-0 HCAPLUS
CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-ethyl-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

[The remaining compounds were deleted to save paper]

L61 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1036703 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 141:420412
TITLE: Substituted tetracycline compounds for the treatment of ***malaria***
INVENTOR(S): Draper, Michael; Nelson, Mark L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 590 pp., Cont.-in-part of U.S. Ser. No. 128,990, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004242548	A1	20041202	US 2003-692563		20031024 <--
US 2004092490	A1	20040513	US 2002-128990		20020424
PRIORITY APPLN. INFO.:			US 2001-286193P	P	20010424
			US 2002-128990	B2	20020424
			US 2002-421259P	P	20021024

OTHER SOURCE(S): MARPAT 141:420412

AB The invention provides a method for treating or preventing ***malaria*** in a subject. The method includes administering an effective amount of a substituted tetracycline compound, such that ***malaria*** is treated or prevented. In one aspect, the invention relates to pharmaceutical compns. which include an effective amount of a tetracycline compound to treat ***malaria*** in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used to in combination with one or more ***antimalarial*** compds. or can be used to treat or prevent ***malaria*** which is resistant to one or more other ***antimalarial*** compds. Preparation of e.g. sancycline derivs. is described.

IC ICM A61K031-65

INCL 514152000

CC 1-5 (Pharmacology)
Section cross-reference(s): 26, 63

ST ***malaria*** treatment tetracycline compd; ***antimalarial*** pharmaceutical sancycline compd prepn

IT Drug resistance
(***antimalarial***; substituted tetracycline compds. for treatment of ***malaria***)

IT Disease, animal
(malaise; substituted tetracycline compds. for treatment of ***malaria***)

IT Spleen, disease
(splenomegaly; substituted tetracycline compds. for treatment of ***malaria***)

IT Anemia (disease)
Antibacterial agents
Antimalarials
Antimicrobial agents
Antipyretics
Combination chemotherapy
Drug delivery systems
Drug interactions
Fever and Hyperthermia
Firmicutes
Headache
Human
Malaria
Plasmodium falciparum
Plasmodium ***malariae***
Plasmodium ovale
Plasmodium vivax
Prophylaxis
(substituted tetracycline compds. for treatment of ***malaria***)

IT Sulfonamides
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. for treatment of ***malaria***)

IT Tetracyclines
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. for treatment of ***malaria***)

IT 54-05-7, Chloroquine 56-54-2, Quinidine 86-42-0, Amodiaquine 90-34-6, Primaquine 130-95-0, Quinine 500-92-5, Proguanil 537-21-3, Chlorproguanil 550-81-2, Amopyroquine 738-70-5, Trimethoprim 37338-39-9 37357-69-0 53230-10-7, Mefloquine 63968-64-9, Artemisinin 69756-53-2, Halofantrine 71963-77-4, Artemether 74847-35-1, Pyronaridine 82186-77-4, Lumefantrine 88495-63-0, Artesunate

95233-18-4, Atovaquone 123407-36-3, Arteflene 201849-42-5
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. for treatment of ***malaria***)

IT 60-54-8 60-54-8D, Tetracycline, derivs. 79-57-2 127-33-3 564-25-0
808-26-4 914-00-1 1665-56-1 ***2444-65-7***
3242-03-3 4495-20-9 4497-07-8 ***5585-59-1***
5874-95-3 5995-55-1 10118-89-5 10118-90-8
10236-47-2 ***15866-90-7 16145-05-4 19109-13-8***
31642-30-5 35689-63-5 35689-65-7
53108-40-0 53108-41-1 53173-80-1
59046-79-6 73351-16-3 ***82336-02-5 113164-67-3***
115207-75-5 ***120793-45-5 146253-71-6***
146253-75-0 146278-01-5 146278-02-6
146278-03-7 149934-16-7 149934-19-0
151922-17-7 153621-68-2 155819-14-0
155819-18-4 161321-34-2 161452-37-5
186759-47-7 186759-49-9 186759-51-3
186759-53-5 186759-55-7 186759-61-5
220620-09-7 233585-94-9 233585-95-0
233585-96-1 233585-97-2 233586-02-2
233586-03-3 233586-04-4 233586-06-6
233586-08-8 233586-09-9 233586-10-2
233586-11-3 233586-12-4 263760-96-9
263760-98-1 263760-99-2 263761-01-9
263761-02-0 263761-08-6 295356-11-5
295356-13-7 295356-16-0 295356-17-1
330627-21-9 330627-22-0 330627-23-1
330627-24-2 330627-26-4 330627-29-7
330627-31-1 330627-32-2 344771-54-6
351336-92-0 351336-94-2 365276-98-8
365276-99-9 365277-00-5 365277-01-6
365277-02-7 365277-03-8 365277-04-9
365277-05-0 365277-06-1 365277-07-2
365277-08-3 365277-11-8 365277-12-9
365277-13-0 365277-14-1 365277-16-3
365277-19-6 365277-20-9 365277-21-0
365277-23-2 365277-24-3 365277-26-5
365277-28-7 365277-29-8 365277-33-4
365277-34-5 365277-35-6 365277-36-7
365277-37-8 365277-38-9 365277-39-0
365277-40-3 365277-41-4 365277-42-5
365277-43-6 365277-44-7 365277-45-8
365277-47-0 365277-48-1 365277-49-2
365277-50-5 365277-51-6 365277-52-7
365277-54-9 365277-55-0 365277-56-1
365277-57-2 365277-58-3 365277-59-4
365277-60-7 365277-61-8 365277-62-9
365277-63-0 365277-64-1 365277-65-2
365277-66-3 365277-88-9 374748-06-8
380435-62-1 380435-63-2 380435-65-4
380435-74-5 380435-76-7 380435-88-1
389081-55-4 389081-56-5 389081-57-6
389081-58-7 389081-59-8 389081-60-1
389081-61-2 389081-62-3 389081-64-5
389081-65-6 389081-66-7 389081-67-8
389081-68-9 389081-69-0 389081-71-4
389081-73-6 389081-74-7 389081-75-8
389081-76-9 389081-77-0 389081-78-1

389081-79-2 389081-80-5 389081-85-0
389139-10-0 389139-12-2 389139-15-5
389139-16-6 389139-17-7 389139-18-8
389139-19-9 389139-20-2 389139-21-3
389139-22-4 389139-23-5 389139-24-6
389139-25-7 389139-26-8 389139-27-9
389139-28-0 389139-29-1 389139-30-4
389139-31-5 389139-32-6 389139-33-7
389139-34-8 389139-35-9 389139-36-0
389139-37-1 389139-38-2 389139-39-3
389139-41-7 389139-42-8 389139-43-9
389139-44-0 389139-45-1 389139-46-2
389139-47-3 389139-48-4 389139-49-5
389139-50-8 389139-51-9 389139-52-0
389139-53-1 389139-54-2 389139-55-3
389139-56-4 389139-57-5 389139-58-6
389139-59-7 389139-60-0 389139-61-1
389139-62-2 389139-63-3 389139-64-4
389139-65-5 389139-66-6 389139-67-7
389139-68-8 389139-69-9 389139-70-2
389139-71-3 389139-72-4 389139-73-5
389139-74-6
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. for treatment of ***malaria***)

IT *389139-75-7 389139-76-8 389139-78-0*
389139-79-1 389139-80-4 389139-81-5
389139-82-6 389139-83-7 389139-85-9
389139-86-0 389139-87-1 389139-88-2
389139-89-3 389139-90-6 389139-91-7
389139-93-9 389139-94-0 389139-96-2
389139-97-3 389139-98-4 389139-99-5
389140-00-5 389140-01-6 389140-02-7
389140-03-8 389140-06-1 389570-43-8
389570-46-1 389570-48-3 389570-49-4
389570-50-7 389570-51-8 389570-52-9
389570-53-0 389570-54-1 389623-72-7
389623-74-9 389623-77-2 389623-80-7
389623-82-9 389623-86-3 389623-88-5
389623-89-6 389623-90-9 389623-91-0
389623-93-2 389623-95-4 389623-96-5
389623-97-6 389623-98-7 389623-99-8
389624-01-5 389624-03-7 389624-04-8
389624-05-9 389624-06-0 389624-07-1
389624-08-2 389624-09-3 389624-11-7
389624-12-8 389624-13-9 389624-14-0
389624-15-1 389624-16-2 389624-18-4
389624-19-5 389624-20-8 389624-21-9
389624-22-0 389624-23-1 389624-24-2
389624-26-4 389624-27-5 389624-28-6
389624-29-7 389624-30-0 389624-31-1
389624-32-2 389624-33-3 389624-34-4
389624-35-5 389624-36-6 389624-37-7
389624-38-8 389624-39-9 389624-40-2
389624-41-3 389624-42-4 389624-43-5
389624-44-6 389624-45-7 389624-46-8
389624-47-9 389624-48-0 389624-49-1
389624-51-5 389624-52-6 389624-53-7
389624-54-8 389624-55-9 389624-56-0

389624-57-1 389624-59-3 389624-60-6
389624-61-7 389624-62-8 389624-63-9
389624-64-0 389624-65-1 389624-66-2
389624-67-3 389624-68-4 389624-69-5
389624-70-8 389624-71-9 389624-72-0
389624-73-1 389624-74-2 389624-75-3
389624-76-4 389624-77-5 389624-78-6
389624-79-7 389624-80-0 389624-81-1
389624-82-2 389624-83-3 389624-84-4
389624-85-5 389624-86-6 389624-87-7
389624-88-8 389624-89-9 389624-90-2
389624-91-3 389624-92-4 389624-93-5
389624-94-6 389624-95-7 389624-96-8
389624-97-9 389624-98-0 389624-99-1
389625-00-7 389625-01-8 389625-02-9
389625-03-0 389625-04-1 389625-05-2
389625-06-3 389625-07-4 389625-09-6
389625-10-9 389625-11-0 389625-12-1
439217-57-9 439217-59-1 459425-79-7
459425-80-0 459425-96-8 459426-11-0
459809-42-8 459809-43-9 459809-44-0
459809-45-1 459809-46-2 459809-47-3
459809-48-4 459809-49-5 459809-50-8
459809-51-9 459809-52-0 459809-53-1
459809-54-2 459809-55-3 459809-57-5
459809-58-6 459809-59-7 459809-61-1
459809-63-3 459809-65-5 459809-66-6
459809-67-7 459809-68-8 459809-70-2
459809-74-6 459809-76-8 459809-77-9
459809-79-1 459809-81-5 459809-82-6
459809-86-0 459809-88-2 459809-91-7
459809-92-8 459809-95-1 459809-96-2
459809-97-3 459809-98-4 459809-99-5
459810-00-5 459810-01-6 459810-02-7
459810-03-8 459810-04-9 459810-06-1
459810-07-2 459810-08-3 459810-09-4
460068-27-3 460068-29-5 460068-30-8
460068-31-9 460068-32-0 460068-33-1
460068-34-2 460068-35-3 460068-36-4
460068-38-6 460068-39-7 460068-40-0
460068-41-1 460068-42-2 460068-43-3 46006
8-44-4 460068-45-5 460068-46-6
460068-47-7 460068-48-8 460068-49-9
460068-50-2 460068-51-3 460068-52-4
460068-53-5 460068-54-6
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. for treatment of ***malaria***)

IT 460068-55-7 460068-57-9 460068-58-0
460068-59-1 460068-60-4 460068-61-5
460068-62-6 460068-63-7 460068-64-8
460068-65-9 460068-66-0 460068-67-1
460068-68-2 460068-69-3 460068-70-6
460068-71-7 460068-72-8 460068-73-9
460068-74-0 460068-75-1 460068-76-2
460068-77-3 460068-78-4 460068-79-5
460068-80-8 460068-81-9 460068-82-0
460068-84-2 460068-85-3 460068-86-4
460068-87-5 460068-88-6 460068-90-0

460068-92-2 460068-93-3 460068-94-4
460068-95-5 460068-96-6 460068-97-7
460068-99-9 460069-34-5 460069-38-9
460069-65-2 460069-70-9 460069-89-0
460069-96-9 460070-02-4 460070-03-5
460070-53-5 460070-61-5 460070-66-0
460070-73-9 460070-76-2 460070-79-5
460070-92-2 460070-95-5 460071-02-7
460071-04-9 460071-06-1 460071-09-4
460071-12-9 460071-14-1 460071-17-4
460071-19-6 460071-29-8 460071-33-4
460071-37-8 460071-66-3 460071-69-6
460071-80-1 460071-83-4 460071-87-8
460071-89-0 460071-91-4 460071-93-6
460071-97-0 460071-99-2 460072-01-9
460072-03-1 460072-05-3 460072-07-5
460072-09-7 460072-10-0 460072-12-2
460072-15-5 460072-17-7 460072-19-9
460072-21-3 460072-25-7 460072-28-0
460072-29-1 460072-30-4 460072-31-5
460072-33-7 460072-36-0 460072-40-6
460072-43-9 460072-45-1 460072-47-3
460072-49-5 460072-59-7 460072-63-3
460072-65-5 460072-70-2 460072-73-5
460072-75-7 460072-78-0 460072-82-6
460072-86-0 460072-89-3 460072-91-7
460072-93-9 460073-01-2 460073-03-4
460073-05-6 460073-07-8 460073-09-0
460073-11-4 460073-15-8 460073-17-0
460073-21-6 460073-22-7 460073-23-8
460073-25-0 460073-27-2 460073-29-4
460073-31-8 460073-35-2 460073-37-4
460073-40-9 460073-41-0 460073-43-2
460073-45-4 460073-47-6 460073-49-8
460073-51-2 460073-53-4 460073-55-6
460073-58-9 460073-62-5 460073-64-7
460073-68-1 460073-70-5 460073-72-7
460073-74-9 460073-76-1 460073-78-3
460073-80-7 460073-82-9 460073-84-1
460073-86-3 460073-88-5 460073-90-9
460073-92-1 460073-94-3 460073-96-5
460073-98-7 460074-00-4 460074-02-6
460074-04-8 460074-06-0 460074-09-3
460074-11-7 460074-13-9 460074-15-1
460074-19-5 460074-21-9 460074-23-1
460074-26-4 460074-28-6 460074-30-0
460074-34-4 460074-36-6 460074-38-8
460074-40-2 460074-42-4 460074-44-6
460074-46-8 460074-48-0 460074-50-4
460074-52-6 460074-54-8 460074-56-0
460074-58-2 460074-60-6 460074-62-8
460074-64-0 460074-66-2 460074-68-4
460074-69-5 460074-71-9 460074-73-1
460074-75-3 460074-77-5 460074-79-7
460074-81-1 460074-83-3 460074-85-5
460074-87-7 460074-89-9 460074-91-3
460074-93-5 460074-95-7 460074-97-9 46007
4-99-1 460075-04-1 460075-06-3
460075-08-5 460075-12-1 460075-14-3

460075-62-1 460076-23-7 460082-77-3
460082-87-5 460082-89-7 460082-90-0
460082-91-1 473972-91-7 473973-13-6
473973-20-5 473973-34-1 473973-37-4
473973-41-0 473973-62-5 473973-64-7
473973-86-3 473973-96-5 473974-12-8
473974-75-3 473974-76-4 473974-77-5
473974-79-7 473974-80-0 473974-81-1
473974-82-2 473974-83-3
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. for treatment of **malaria**)

IT 473974-84-4 473974-85-5 488815-44-7
488815-46-9 488815-47-0 488815-49-2
488815-52-7 488815-53-8 488815-54-9
488815-55-0 488815-56-1 488815-57-2
488815-58-3 488815-59-4 488815-60-7
488815-61-8 488815-62-9 488815-63-0
488815-64-1 488815-65-2 488815-66-3
488815-68-5 488815-69-6 488815-71-0
488815-72-1 488815-73-2 488815-74-3
488815-75-4 488815-76-5 488815-77-6
488815-78-7 488815-80-1 488815-82-3
488815-89-0 488815-93-6 488815-98-1
488816-00-8 488816-13-3 488816-16-6
488816-18-8 488816-19-9 488816-26-8
488816-37-1 488816-39-3 488816-42-8
488816-54-2 488816-64-4 488816-65-5
488816-70-2 488816-71-3 488816-73-5
488816-75-7 488816-82-6 488816-88-2
488816-92-8 488816-93-9 488816-98-4
488817-01-2 488817-06-7 488817-11-4
488817-13-6 488817-14-7 488817-15-8
488817-16-9 488817-17-0 488817-18-1 488817-19-2
488817-20-5 488817-21-6 488817-22-7 488817-23-8
488817-24-9 488817-25-0 488817-26-1
488817-27-2 488817-28-3 488817-29-4
488817-30-7 488817-31-8 488817-32-9
488817-33-0 488817-35-2 488817-36-3
488817-37-4 488817-38-5 488817-39-6
488817-41-0 488817-42-1 488817-44-3
488817-45-4 488817-46-5 488817-47-6
488817-48-7 488817-49-8 488817-50-1
488817-51-2 488817-52-3 488817-53-4
488817-54-5 488817-55-6 488817-56-7
488817-57-8 488817-58-9 488817-59-0
488817-60-3 488817-61-4 488817-62-5
488817-63-6 488817-64-7 488817-65-8
488817-67-0 488817-68-1 488817-73-8
488817-75-0 488817-76-1 488817-79-4
488817-80-7 488817-82-9 488817-89-6
488817-91-0 488817-92-1 488817-94-3
488817-95-4 488817-96-5 488817-97-6
488818-04-8 488818-06-0 488818-07-1
488818-08-2 488818-10-6 488818-11-7
488818-12-8 488818-13-9 488818-14-0
488818-16-2 488818-17-3 488818-18-4
488818-19-5 488818-20-8 488818-21-9
488818-23-1 488818-25-3 488818-27-5

488818-28-6 488818-29-7 488818-30-0
488818-31-1 488818-32-2 488818-33-3
488818-34-4 488818-35-5 488818-36-6
488818-37-7 488818-38-8 488818-39-9
488818-40-2 488818-41-3 488818-42-4
488818-43-5 488818-44-6 488818-45-7
488818-46-8 488818-47-9 488818-48-0
488818-49-1 488818-50-4 488818-51-5
488818-52-6 488818-53-7 488818-54-8
488818-55-9 488818-56-0 488818-57-1
488818-58-2 488818-59-3 488818-60-6
488818-61-7 488818-63-9 488818-64-0
488818-65-1 488818-66-2 488818-67-3
488818-68-4 488818-69-5 488818-70-8 48881
8-71-9 488818-72-0 488818-73-1
488818-74-2 488818-75-3 488818-76-4
488818-77-5 488818-78-6 488818-79-7
488818-80-0 488818-81-1 488818-82-2
488818-83-3 488818-84-4 488818-85-5
488818-86-6 488818-87-7 488818-88-8
488818-89-9 488818-90-2 488818-91-3
488818-92-4 488818-93-5 488818-94-6
488818-95-7 488818-97-9 488818-98-0
488818-99-1 488819-00-7 488819-01-8
488819-02-9 488819-03-0 488819-04-1
488819-05-2 488819-06-3 488819-07-4
488819-08-5 488819-14-3 488819-16-5
488819-17-6 488819-18-7 488819-19-8
488819-20-1 488819-21-2 488819-22-3
488819-23-4 488819-24-5 488819-25-6
488819-26-7 488819-27-8 488819-28-9
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. for treatment of ***malaria***)

IT ***488819-29-0 488819-30-3 488819-31-4***
488819-32-5 488819-33-6 488819-34-7
488819-35-8 488819-36-9 488819-37-0
488819-38-1 488819-39-2 488819-40-5
488819-41-6 488819-42-7 488819-43-8
488819-44-9 488819-45-0 488819-46-1
488819-47-2 488819-48-3 488819-49-4
488819-50-7 488819-52-9 488819-53-0
488819-54-1 488819-55-2 488819-56-3
488819-57-4 488819-58-5 488819-59-6
488819-60-9 488819-61-0 488819-62-1
488819-63-2 488819-64-3 488819-65-4
488819-66-5 488819-67-6 488819-68-7
488819-69-8 488819-70-1 488819-71-2
488819-72-3 488819-73-4 488819-74-5
488819-75-6 488819-76-7 488819-77-8
488819-78-9 488819-79-0 488819-80-3
488819-82-5 488819-84-7 488819-85-8
488819-86-9 488819-87-0 488819-88-1
488819-89-2 488819-90-5 488819-91-6
488819-92-7 488819-93-8 488819-94-9
488819-95-0 ***488819-96-1 488819-97-2***
488819-98-3 488819-99-4 488820-00-4
488820-01-5 488820-02-6 488820-03-7
488820-04-8 488820-05-9 488820-06-0 488820-07-1

488820-09-3 488820-10-6 488820-11-7
488820-12-8 488820-13-9 488820-14-0
488820-15-1 488820-16-2 488820-17-3
488820-18-4 488820-19-5 488820-20-8
488820-21-9 488820-22-0 488820-23-1
488820-24-2 488820-25-3 488820-26-4
488820-27-5 488820-28-6 488820-29-7
488820-30-0 488820-31-1 488820-32-2
488820-33-3 488820-34-4 488820-43-5
488820-48-0 577795-55-2 577795-64-3
601454-79-9 601454-80-2 601454-82-4
601454-85-7 601454-92-6 601454-95-9
601454-97-1 601454-98-2 601454-99-3
601455-02-1 601455-03-2 601455-04-3
601455-05-4 601455-07-6 601455-09-8
601455-11-2 601455-12-3 601455-13-4
601455-15-6 601455-16-7 601455-17-8
601455-18-9 601455-19-0 601455-20-3
601455-21-4 601455-22-5 601455-23-6
601455-24-7 601455-25-8 601455-26-9
601455-27-0 601455-29-2 601455-30-5
601455-31-6 601455-32-7 601455-33-8
601455-34-9 601455-35-0 601455-36-1
601455-37-2 601455-38-3 601455-39-4
601455-41-8 601455-42-9 601455-43-0
601455-44-1 601455-45-2 601455-46-3
601455-47-4 601455-49-6 601455-50-9
601455-52-1 601455-53-2 601455-54-3
601455-55-4 601455-56-5 601455-57-6
601455-58-7 601455-60-1 601455-62-3 60145
5-63-4 601455-65-6 601455-66-7
601455-67-8 601455-68-9 601455-69-0
601455-71-4 601455-72-5 601455-73-6
601455-75-8 601455-76-9 601455-77-0
601455-78-1 601455-79-2 601455-80-5
601455-81-6 601455-83-8 601455-84-9
601455-85-0 601455-86-1 601455-87-2
601455-89-4 601455-90-7 601455-91-8
601455-92-9 601455-95-2 601470-72-8
607400-44-2 607400-46-4 607400-50-0
607400-72-6 607401-16-1 607401-26-3
607401-28-5 607401-38-7 607401-41-2
607401-43-4 607401-45-6 607401-48-9
607401-54-7 607401-57-0 607401-59-2
607401-63-8 607401-65-0 607401-67-2
607401-69-4 607401-71-8 607401-73-0
607401-75-2 607401-77-4 607401-79-6
607401-81-0 607401-83-2 607401-86-5
607401-98-9 607402-03-9 607402-08-4
607402-10-8 607402-12-0 607402-14-2
607402-16-4 607402-18-6 607402-20-0
607402-22-2 607402-24-4 607402-28-8
607402-58-4 607402-71-1 607402-72-2
607402-73-3
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. for treatment of **malaria**)

IT 607402-74-4 607402-75-5 607402-76-6
607402-77-7 607402-79-9 607402-80-2

607402-81-3 607402-82-4 607402-83-5
607402-84-6 607402-85-7 607738-53-4 644995-53-9
685831-46-3 685831-47-4 685831-48-5
685831-49-6 685831-50-9 685831-51-0
685831-52-1 685832-62-6 685832-63-7
685832-64-8 685832-65-9 685832-66-0
685832-68-2 685832-71-7 685832-75-1
685832-82-0 685832-83-1 685832-84-2
685832-85-3 685832-86-4 685832-87-5
685832-88-6 685832-89-7 685832-90-0
685832-91-1 685832-92-2 685832-93-3
685832-94-4 685832-95-5 685832-96-6
685832-97-7 685832-98-8 685832-99-9
685833-00-5 685833-01-6 685833-02-7
685833-03-8 685833-04-9 685833-05-0
685833-06-1 685833-07-2 685833-08-3
685833-09-4 685833-10-7 685833-11-8
685833-12-9 685833-13-0 685833-14-1
685833-15-2 685833-16-3 685833-17-4
685833-18-5 685833-19-6 685833-20-9
685833-21-0 685833-22-1 685833-23-2
685833-24-3 685833-25-4 685833-26-5
685833-27-6 685833-28-7 685833-29-8
685833-30-1 685833-31-2 685833-32-3
685833-33-4 685833-34-5 685833-35-6
685833-36-7 685833-37-8 685833-38-9
685833-39-0 685833-40-3 685833-41-4
685833-42-5 685833-43-6 685833-44-7
685833-45-8 685833-46-9 685833-47-0
685833-48-1 685833-49-2 685833-50-5
685833-51-6 685833-52-7 685833-53-8
685833-54-9 685833-55-0 685833-56-1
685833-57-2 685833-66-3 685833-68-5
685833-69-6 685833-82-3 685834-60-0
685834-61-1 685834-62-2 685834-63-3
685834-71-3 685834-72-4 685834-74-6
685834-75-7 685834-76-8 685834-77-9
685834-83-7 685834-85-9 685834-88-2
685834-89-3 685834-91-7 685834-92-8
685834-93-9 685859-06-7 685859-07-8
685859-08-9 685859-09-0 685859-10-3
685859-11-4 685859-12-5 685859-14-7
685859-18-1 685859-19-2 685859-20-5
685859-21-6 685859-24-9 685859-28-3
685859-34-1 685859-35-2 685860-95-1
685860-96-2 685860-97-3 685860-98-4
685860-99-5 685861-00-1 685861-04-5
685861-07-8 685862-44-6 685881-89-4
685881-91-8
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. for treatment of ***malaria***)

IT 98-80-6, Phenylboronic acid 1066-54-2, Trimethylsilylacetylene 1679-18-1, 4-Chlorophenylboronic acid 1765-93-1, 4-Fluorophenylboronic acid 14047-29-1, p-Carboxyphenylboronic acid 35037-73-1, 4-Trifluoromethoxyphenyl isocyanate 59046-78-5, Minocycline bishydrochloride 685834-86-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(substituted tetracycline compds. for treatment of ***malaria***)

IT 263761-05-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(substituted tetracycline compds. for treatment of ***malaria***)

IT *808-26-4 914-00-1 2444-65-7 3242-03-3*
4495-20-9 5585-59-1 5874-95-3
5995-55-1 10118-89-5 15866-90-7
16145-05-4 19109-13-8 31642-30-5
35689-63-5 35689-65-7 53108-40-0
53108-41-1 53173-80-1 59046-79-6
82336-02-5 113164-67-3 120793-45-5
146253-71-6 146253-75-0 146278-01-5
146278-02-6 146278-03-7 149934-16-7
149934-19-0 151922-17-7 153621-68-2
155819-14-0 155819-18-4 161321-34-2
161452-37-5 186759-47-7 186759-49-9
186759-51-3 186759-53-5 186759-55-7
186759-61-5 220620-09-7 233585-94-9
233585-95-0 233585-96-1 233585-97-2
233586-02-2 233586-03-3 233586-04-4
233586-06-6 233586-08-8 233586-09-9
233586-10-2 233586-11-3 233586-12-4
263760-96-9 263760-98-1 263760-99-2
263761-01-9 263761-02-0 263761-08-6
295356-11-5 295356-13-7 295356-16-0
295356-17-1 330627-21-9 330627-22-0
330627-23-1 330627-24-2 330627-26-4
330627-29-7 330627-31-1 330627-32-2
344771-54-6 351336-92-0 351336-94-2
365276-98-8 365276-99-9 365277-00-5
365277-01-6 365277-02-7 365277-03-8
365277-04-9 365277-05-0 365277-06-1
365277-07-2 365277-08-3 365277-11-8
365277-12-9 365277-13-0 365277-14-1
365277-16-3 365277-19-6 365277-20-9
365277-21-0 365277-23-2 365277-24-3
365277-26-5 365277-28-7 365277-29-8
365277-33-4 365277-34-5 365277-35-6
365277-36-7 365277-37-8 365277-38-9
365277-39-0 365277-40-3 365277-41-4
365277-42-5 365277-43-6 365277-44-7
365277-45-8 365277-47-0 365277-48-1
365277-49-2 365277-50-5 365277-51-6
365277-52-7 365277-54-9 365277-55-0
365277-56-1 365277-57-2 365277-58-3
365277-59-4 365277-60-7 365277-61-8
365277-62-9 365277-63-0 365277-64-1
365277-65-2 365277-66-3 365277-88-9
374748-06-8 380435-62-1 380435-63-2
380435-65-4 380435-74-5 380435-76-7
380435-88-1 389081-55-4 389081-56-5
389081-57-6 389081-58-7 389081-59-8
389081-60-1 389081-61-2 389081-62-3
389081-64-5 389081-65-6 389081-66-7
389081-67-8 389081-68-9 389081-69-0
389081-71-4 389081-73-6 389081-74-7
389081-75-8 389081-76-9 389081-77-0
389081-78-1 389081-79-2 389081-80-5
389081-85-0 389139-10-0 389139-12-2

389139-15-5 389139-16-6 389139-17-7
389139-18-8 389139-19-9 389139-20-2
389139-21-3 389139-22-4 389139-23-5
389139-24-6 389139-25-7 389139-26-8
389139-27-9 389139-28-0 389139-29-1
389139-30-4 389139-31-5 389139-32-6
389139-33-7 389139-34-8 389139-35-9
389139-36-0 389139-37-1 389139-38-2
389139-39-3 389139-41-7 389139-42-8
389139-43-9 389139-44-0 389139-45-1
389139-46-2 389139-47-3 389139-48-4
389139-49-5 389139-50-8 389139-51-9
389139-52-0 389139-53-1 389139-54-2
389139-55-3 389139-56-4 389139-57-5
389139-58-6 389139-59-7 389139-60-0
389139-61-1 389139-62-2 389139-63-3
389139-64-4 389139-65-5 389139-66-6
389139-67-7 389139-68-8 389139-69-9
389139-70-2 389139-71-3 389139-72-4
389139-73-5 389139-74-6 389139-75-7
389139-76-8 389139-78-0 389139-79-1
389139-80-4 389139-81-5 389139-82-6
389139-83-7 389139-85-9 389139-86-0
389139-87-1
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. for treatment of ***malaria***)

RN 808-26-4 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 914-00-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S,4aR,5S,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 2444-65-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3242-03-3 HCAPLUS
CN 2-Naphthacenecarboxamide, 9-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4495-20-9 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4aR,5R,5aR,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 5585-59-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

[Remaining compounds were deleted to save paper]

L61 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:633439 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 141:167771
TITLE: Tetracycline compounds having target therapeutic activities
INVENTOR(S): Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 277 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064728	A2	20040805	WO 2004-US1036	20040116
WO 2004064728	A3	20041216		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

PRIORITY APPLN. INFO.: US 2003-441141P P 20030116
OTHER SOURCE(S): MARPAT 141:167771
AB Methods and compds. for treating diseases, e.g. inflammation process-associated states, with tetracycline compds. having a target therapeutic activity are described. Preparation of selected tetracycline

compds. is described.
IC ICM A61K
CC 1-7 (Pharmacology)
Section cross-reference(s): 26

L61 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:371069 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 140:386006
TITLE: Substituted tetracycline compounds for the treatment of ***malaria***
INVENTOR(S): Draper, Michael; Nelson, Mark L.
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038001	A2	20040506	WO 2003-US33927	20031024
WO 2004038001	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502464	AA	20040506	CA 2003-2502464	20031024
AU 2003287218	A1	20040513	AU 2003-287218	20031024
EP 1556007	A2	20050727	EP 2003-781398	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503898	T2	20060202	JP 2004-547165	20031024
PRIORITY APPLN. INFO.:			US 2002-421259P P	20021024
			WO 2003-US33927 W	20031024

OTHER SOURCE(S): MARPAT 140:386006
AB The invention provides a method for treating or preventing ***malaria*** in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound, such that ***malaria*** is treated or prevented. In one aspect, the invention relates to pharmaceutical compns. which include an effective amount of a tetracycline compound to treat ***malaria*** in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used to in combination with one or more ***antimalarial*** compds. or can be used to treat or prevent ***malaria*** which is resistant to one or more other ***antimalarial*** compds. Compound preparation is described.
IC ICM C12N
CC 1-5 (Pharmacology)
Section cross-reference(s): 25, 63
ST tetracycline deriv prepn ***malaria*** treatment
IT Sulfonamides
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and resistance to; tetracycline derivs. for ***malaria*** treatment)

IT Disease, animal
(malaise; tetracycline derivs. for ***malaria*** treatment)

IT Drug delivery systems
(prodrugs; tetracycline derivs. for ***malaria*** treatment)

IT Spleen, disease
(splenomegaly; tetracycline derivs. for ***malaria*** treatment)

IT Anemia (disease)
Antimalarials
Antimicrobial agents
Antipyretics
Drug delivery systems
Drug interactions
Drug resistance
Fever and Hyperthermia
Headache
Human
Malaria
Plasmodium (***malarial*** genus)
Plasmodium falciparum
Plasmodium ***malariae***
Plasmodium ovale
Plasmodium vivax
(tetracycline derivs. for ***malaria*** treatment)

IT Tetracyclines
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline derivs. for ***malaria*** treatment)

IT 54-05-7, Chloroquine 56-54-2, Quinidine 86-42-0, Amodiaquine 90-34-6, Primaquine 130-95-0, Quinine 500-92-5, Proguanil 537-21-3, Chlorproguanil 550-81-2, Amopyroquine 738-70-5, Trimethoprim 37338-39-9 37357-69-0 53230-10-7, Mefloquine 63968-64-9, Artemisinin 69756-53-2, Halofantrine 71963-77-4, Artemether 74847-35-1, Pyronaridine 82186-77-4, Lumefantrine 88495-63-0, Artesunate 95233-18-4, Atovaquone 123407-36-3, Arteflene 201849-42-5
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and resistance to; tetracycline derivs. for ***malaria*** treatment)

IT 60-54-8 79-57-2 127-33-3 564-25-0 ***808-26-4*** ***914-00-1*** 1665-56-1 ***2444-65-7 3242-03-3*** ***4495-20-9*** 4497-07-8 ***5585-59-1 5874-95-3*** ***5995-55-1 10118-89-5*** 10118-90-8 10236-47-2 ***15866-90-7 16145-05-4 19109-13-8*** ***31642-30-5 35689-63-5 35689-65-7*** ***53108-40-0 53108-41-1 53173-80-1*** ***59046-79-6*** 73351-16-3 ***82336-02-5 113164-67-3*** 115207-75-5 ***120793-45-5 146253-71-6*** ***146253-75-0 146278-01-5 146278-02-6*** ***146278-03-7 149934-16-7 149934-19-0*** ***151922-17-7 153621-68-2 155819-14-0*** ***155819-18-4 161321-34-2 161452-37-5*** ***186759-47-7 186759-49-9 186759-51-3*** ***186759-53-5 186759-55-7 186759-61-5*** ***220620-09-7 233585-94-9 233585-95-0*** ***233585-96-1 233585-97-2 233586-02-2*** ***233586-03-3 233586-04-4 233586-06-6***

233586-08-8 233586-09-9 233586-10-2
233586-11-3 233586-12-4 263760-96-9
263760-98-1 263760-99-2 263761-01-9
263761-02-0 263761-08-6 295356-11-5
295356-13-7 295356-16-0 295356-17-1
330627-21-9 330627-22-0 330627-23-1
330627-24-2 330627-26-4 330627-29-7
330627-31-1 330627-32-2 344771-54-6
351336-92-0 351336-94-2 365276-98-8
365276-99-9 365277-00-5 365277-01-6
365277-02-7 365277-03-8 365277-04-9
365277-05-0 365277-06-1 365277-07-2
365277-08-3 365277-11-8 365277-12-9
365277-13-0 365277-14-1 365277-16-3
365277-19-6 365277-20-9 365277-21-0
365277-23-2 365277-24-3 365277-26-5
365277-28-7 365277-29-8 365277-33-4
365277-34-5 365277-35-6 365277-36-7
365277-37-8 365277-38-9 365277-39-0
365277-40-3 365277-41-4 365277-42-5
365277-43-6 365277-44-7 365277-45-8
365277-47-0 365277-48-1 365277-49-2
365277-50-5 365277-51-6 365277-52-7
365277-54-9 365277-55-0 365277-56-1
365277-57-2 365277-58-3 365277-59-4
365277-60-7 365277-61-8 365277-62-9
365277-63-0 365277-64-1 365277-65-2
365277-66-3 365277-88-9 374748-06-8
380435-62-1 380435-63-2 380435-65-4
380435-74-5 380435-76-7 380435-88-1
389081-55-4 389081-56-5 389081-57-6
389081-58-7 389081-59-8 389081-60-1
389081-61-2 389081-62-3 389081-64-5
389081-65-6 389081-66-7 389081-67-8
389081-68-9 389081-69-0 389081-71-4
389081-73-6 389081-74-7 389081-75-8
389081-76-9 389081-77-0 389081-78-1
389081-79-2 389081-80-5 389081-85-0
389139-10-0 389139-12-2 389139-15-5
389139-16-6 389139-17-7 389139-18-8
389139-19-9 389139-20-2 389139-21-3
389139-22-4 389139-23-5 389139-24-6
389139-25-7 389139-26-8 389139-27-9
389139-28-0 389139-29-1 389139-30-4
389139-31-5 389139-32-6 389139-33-7
389139-34-8 389139-35-9 389139-36-0
389139-37-1 389139-38-2 389139-39-3
389139-41-7 389139-42-8 389139-43-9
389139-44-0 389139-45-1 389139-46-2 38913
9-47-3 389139-48-4 389139-49-5
389139-50-8 389139-51-9 389139-52-0
389139-53-1 389139-54-2 389139-55-3
389139-56-4 389139-57-5 389139-58-6
389139-59-7 389139-60-0 389139-61-1
389139-62-2 389139-63-3 389139-64-4
389139-65-5 389139-66-6 389139-67-7
389139-68-8 389139-69-9 389139-70-2
389139-71-3 389139-72-4 389139-73-5
389139-74-6 389139-75-7

RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(tetracycline derivs. for ***malaria*** treatment)

IT ***389139-76-8 389139-78-0 389139-79-1***
389139-80-4 389139-81-5 389139-82-6
389139-83-7 389139-85-9 389139-86-0
389139-87-1 389139-88-2 389139-89-3
389139-90-6 389139-91-7 389139-93-9
389139-94-0 389139-96-2 389139-97-3
389139-98-4 389139-99-5 389140-00-5
389140-01-6 389140-02-7 389140-03-8
389140-06-1 389570-43-8 389570-46-1
389570-48-3 389570-49-4 389570-50-7
389570-51-8 389570-52-9 389570-53-0
389570-54-1 389623-72-7 389623-74-9
389623-77-2 389623-80-7 389623-82-9
389623-86-3 389623-88-5 389623-89-6
389623-90-9 389623-91-0 389623-93-2
389623-95-4 389623-96-5 389623-97-6
389623-98-7 389623-99-8 389624-01-5
389624-03-7 389624-04-8 389624-05-9
389624-06-0 389624-07-1 389624-08-2
389624-09-3 389624-11-7 389624-12-8
389624-13-9 389624-14-0 389624-15-1
389624-16-2 389624-18-4 389624-19-5
389624-20-8 389624-21-9 389624-22-0
389624-23-1 389624-24-2 389624-26-4
389624-27-5 389624-28-6 389624-29-7
389624-30-0 389624-31-1 389624-32-2
389624-33-3 389624-34-4 389624-35-5
389624-36-6 389624-37-7 389624-38-8
389624-39-9 389624-40-2 389624-41-3
389624-42-4 389624-43-5 389624-44-6
389624-45-7 389624-46-8 389624-47-9
389624-48-0 389624-49-1 389624-51-5
389624-52-6 389624-53-7 389624-54-8
389624-55-9 389624-56-0 389624-57-1
389624-59-3 389624-60-6 389624-61-7
389624-62-8 389624-63-9 389624-64-0
389624-65-1 389624-66-2 389624-67-3
389624-68-4 389624-69-5 389624-70-8
389624-71-9 389624-72-0 389624-73-1
389624-74-2 389624-75-3 389624-76-4
389624-77-5 389624-78-6 389624-79-7
389624-80-0 389624-81-1 389624-82-2
389624-83-3 389624-84-4 389624-85-5
389624-86-6 389624-87-7 389624-88-8
389624-89-9 389624-90-2 389624-91-3
389624-92-4 389624-93-5 389624-94-6
389624-95-7 389624-96-8 389624-97-9
389624-98-0 389624-99-1 389625-00-7
389625-01-8 389625-02-9 389625-03-0
389625-04-1 389625-05-2 389625-06-3
389625-07-4 389625-09-6 389625-10-9
389625-11-0 389625-12-1 439217-57-9
439217-59-1 459425-79-7 459425-80-0
459425-96-8 459426-11-0 459809-42-8
459809-43-9 459809-44-0 459809-45-1
459809-46-2 459809-47-3 459809-48-4

459809-49-5 459809-50-8 459809-51-9
459809-52-0 459809-53-1 459809-54-2
459809-55-3 459809-57-5 459809-58-6
459809-59-7 459809-61-1 459809-63-3
459809-65-5 459809-66-6 459809-67-7
459809-68-8 459809-70-2 459809-74-6 45980
9-76-8 459809-77-9 459809-79-1
459809-81-5 459809-82-6 459809-86-0
459809-88-2 459809-91-7 459809-92-8
459809-95-1 459809-96-2 459809-97-3
459809-98-4 459809-99-5 459810-00-5
459810-01-6 459810-02-7 459810-03-8
459810-04-9 459810-06-1 459810-07-2
459810-08-3 459810-09-4 460068-27-3
460068-29-5 460068-30-8 460068-31-9
460068-32-0 460068-33-1 460068-34-2
460068-35-3 460068-36-4 460068-38-6
460068-39-7 460068-40-0 460068-41-1
460068-42-2 460068-43-3 460068-44-4
460068-45-5 460068-46-6 460068-47-7
460068-48-8 460068-49-9 460068-50-2
460068-51-3 460068-52-4 460068-53-5
460068-54-6 460068-55-7
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tetracycline derivs. for **malaria** treatment)

IT 460068-57-9 460068-58-0 460068-59-1
460068-60-4 460068-61-5 460068-62-6
460068-63-7 460068-64-8 460068-65-9
460068-66-0 460068-67-1 460068-68-2
460068-69-3 460068-70-6 460068-71-7
460068-72-8 460068-73-9 460068-74-0
460068-75-1 460068-76-2 460068-77-3
460068-78-4 460068-79-5 460068-80-8
460068-81-9 460068-82-0 460068-84-2
460068-85-3 460068-86-4 460068-87-5
460068-88-6 460068-90-0 460068-92-2
460068-93-3 460068-94-4 460068-95-5
460068-96-6 460068-97-7 460068-99-9
460069-34-5 460069-38-9 460069-65-2
460069-70-9 460069-89-0 460069-96-9
460070-02-4 460070-03-5 460070-53-5
460070-61-5 460070-66-0 460070-73-9
460070-76-2 460070-79-5 460070-92-2
460070-95-5 460071-02-7 460071-04-9
460071-06-1 460071-09-4 460071-12-9
460071-14-1 460071-17-4 460071-19-6
460071-29-8 460071-33-4 460071-37-8
460071-66-3 460071-69-6 460071-80-1
460071-83-4 460071-87-8 460071-89-0
460071-91-4 460071-93-6 460071-97-0
460071-99-2 460072-01-9 460072-03-1
460072-05-3 460072-07-5 460072-09-7
460072-10-0 460072-12-2 460072-15-5
460072-17-7 460072-19-9 460072-21-3
460072-25-7 460072-28-0 460072-29-1
460072-30-4 460072-31-5 460072-33-7
460072-36-0 460072-40-6 460072-43-9
460072-45-1 460072-47-3 460072-49-5

460072-59-7 460072-63-3 460072-65-5
460072-70-2 460072-73-5 460072-75-7
460072-78-0 460072-82-6 460072-86-0
460072-89-3 460072-91-7 460072-93-9
460073-01-2 460073-03-4 460073-05-6
460073-07-8 460073-09-0 460073-11-4
460073-15-8 460073-17-0 460073-21-6
460073-22-7 460073-23-8 460073-25-0
460073-27-2 460073-29-4 460073-31-8
460073-35-2 460073-37-4 460073-40-9
460073-41-0 460073-43-2 460073-45-4
460073-47-6 460073-49-8 460073-51-2
460073-53-4 460073-55-6 460073-58-9
460073-62-5 460073-64-7 460073-68-1
460073-70-5 460073-72-7 460073-74-9
460073-76-1 460073-78-3 460073-80-7
460073-82-9 460073-84-1 460073-86-3
460073-88-5 460073-90-9 460073-92-1
460073-94-3 460073-96-5 460073-98-7
460074-00-4 460074-02-6 460074-04-8
460074-06-0 460074-09-3 460074-11-7
460074-13-9 460074-15-1 460074-19-5
460074-21-9 460074-23-1 460074-26-4
460074-28-6 460074-30-0 460074-34-4
460074-36-6 460074-38-8 460074-40-2
460074-42-4 460074-44-6 460074-46-8
460074-48-0 460074-50-4 460074-52-6
460074-54-8 460074-56-0 460074-58-2
460074-60-6 460074-62-8 460074-64-0
460074-66-2 460074-68-4 460074-69-5
460074-71-9 460074-73-1 460074-75-3
460074-77-5 460074-79-7 460074-81-1
460074-83-3 460074-85-5 460074-87-7
460074-89-9 460074-91-3 460074-93-5
460074-95-7 460074-97-9 460074-99-1
460075-04-1 460075-06-3 460075-08-5
460075-12-1 460075-14-3 460075-62-1
460076-23-7 460082-77-3 460082-87-5
460082-89-7 460082-90-0 460082-91-1
473972-91-7 473973-13-6 473973-20-5
473973-34-1 473973-37-4 473973-41-0
473973-62-5 473973-64-7 473973-86-3
473973-96-5 473974-12-8 473974-75-3
473974-76-4 473974-77-5 473974-79-7
473974-80-0 473974-81-1 473974-82-2
473974-83-3 473974-84-4
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tetracycline derivs. for **malaria** treatment)

IT 473974-85-5 488815-44-7 488815-46-9
488815-47-0 488815-49-2 488815-52-7
488815-53-8 488815-54-9 488815-55-0
488815-56-1 488815-57-2 488815-58-3
488815-59-4 488815-60-7 488815-61-8
488815-62-9 488815-63-0 488815-64-1
488815-65-2 488815-66-3 488815-68-5
488815-69-6 488815-71-0 488815-72-1
488815-73-2 488815-74-3 488815-75-4
488815-76-5 488815-77-6 488815-78-7

488815-80-1 488815-82-3 488815-89-0
488815-93-6 488815-98-1 488816-00-8
488816-13-3 488816-16-6 488816-18-8
488816-19-9 488816-26-8 488816-37-1
488816-39-3 488816-42-8 488816-54-2
488816-64-4 488816-65-5 488816-70-2
488816-71-3 488816-73-5 488816-75-7
488816-82-6 488816-88-2 488816-92-8
488816-93-9 488816-98-4 488817-01-2
488817-06-7 488817-11-4 488817-13-6
488817-14-7 488817-15-8 488817-16-9
488817-17-0 488817-18-1 488817-19-2 488817-20-5
488817-21-6 488817-22-7 488817-23-8
488817-24-9 488817-25-0 488817-26-1
488817-27-2 488817-28-3 488817-29-4
488817-30-7 488817-31-8 488817-32-9
488817-33-0 488817-35-2 488817-36-3
488817-37-4 488817-38-5 488817-39-6
488817-41-0 488817-42-1 488817-44-3
488817-45-4 488817-46-5 488817-47-6
488817-48-7 488817-49-8 488817-50-1
488817-51-2 488817-52-3 488817-53-4
488817-54-5 488817-55-6 488817-56-7
488817-57-8 488817-58-9 488817-59-0
488817-60-3 488817-61-4 488817-62-5
488817-63-6 488817-64-7 488817-65-8
488817-67-0 488817-68-1 488817-73-8
488817-75-0 488817-76-1 488817-79-4
488817-80-7 488817-82-9 488817-89-6
488817-91-0 488817-92-1 488817-94-3
488817-95-4 488817-96-5 488817-97-6
488818-04-8 488818-06-0 488818-07-1
488818-08-2 488818-10-6 488818-11-7
488818-12-8 488818-13-9 488818-14-0
488818-16-2 488818-17-3 488818-18-4
488818-19-5 488818-20-8 488818-21-9
488818-23-1 488818-25-3 488818-27-5
488818-28-6 488818-29-7 488818-30-0
488818-31-1 488818-32-2 488818-33-3 48881
8-34-4 488818-35-5 488818-36-6
488818-37-7 488818-38-8 488818-39-9
488818-40-2 488818-41-3 488818-42-4
488818-43-5 488818-44-6 488818-45-7
488818-46-8 488818-47-9 488818-48-0
488818-49-1 488818-50-4 488818-51-5
488818-52-6 488818-53-7 488818-54-8
488818-55-9 488818-56-0 488818-57-1
488818-58-2 488818-59-3 488818-60-6
488818-61-7 488818-63-9 488818-64-0
488818-65-1 488818-66-2 488818-67-3
488818-68-4 488818-69-5 488818-70-8
488818-71-9 488818-72-0 488818-73-1
488818-74-2 488818-75-3 488818-76-4
488818-77-5 488818-78-6 488818-79-7
488818-80-0 488818-81-1 488818-82-2
488818-83-3 488818-84-4 488818-85-5
488818-86-6 488818-87-7 488818-88-8
488818-89-9 488818-90-2 488818-91-3
488818-92-4 488818-93-5 488818-94-6

488818-95-7 488818-97-9 488818-98-0
488818-99-1 488819-00-7 488819-01-8
488819-02-9 488819-03-0 488819-04-1
488819-05-2 488819-06-3 488819-07-4
488819-08-5 488819-14-3 488819-16-5
488819-17-6 488819-18-7 488819-19-8
488819-20-1 488819-21-2 488819-22-3
488819-23-4 488819-24-5 488819-25-6
488819-26-7 488819-27-8 488819-28-9
488819-29-0
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(tetracycline derivs. for ***malaria*** treatment)

IT *488819-30-3 488819-31-4 488819-32-5*
488819-33-6 488819-34-7 488819-35-8
488819-36-9 488819-37-0 488819-38-1
488819-39-2 488819-40-5 488819-41-6
488819-42-7 488819-43-8 488819-44-9
488819-45-0 488819-46-1 488819-47-2
488819-48-3 488819-49-4 488819-50-7
488819-52-9 488819-53-0 488819-54-1
488819-55-2 488819-56-3 488819-57-4
488819-58-5 488819-59-6 488819-60-9
488819-61-0 488819-62-1 488819-63-2
488819-64-3 488819-65-4 488819-66-5
488819-67-6 488819-68-7 488819-69-8
488819-70-1 488819-71-2 488819-72-3
488819-73-4 488819-74-5 488819-75-6
488819-76-7 488819-77-8 488819-78-9
488819-79-0 488819-80-3 488819-82-5
488819-84-7 488819-85-8 488819-86-9
488819-87-0 488819-88-1 488819-89-2
488819-90-5 488819-91-6 488819-92-7
488819-93-8 488819-94-9 488819-95-0
488819-96-1 488819-97-2 488819-98-3
488819-99-4 488820-00-4 488820-01-5
488820-02-6 488820-03-7 488820-04-8
488820-05-9 488820-06-0 488820-07-1 *488820-09-3*
488820-10-6 488820-11-7 488820-12-8
488820-13-9 488820-14-0 488820-15-1
488820-16-2 488820-17-3 488820-18-4
488820-19-5 488820-20-8 488820-21-9
488820-22-0 488820-23-1 488820-24-2
488820-25-3 488820-26-4 488820-27-5
488820-28-6 488820-29-7 488820-30-0
488820-31-1 488820-32-2 488820-33-3
488820-34-4 488820-43-5 488820-48-0
577795-55-2 577795-64-3 601454-79-9
601454-80-2 601454-82-4 601454-85-7
601454-92-6 601454-95-9 601454-97-1
601454-98-2 601454-99-3 601455-02-1
601455-03-2 601455-04-3 601455-05-4
601455-07-6 601455-09-8 601455-11-2
601455-12-3 601455-13-4 601455-15-6
601455-16-7 601455-17-8 601455-18-9
601455-19-0 601455-20-3 601455-21-4
601455-22-5 601455-23-6 601455-24-7
601455-25-8 601455-26-9 601455-27-0
601455-29-2 601455-30-5 601455-31-6

601455-32-7 601455-33-8 601455-34-9
601455-35-0 601455-36-1 601455-37-2
601455-38-3 601455-39-4 601455-41-8
601455-42-9 601455-43-0 601455-44-1
601455-45-2 601455-46-3 601455-47-4
601455-49-6 601455-50-9 601455-52-1
601455-53-2 601455-54-3 601455-55-4
601455-56-5 601455-57-6 601455-58-7
601455-60-1 601455-62-3 601455-63-4
601455-65-6 601455-66-7 601455-67-8
601455-68-9 601455-69-0 601455-71-4
601455-72-5 601455-73-6 601455-75-8
601455-76-9 601455-77-0 601455-78-1
601455-79-2 601455-80-5 601455-81-6
601455-83-8 601455-84-9 601455-85-0
601455-86-1 601455-87-2 601455-89-4
601455-90-7 601455-91-8 601455-92-9
601455-95-2 601470-72-8 607400-44-2
607400-46-4 607400-50-0 607400-72-6
607401-16-1 607401-26-3 607401-28-5
607401-38-7 607401-41-2 607401-43-4
607401-45-6 607401-48-9 607401-54-7
607401-57-0 607401-59-2 607401-63-8
607401-65-0 607401-67-2 607401-69-4
607401-71-8 607401-73-0 607401-75-2
607401-77-4 607401-79-6 607401-81-0
607401-83-2 607401-86-5 607401-98-9
607402-03-9 607402-08-4 607402-10-8
607402-12-0 607402-14-2 607402-16-4
607402-18-6 607402-20-0 607402-22-2
607402-24-4 607402-28-8 607402-58-4
607402-71-1 607402-72-2 607402-73-3
607402-74-4
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(tetracycline derivs. for ***malaria*** treatment)

IT 607402-75-5 607402-76-6 607402-77-7
607402-79-9 607402-80-2 607402-81-3
607402-82-4 607402-83-5 607402-84-6
607402-85-7 607738-53-4 644995-53-9 685831-46-3
685831-47-4 685831-48-5 685831-49-6
685831-50-9 685831-51-0 685831-52-1
685832-62-6 685832-63-7 685832-64-8
685832-65-9 685832-66-0 685832-68-2
685832-71-7 685832-75-1 685832-82-0
685832-83-1 685832-84-2 685832-85-3
685832-86-4 685832-87-5 685832-88-6
685832-89-7 685832-90-0 685832-91-1
685832-92-2 685832-93-3 685832-94-4
685832-95-5 685832-96-6 685832-97-7
685832-98-8 685832-99-9 685833-00-5
685833-01-6 685833-02-7 685833-03-8
685833-04-9 685833-05-0 685833-06-1
685833-07-2 685833-08-3 685833-09-4
685833-10-7 685833-11-8 685833-12-9
685833-13-0 685833-14-1 685833-15-2
685833-16-3 685833-17-4 685833-18-5
685833-19-6 685833-20-9 685833-21-0
685833-22-1 685833-23-2 685833-24-3

685833-25-4 685833-26-5 685833-27-6
685833-28-7 685833-29-8 685833-30-1
685833-31-2 685833-32-3 685833-33-4
685833-34-5 685833-35-6 685833-36-7
685833-37-8 685833-38-9 685833-39-0
685833-40-3 685833-41-4 685833-42-5
685833-43-6 685833-44-7 685833-45-8
685833-46-9 685833-47-0 685833-48-1
685833-49-2 685833-50-5 685833-51-6
685833-52-7 685833-53-8 685833-54-9
685833-55-0 685833-56-1 685833-57-2
685833-66-3 685833-68-5 685833-69-6
685833-82-3 685834-60-0 685834-61-1
685834-62-2 685834-63-3 685834-71-3
685834-72-4 685834-74-6 685834-75-7
685834-76-8 685834-77-9 685834-83-7
685834-85-9 685834-88-2 685834-89-3
685834-91-7 685834-92-8 685834-93-9
685859-06-7 685859-07-8 685859-08-9
685859-09-0 685859-10-3 685859-11-4
685859-12-5 685859-14-7 685859-18-1
685859-19-2 685859-20-5 685859-21-6
685859-24-9 685859-28-3 685859-34-1
685859-35-2 685860-95-1 685860-96-2
685860-97-3 685860-98-4 685860-99-5
685861-00-1 685861-04-5 685861-07-8
685862-44-6 685881-89-4 685881-91-8
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tetracycline derivs. for **malaria** treatment)

IT 98-80-6, Phenylboronic acid 1066-54-2, Trimethylsilylacetylene 1679-18-1, 4-Chlorophenylboronic acid 1765-93-1, 4-Fluorophenylboronic acid 14047-29-1, p-Carboxyphenylboronic acid 59046-78-5 158626-12-1 685834-86-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(tetracycline derivs. for **malaria** treatment)

IT 263761-05-3P, 7-Ethynylsancycline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tetracycline derivs. for **malaria** treatment)

IT 389140-04-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(tetracycline derivs. for **malaria** treatment)

IT 808-26-4 914-00-1 2444-65-7 3242-03-3
4495-20-9 5585-59-1 5874-95-3
5995-55-1 10118-89-5 15866-90-7
16145-05-4 19109-13-8 31642-30-5
35689-63-5 35689-65-7 53108-40-0
53108-41-1 53173-80-1 59046-79-6
82336-02-5 113164-67-3 120793-45-5
146253-71-6 146253-75-0 146278-01-5
146278-02-6 146278-03-7 149934-16-7
149934-19-0 151922-17-7 153621-68-2
155819-14-0 155819-18-4 161321-34-2
161452-37-5 186759-47-7 186759-49-9
186759-51-3 186759-53-5 186759-55-7
186759-61-5 220620-09-7 233585-94-9
233585-95-0 233585-96-1 233585-97-2
233586-02-2 233586-03-3 233586-04-4

233586-06-6 233586-08-8 233586-09-9
233586-10-2 233586-11-3 233586-12-4
263760-96-9 263760-98-1 263760-99-2
263761-01-9 263761-02-0 263761-08-6
295356-11-5 295356-13-7 295356-16-0
295356-17-1 330627-21-9 330627-22-0
330627-23-1 330627-24-2 330627-26-4
330627-29-7 330627-31-1 330627-32-2
344771-54-6 351336-92-0 351336-94-2
365276-98-8 365276-99-9 365277-00-5
365277-01-6 365277-02-7 365277-03-8
365277-04-9 365277-05-0 365277-06-1
365277-07-2 365277-08-3 365277-11-8
365277-12-9 365277-13-0 365277-14-1
365277-16-3 365277-19-6 365277-20-9
365277-21-0 365277-23-2 365277-24-3
365277-26-5 365277-28-7 365277-29-8
365277-33-4 365277-34-5 365277-35-6
365277-36-7 365277-37-8 365277-38-9
365277-39-0 365277-40-3 365277-41-4
365277-42-5 365277-43-6 365277-44-7
365277-45-8 365277-47-0 365277-48-1
365277-49-2 365277-50-5 365277-51-6
365277-52-7 365277-54-9 365277-55-0
365277-56-1 365277-57-2 365277-58-3
365277-59-4 365277-60-7 365277-61-8
365277-62-9 365277-63-0 365277-64-1
365277-65-2 365277-66-3 365277-88-9
374748-06-8 380435-62-1 380435-63-2
380435-65-4 380435-74-5 380435-76-7
380435-88-1 389081-55-4 389081-56-5
389081-57-6 389081-58-7 389081-59-8
389081-60-1 389081-61-2 389081-62-3
389081-64-5 389081-65-6 389081-66-7
389081-67-8 389081-68-9 389081-69-0
389081-71-4 389081-73-6 389081-74-7
389081-75-8 389081-76-9 389081-77-0
389081-78-1 389081-79-2 389081-80-5
389081-85-0 389139-10-0 389139-12-2
389139-15-5 389139-16-6 389139-17-7
389139-18-8 389139-19-9 389139-20-2
389139-21-3 389139-22-4 389139-23-5
389139-24-6 389139-25-7 389139-26-8
389139-27-9 389139-28-0 389139-29-1
389139-30-4 389139-31-5 389139-32-6
389139-33-7 389139-34-8 389139-35-9
389139-36-0 389139-37-1 389139-38-2
389139-39-3 389139-41-7 389139-42-8
389139-43-9 389139-44-0 389139-45-1
389139-46-2 389139-47-3 389139-48-4
389139-49-5 389139-50-8 389139-51-9
389139-52-0 389139-53-1 389139-54-2
389139-55-3 389139-56-4 389139-57-5
389139-58-6 389139-59-7 389139-60-0
389139-61-1 389139-62-2 389139-63-3
389139-64-4 389139-65-5 389139-66-6
389139-67-7 389139-68-8 389139-69-9
389139-70-2 389139-71-3 389139-72-4
389139-73-5 389139-74-6 389139-75-7

389139-76-8 389139-78-0 389139-79-1
389139-80-4 389139-81-5 389139-82-6
389139-83-7 389139-85-9 389139-86-0
389139-87-1
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(tetracycline derivs. for ***malaria*** treatment)

RN 808-26-4 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 914-00-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S,4aR,5S,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 2444-65-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3242-03-3 HCAPLUS
CN 2-Naphthacenecarboxamide, 9-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4495-20-9 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4aR,5R,5aR,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 5585-59-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

[Remaining compounds were deleted to save paper]

L61 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:41226 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 140:105321
TITLE: Methods and compositions relating to isoleucine boroproline compounds
INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709
WO 2004004658	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491466	AA	20040115	CA 2003-2491466	20030709
AU 2003265264	A1	20040123	AU 2003-265264	20030709
US 2004077601	A1	20040422	US 2003-616694	20030709
US 2005084490	A1	20050421	US 2003-616409	20030709
EP 1578434	A2	20050928	EP 2003-763380	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507352	T2	20060302	JP 2004-562634	20030709
CN 1802090	A	20060712	CN 2003-821282	20030709

PRIORITY APPLN. INFO.:

US 2002-394856P	P	20020709
US 2002-414978P	P	20021001
US 2003-466435P	P	20030428
WO 2003-US21405	W	20030709

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COA1R) (where Am and A1 are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptiolyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α-aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

IC ICM A61K
CC 1-12 (Pharmacology)
Section cross-reference(s): 15
IT Acute lymphocytic leukemia
Acute myeloid leukemia
Angiogenesis inhibitors

Anti-infective agents
Antibacterial agents
Antibacterial agents
Antibiotics
Antiemetics
Antimicrobial agents
Antitumor agents
Antiviral agents
Biliary tract, neoplasm
Bladder, neoplasm
Bone, neoplasm
Brain, neoplasm
Central nervous system, neoplasm
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Digestive tract, neoplasm
Drug delivery systems
Esophagus, neoplasm
Eye, neoplasm
Fungicides
Head and Neck
Head and Neck, neoplasm
Hodgkin's disease
Human
Immunodeficiency
Immunostimulants
Infection
Influenza A virus
Kidney, neoplasm
Larynx, neoplasm
Leprosy
Leukemia
Liver, neoplasm
Lymphoma
Malaria
Mammary gland, neoplasm
Melanoma
Mouth, neoplasm
Multiple myeloma
Multiple sclerosis
Mycosis
Nausea
Neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Parasiticides
Prostate gland, neoplasm
Radiotherapy
Respiratory system, neoplasm
Sarcoma
Skin, neoplasm
Staphylococcus
Stomach, neoplasm
Testis, neoplasm
Thyroid gland, neoplasm
Tuberculosis
Tuberculostatics
Urinary system, neoplasm
Uterus, neoplasm

Vaccines
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT 50-18-0, Cyclophosphamide 50-44-2 50-59-9, Cephaloridine 50-63-5, Chloroquine phosphate 50-65-7, Niclosamide 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, Fluorouracil 52-68-6, Metrifonate 53-03-2, Prednisone 54-42-2, Idoxuridine 54-85-3, Isoniazid 55-86-7, Mechlorethamine hydrochloride 56-75-7, Chloramphenicol 57-62-5, Chlortetracycline 57-68-1, Sulfamethazine 57-92-1, Streptomycin, biological studies 58-71-9, Cephalothin sodium 59-05-2, Methotrexate 60-54-8, Tetracycline 61-32-5, Methicillin 63-45-6, Primaquine phosphate 64-72-2, Chlortetracycline hydrochloride 64-73-3, Demeclocycline hydrochloride 64-75-5, Tetracycline hydrochloride 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 68-35-9, Sulfadiazine 68-41-7, Cycloserine 69-05-6, Quinacrine hydrochloride 69-52-3, Ampicillin sodium 69-53-4, Ampicillin 69-57-8, Penicillin g sodium 69-74-9, Cytarabine hydrochloride 70-00-8, Trifluridine 70-10-0, Ticlatone 72-14-0, Sulfathiazole 74-55-5, Ethambutol 77-46-3, Acedapsone 79-57-2, Oxytetracycline 80-08-0, Dapsone 80-74-0, Sulfisoxazole acetyl 83-73-8, Iodoquinol 87-08-1, Penicillin v 88-04-0, Chloroxylenol 90-89-1, Diethylcarbamazine 97-18-7, Bithionol 98-96-4, Pyrazinamide 100-97-0, Methenamine, biological studies 102-76-1, Triacetin 106-48-9 110-85-0, Piperazine, biological studies 112-38-9, Undecylenic acid 113-98-4, Penicillin g potassium 114-07-8, Erythromycin 115-02-6, Azaserine 121-19-7, Roxarsone 121-81-3, Nitromide 122-16-7, Sulfanitran 124-07-2, Octanoic acid, biological studies 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-56-0, Sulfacetamide sodium 127-69-5, Gantrisin 127-71-9, Sulfabenzamide 127-77-5, Sulfabenz 127-79-7, Sulfamerazine 128-12-1, Acetosulfone sodium 130-16-5, Cloxyquin 132-92-3, Methicillin sodium 132-98-9, Penicillin v potassium 133-10-8, p-Aminosalicylate sodium 133-11-9, Phenyl aminosalicylate 133-51-7, Meglumine antimoniate 134-36-1, Erythromycin propionate 137-26-8, Thiram 138-39-6, Mafenide 140-64-7, Pentamidine isethionate 143-67-9, Vinblastine sulfate 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 145-63-1, Suramin 147-52-4, Nafcillin 147-94-4, Cytarabine 148-79-8, Thiabendazole 148-82-3, Melphalan 152-47-6, Sulfalene 153-61-7, Cephalothin 154-21-2, Lincomycin 288-32-4, Imidazole, biological studies 288-32-4D, Imidazole, derivs. 305-03-3, Chlorambucil 343-55-5, Dicloxacillin sodium 366-70-1, Procarbazine hydrochloride 389-08-2, Nalidixic acid 443-48-1, Metronidazole 494-79-1, Melarsoprol 500-92-5, Proguanil 527-75-3, Berythromycin 528-96-1, Benzoylpas calcium 530-43-8, Chloramphenicol palmitate 536-33-4, Ethionamide 547-32-0, Sulfadiazine sodium 554-72-3, Tryparsamide 555-84-0, Nifuradene 557-08-4, Zinc undecyl enate 564-25-0, Doxycycline 575-54-2, Penicillins 587-23-5, Methenamine mandelate 599-79-1, Sulfasalazine 632-00-8, Sulfasomizole 642-78-4, Cloxacillin sodium 643-22-1, Erythromycin stearate 651-06-9, Sulfameter 665-66-7, Amantadine hydrochloride 723-46-6, Sulfamethoxazole 729-99-7, Sulfamoxole 735-52-4, Cetophenicol 738-70-5, Trimethoprim 751-94-0, Fusidate sodium ***751-97-3***, Rolitetracycline 768-94-5, Amantadine 777-11-7, Haloprogin 801-52-5, Porfiromycin 804-63-7, Quinine sulfate ***808-26-4***, Sancycline 847-25-6, Racephenicol 852-19-7, Sulfazamet 859-18-7, Lincomycin hydrochloride 909-14-8 ***914-00-1***, Methacycline 982-57-0, Chloramphenicol sodium succinate 983-85-7, Penamecillin 985-16-0, Nafcillin sodium ***987-02-0***, Demecycline 1018-71-9, Pyrrolnitrin 1070-11-7,

Ethambutol hydrochloride 1173-88-2, Oxacillin sodium 1220-83-3, Sulfamonomethoxine 1264-62-6, Erythromycin ethyl succinate 1264-72-8, Colistin sulfate 1322-14-1, Calcium undecylenate 1336-20-5, Tetracycline phosphate complex 1392-21-8, Kitasamycin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1402-82-0, Amphomycin 1403-17-4, Candicidin 1403-66-3, Gentamicin 1403-71-0, Hamycin 1404-00-8, Mitomycin 1404-08-6, Neutramycin 1404-48-4, Relomycin 1404-59-7, Rutamycin 1404-88-2, Tyrothricin 1404-90-6, Vancomycin 1404-93-9, Vancomycin hydrochloride 1405-00-1, Viridofulvin 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin b sulfate 1405-37-4, Capreomycin sulfate 1405-41-0, Gentamicin sulfate 1405-52-3, Sulfomyxin 1405-87-4, Bacitracin 1405-89-6, Bacitracin zinc 1405-97-6, Gramicidin 1406-04-8, Neomycin undecyl enate 1406-11-7, Polymyxin 1432-75-3, Nitralamine hydrochloride 1476-53-5, Novobiocin sodium 1501-84-4, Rimantadine hydrochloride 1538-09-6 1617-53-4, Amentoflavone 1910-68-5, Methisazone ***2013-58-3***, Meclocycline 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2058-46-0, Oxytetracycline hydrochloride 2068-78-2, Vincristine sulfate 2398-96-1, Tolnaftate 2447-57-6, Sulfadoxine 2750-76-7, Rifamide 2751-09-9, Troleandomycin 3056-17-5, Stavudine 3116-76-5, Dicloxacillin 3270-71-1, Nifuraldezone 3374-05-8, Nalidixate sodium 3424-98-4 3485-14-1, Cyclacillin 3511-16-8, Hetacillin 3521-62-8, Erythromycin estolate 3545-67-3, Chloroquine hydrochloride 3570-75-0, Nifurthiazole 3577-01-3, Cephaloglycin 3696-28-4, Dipyrithione 3736-81-0, Diloxanide furoate 3778-73-2, Ifosfamide 3795-88-8, Levofuraltadone 3810-74-0, Streptomycin sulfate 3847-29-8, Erythromycin lactobionate 3922-90-5, Oleandomycin ***3963-95-9***, Methacycline hydrochloride 4117-65-1, Aspartocin 4197-24-4, Carbol-fuchsin 4291-63-8, Cladribine 4299-60-9, Sulfisoxazole diolamine 4342-03-4, Dacarbazine 4375-07-9D, Epipodophyllotoxin, antibody conjugates 4428-95-9 4575-42-2, Coumermycin sodium 4697-36-3, Carbenicillin 4800-94-6, Carbenicillin disodium 4803-44-5, Levopropylcillin potassium 4803-45-6, Thiphencillin potassium 4914-30-1, Dehydroemetine 4936-47-4, Nifuratel 5036-03-3, Nifurdazil 5055-20-9, Nifurquinazol 5118-17-2, Furazolium chloride 5250-39-5, Floxacillin 5321-32-4, Hetacillin potassium 5355-16-8, Diaveridine 5490-27-7, Dihydrostreptomycin sulfate 5536-17-4, Vidarabine 5560-62-3, Biphenamine hydrochloride 5578-73-4, Sanguinarium chloride 5579-95-3, Nifurmerone ***5585-59-1***, Nitrocycline 5588-20-5, Chlordantoin 5667-71-0, Streptonicozid 5714-05-6, Quindecamine acetate 5714-73-8, Methenamine hippurate ***5874-95-3***, Amicycline 5928-84-7, Penicillin v benzathine
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT 5980-31-4, Hexedine 6576-51-8, Stallimycin hydrochloride 6591-72-6, Penicillin v hydrabamine 6804-07-5, Carbadox 6981-18-6, Ormetoprim 6990-06-3, Fusidic acid 7054-25-3, Quinidine gluconate 7179-50-2, Oxytetracycline calcium 7481-89-2, Zalcitabine 7527-91-5, Acrisorcin 7542-37-2, Paromomycin 7681-11-0, Potassium iodide, biological studies 7681-93-8, Natamycin 8017-57-0D, Trisulfapyrimidine, derivs. 8025-81-8, Spiramycin 8063-07-8, Kanamycin 8063-91-0, Mirincamycin hydrochloride 8064-90-2 8068-28-8, Colistimethate sodium 9001-06-3, Chitinase 9015-68-3, Asparaginase 9041-93-4, Bleomycin sulfate 10118-85-1, Lydimycin 10118-90-8, Minocycline 10500-82-0, Famotine hydrochloride 10540-97-3, Memotine hydrochloride 11006-76-1, Virginiamycin 11006-77-2, Statolon 11015-37-5, Bambermycin 11016-07-2, Fungimycin 11033-34-4, Steffimycin 11048-13-8, Nebramycin

11048-15-0, Kalafungin 11051-71-1, Avilamycin 11056-09-0, Ranimycin 11056-11-4, Biniramycin 11056-12-5, Cirolemycin 11056-13-6, Denofungin 11056-18-1, Scopafungin 11056-20-5, Zorbamycin 11078-21-0, Filipin 11096-49-4, Partricin 11096-79-0, Alamecin 11111-12-9, Cephalosporin 11121-32-7, Mepartricin 13292-46-1, Rifampin 13292-46-1D, Rifampin, derivs. 13392-28-4, Rimantadine 13411-16-0, Nifurpirinol 13463-41-7, Pyrithione zinc 13614-98-7, Minocycline hydrochloride 14088-71-2, Proclonol 14698-29-4, Oxolinic acid 15037-55-5, Ethonam nitrate 15176-29-1, Edoxudine 15318-45-3, Thiamphenicol 15475-56-6, Methotrexate sodium 15663-27-1, Cisplatin 15686-71-2, Cephalexin 16037-91-5, Stibogluconate sodium 16846-24-5, Josamycin 16915-79-0, Mequidox 17090-79-8, Monensin 17230-86-3, Carbenicillin potassium 17692-15-8, Furazolium tartrate 17784-12-2, Sulfacytine 18323-44-9, Clindamycin 19387-91-8, Tinidazole 19561-70-7, Nifuratrone 19885-51-9, Aranotin ***20685-78-3***, Rolitetracycline nitrate 21462-39-5, Clindamycin hydrochloride 21593-23-7, Cephapirin 21638-36-8, Nifurimide 21649-57-0, Carbenicillin phenylsodium 21679-14-1, Fludarabine 21736-83-4, Spectinomycin hydrochloride 21738-42-1, Oxamniquine 22204-24-6, Pyrantel pamoate 22373-78-0, Monensin sodium 22484-64-6, Sulfanilate zinc 22573-93-9, Alexidine 22832-87-7, Miconazole nitrate 22916-38-7, Orconazole nitrate 22916-47-8, Miconazole 22994-85-0, Benznidazole 23067-13-2, Erythromycin gluceptate 23155-02-4, Fosfomycin 23214-92-8, Doxorubicin 23239-41-0, Cephacetrile sodium 23256-30-6, Nifurtimox ***23313-80-6***, Epitetracycline hydrochloride 23319-48-4, Megalomicin potassium phosphate 23444-86-2, Suncillin sodium 23541-50-6, Daunorubicin hydrochloride 23593-75-1, Clotrimazole 23736-58-5, Cloxacillin benzathine 24169-02-6, Econazole nitrate 24356-60-3, Cephapirin sodium 24390-14-5, Doxycycline hyclate 24729-96-2, Clindamycin phosphate 25316-40-9, Doxorubicin hydrochloride 25389-94-0, Kanamycin sulfate 25507-04-4, Clindamycin palmitate hydrochloride 25526-93-6, Alovudine 25953-19-9, Cefazolin 26309-95-5, Pivampicillin hydrochloride 26605-69-6, Carbenicillinindanylsodium 26774-90-3, Epicillin 26786-84-5, Lomofungin 26787-78-0, Amoxicillin 27164-46-1, Cefazolin sodium 27220-47-9, Econazole 27523-40-6, Isoconazole 27591-69-1, Tilorone hydrochloride 27762-78-3, Kethoxal 27823-62-7, Chlortetracycline bisulfate 27877-51-6, Tolindate 28069-65-0, Cuprimyxin 28088-64-4, Aminosalicylic acid 28657-80-9, Cinoxacin 29342-05-0, Ciclopirox 29457-07-6, Ticarcillin disodium 29767-20-2, Teniposide 29984-33-6, Vidarabine phosphate 30034-03-8, Cefamandole sodium 30516-87-1, Zidovudine 31342-36-6, Chloramphenicol pantothenate complex 31431-39-7, Mebendazole 32385-11-8, Sisomicin 32886-97-8, Amdinocillin pivoxil 32887-01-7, Amdinocillin 32986-56-4, Tobramycin 33069-62-4, Taxol 33419-42-0, Etoposide 33564-30-6, Cefoxitin sodium 34444-01-4, Cefamandole 35523-45-6, Fludalanine 35554-44-0, Enilconazole 35607-20-6, Avridine 35607-66-0, Cefoxitin 35834-26-5, Rosaramicin 36791-04-5, Ribavirin 36983-81-0, Fosfonet sodium 37091-65-9, Azlocillin sodium 37091-66-0, Azlocillin 37321-09-8, Apramycin 37332-99-3, Avoparcin 37338-39-9 37517-28-5, Amikacin 37661-08-8, Bacampicillin hydrochloride 38070-41-6, Tiodonium chloride 38821-53-3, Cephradine 39030-72-3, Pivampicillin pamoate 39809-25-1, Penciclovir 39831-55-5, Amikacin sulfate 39878-70-1, Talampicillin hydrochloride 40034-42-2, Rosoxacin 40966-79-8, Sarpicillin 41575-94-4, Carboplatin 41621-49-2, Ciclopirox olamine 42057-22-7, Mezlocillin sodium 42190-91-0, Pivampicillin probenate 42540-40-9, Cefamandole nafate 42835-25-6, Flumequine 43143-11-9, Bispyrithione magsulfex 43169-50-2, Betamicin sulfate 49620-13-5, Robustaflavone 49842-07-1, Tobramycin sulfate 50370-12-2, Cefadroxil 50838-36-3, Tolciclate 51022-98-1,

Butirosin sulfate 51481-64-2, Rosaramicin propionate 51481-65-3, Mezlocillin 51547-64-9, Rosaramicin stearate 51627-14-6, Cefatrizine 51627-20-4, Cefaparole 51762-05-1, Cefroxadine 52123-49-6, Cefazaflur sodium 52152-93-9, Cefsulodin sodium 53066-26-5, Lexithromycin 53179-09-2, Sisomicin sulfate 53230-10-7, Mefloquine 53678-77-6, Muramyl dipeptide 53808-87-0, Tetroxoprim 53910-25-1, Pentostatin 53994-73-3, Cefaclor 54965-21-8, Albendazole 55103-30-5, Rosaramicin butyrate 55162-26-0, Pirbenicillin sodium 55242-74-5, Oxifungin hydrochloride 55242-77-8, Triafungin 55268-74-1, Praziquantel 55268-75-2, Cefuroxime 55298-68-5, Neomycin palmitate 55694-87-6, Pentizidone sodium 55852-84-1, Bacitracin methylene disalicylate 56093-45-9, Selenium sulfide 56219-57-9, Arildone 56238-63-2, Cefuroxime sodium 56390-09-1, Epirubicin hydrochloride 56391-57-2, Netilmicin sulfate 56433-46-6, Cetocycline hydrochloride 56585-33-2, Trimethoprim sulfate 56689-42-0, Repromicin 56796-20-4, Cefmetazole 56796-39-5, Cefmetazole sodium 57363-13-0, Droxacin sodium 57852-57-0, Idarubicin hydrochloride 58001-44-8, Clavulanic acid 58152-03-7, Isepamicin 58795-03-2, Apalcillin sodium 58857-02-6, Ambruticin 58944-73-3, Sinefungin 59070-06-3, Ticarcillin cresylsodium 59277-89-3, Acyclovir 59695-59-9, Cephalexin hydrochloride 59703-84-3, Piperacillin sodium 59733-86-7, Butikacin 59794-18-2, Paulomycin 59831-63-9, Doconazole 60207-31-0, Azaconazole 60628-96-8, Bifonazole 60802-40-6, Rosaramicin sodium phosphate 60925-61-3, Ceforanide 61036-62-2, Teicoplanin 61270-78-8, Cefonicid sodium 61318-91-0, Sulconazole nitrate 61379-65-5, Rifapentine 61477-96-1, Piperacillin 62013-04-1, Dirithromycin 62587-73-9, Cefsulodin 62893-19-0, Cefoperazone 62893-20-3, Cefoperazone sodium 62973-77-7, Parconazole hydrochloride 63198-97-0, Viroxime

RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)

(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT 63527-52-6, Cefotaxime 63585-09-1, Foscarnet sodium 64211-46-7, Oxiconazole nitrate 64221-86-9, Imipenem 64221-86-9D, Imipenem, derivs. 64485-93-4, Cefotaxime sodium 64544-07-6, Cefuroxime axetil 64872-77-1, Butoconazole nitrate 64952-97-2, Moxalactam 65025-62-9, (-)-Soulattrolide 65052-63-3, Cefetamet 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 65473-14-5, Naftifine hydrochloride 65899-73-2, Tioconazole 66148-78-5, Temocillin 66309-69-1, Cefotiam hydrochloride 66887-96-5, Propikacin 67337-44-4, Sarmoxicillin 67915-31-5, Terconazole 68401-82-1, Ceftizoxime sodium 68693-30-1, Somantadine hydrochloride 68902-57-8, Metioprim 69123-90-6, Fiacitabine 69123-98-4, Fialuridine 69198-10-3, Metronidazole hydrochloride 69402-03-5, Piridicillin sodium 69521-94-4, Thymosin α-1 69655-05-6, Didanosine 69657-51-8, Acyclovir sodium 69712-56-7, Cefotetan 69756-53-2, Halofantrine 70052-12-9, Eflornithine 70288-86-7, Ivermectin 70458-92-3, Pefloxacin 70458-95-6, Pefloxacin mesylate 70458-96-7, Norfloxacin 70797-11-4, Cefpiramide 71002-10-3, Vidarabine sodium phosphate 71420-79-6 72275-67-3, Astromicin sulfate 72301-78-1, Zinviroxime 72301-79-2, Enviroxime 72558-82-8, Ceftazidime 72559-06-9, Rifabutin 73334-05-1, Metronidazole phosphate 73384-59-5, Ceftriaxone 73514-87-1, Fosarilate ***73816-42-9***, Meclocycline sulfosalicylate 74011-58-8, Enoxacin 74356-00-6, Cefotetan disodium 74578-69-1, Ceftriaxone sodium 74682-62-5, Ticarcillin monosodium 74849-93-7, Cefpiramide sodium 75738-58-8, Cefmenoxime hydrochloride 76168-82-6, Ramoplanin 76470-66-1, Loracarbef 76497-13-7, Sultamicillin 76610-84-9, Cefbuperazone 77146-42-0, Chlorhexidine phosphanilate 77181-69-2,

Sorivudine 78040-85-4, Coumermycin 78110-38-0, Aztreonam 78186-33-1, Fumoxicillin 78613-35-1, Amorolfine 78822-40-9, Pirlimycin hydrochloride 78964-85-9, Fosfomycin tromethamine 79350-37-1, Cefixime 79404-91-4, Cilofungin 79660-72-3, Fleroxacin 80168-44-1, Zinoconazole hydrochloride 80214-83-1, Roxithromycin 80621-81-4, Rifaximin 80883-55-2, Enviradene 81103-11-9, Clarithromycin 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 83038-87-3, Doxycycline fosfatex 83200-96-8D, Carbapenem, derivs. 83905-01-5, Azithromycin 84408-37-7, Desciclovir 84625-61-6, Itraconazole 84880-03-5, Cefpimizole 85287-61-2, Cefpimizole sodium 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86393-37-5, Amifloxacin 86832-68-0, Carumonam sodium 87239-81-4, Cefpodoxime proxetil 87495-31-6, Disoxaril 87806-31-3, Porfimer sodium 88036-80-0, Amifloxacin mesylate 88040-23-7, Cefepime 90849-08-4, Oximonam sodium 90850-05-8, Gloximonam 90898-90-1, Oximonam 91161-71-6, Terbinafine 91618-36-9, Ibafloxacin 91832-40-5, Cefdinir 92562-88-4 92665-29-7, Cefprozil 93107-08-5, Ciprofloxacin hydrochloride 94088-85-4, Doxycycline calcium 94168-98-6, Rifametane 95058-81-4, Gemcitabine 96036-03-2, Meropenem 96128-89-1, Erythromycin acistrate 97519-39-6, Ceftibuten 97673-66-0, Trospectomycin sulfate 97682-44-5, Irinotecan 98079-51-7, Lomefloxacin 98079-52-8, Lomefloxacin hydrochloride 98753-19-6, Cefpirome sulfate 100234-70-6, Resorcinomycin A 100490-36-6, Tosufloxacin 100680-33-9, Cefuroxime pivoxetil 101828-21-1, Butenafine 102426-96-0, Paldimycin 103060-53-3, Daptomycin 104227-87-4, Famciclovir 104456-95-3, Cisconazole 105784-61-0, Temafloxacin hydrochloride 105956-99-8, Clinafloxacin hydrochloride 106941-25-7, Adefovir 107648-80-6, Cefepime hydrochloride 107910-75-8, Ganciclovir sodium 108319-06-8, Temafloxacin 110042-95-0, Acemannan 110588-57-3, Saperconazole 110871-86-8, Sparfloxacin 110942-02-4, Aldesleukin 112362-50-2, Dalfopristin 113102-19-5, Rifamexil 113852-37-2, Cidofovir 114394-67-1, Lomefloxacin mesylate 114977-28-5, Taxotere 117091-64-2, Etoposide phosphate 117211-03-7, Cefetecol 119413-54-6, Topotecan hydrochloride 120138-50-3, Quinupristin 120410-24-4, Biapenem 120788-07-0, Sulopenem 122111-03-9, Gemcitabine hydrochloride 124436-59-5, Pirodavir 124832-27-5, Valacyclovir hydrochloride 125317-39-7, Vinorelbine tartrate 127464-60-2, Vascular endothelial growth factor 127759-89-1, Lobucavir 127779-20-8, Saquinavir 127785-64-2, Basifungin 129618-40-2, Nevirapine 130167-69-0, Pegaspargase 132210-43-6, Cipamfylline 134678-17-4, Lamivudine 136817-59-9, Delavirdine 137487-62-8, Alvircept sudotox 138540-32-6, Atevirdine mesylate 139442-47-0, LFM-A 12 141611-76-9, Sanfetrinem sodium 142217-69-4, Entecavir 142340-99-6, Adefovir dipivoxil 142632-32-4, (+)Calanolide A 143491-57-0, Emtricitabine 147221-93-0, Delavirdine mesylate 149845-06-7, Saquinavir mesylate 150378-17-9, Indinavir 150572-30-8 151581-81-6, Pradimicin 152121-44-3 152923-56-3, Daclizumab 154598-52-4, Efavirenz 155213-67-5, Ritonavir 156586-89-9, Panorex 159989-64-7, Nelfinavir 163252-36-6, Clevudine 163661-45-8, (-)-Calanolide A 164301-51-3, CNI-1493 167869-21-8, PD98059 170277-31-3, Infliximab 174722-31-7, Rituxan 179463-17-3, MK 991 180288-69-1, Herceptin 183319-69-9, Tarceva 184475-35-2, Iressa 185243-69-0, Etanercept 187029-72-7, (-)-7,8-Dihydrosoulattrolide 188039-54-5, Palivizumab 205923-56-4, IMC-C225 206181-63-7, Zevalin 208538-73-2, FK 463 208921-02-2, Tositumomab 211555-05-4, WHI-P97 213327-37-8, Oregovomab 216503-57-0, Campath 216503-58-1, Mitumomab 216974-75-3, Avastin 220578-59-6, Mylotarg 339150-51-5, CeaVac 339150-82-2, LymphoCide 339151-95-0, MDX-22 339151-96-1, MDX-447 339152-71-5, MDX-210 339286-23-6, Gliomab-H 339286-24-7, GNI-250 339526-30-6, MDX-220 478159-64-7, 2C3 645405-72-7 645405-73-8 645416-54-2, AG 1458 645417-10-3, UK 292 645417-21-6, BAY 38-9502

646031-42-7, Celogovab 646032-07-7, Zamyl
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT ***751-97-3***, Rolitetracycline ***808-26-4***, Sancycline ***914-00-1***, Methacycline ***987-02-0***, Demecycline ***2013-58-3***, Meclocycline ***3963-95-9***, Methacycline hydrochloride ***5585-59-1***, Nitrocycline ***5874-95-3***, Amicycline ***20685-78-3***, Rolitetracycline nitrate ***23313-80-6***, Epitetracycline hydrochloride ***73816-42-9***, Meclocycline sulfosalicylate
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

RN 751-97-3 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-, (4S,4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 808-26-4 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 914-00-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S,4aR,5S,5aR,12aS)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 987-02-0 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 2013-58-3 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S,4aR,5S,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3963-95-9 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, monohydrochloride, (4S,4aR,5S,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 5585-59-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

[Remaining compounds were deleted to save paper]

L61 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:855697 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 139:364941
TITLE: Preparation of 3,4-diaminocyclobutene-1,2-diones as CXC chemokine receptor antagonists
INVENTOR(S): Taveras, Arthur G.; Aki, Cynthia J.; Bond, Richard W.; Chao, Jianping; Dwyer, Michael; Ferreira, Johan A.; Pachter, Jonathan A.; Baldwin, John J.; Kaiser, Bernd; Li, Ge; Merritt, J. Robert; Nelson, Kingsley H.; Rokosz, Laura L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 127 pp., Cont.-in-part of U.S. Ser. No. 62,006.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003204085	A1	20031030	US 2002-208426		20020730
US 2003097004	A1	20030522	US 2002-62006		20020201
US 2004235908	A1	20041125	US 2004-869189		20040616
PRIORITY APPLN. INFO.:			US 2001-265951P	P	20010202
			US 2002-62006	A2	20020201
			US 2002-208426	A3	20020730

OTHER SOURCE(S): MARPAT 139:364941
GI



AB Title compds. I [A = (substituted) aryl, heteroaryl; B = (substituted) Ph, benzotriazolyl, benzimidazolyl, hydroxyimidazolyl, hydroxythienyl, hydroxypyrrolyl, etc.], useful for treating chemokine mediated diseases selected from psoriasis, atopic dermatitis, asthma, arthritis, cancer, etc., were prepared Thus, 1-ethoxy-2-phenylamino-1-cyclobutene-3,4-dione (preparation given) and 2-OH-3-[(2-morpholinoethyl)aminocarbonyl]aniline (preparation given) were refluxed overnight in EtOH to give 34% title compound (II). I showed CXCR2 receptor binding activity in the range of 1-10000 nM. Pharmaceutical composition comprising the compound I is claimed.

IC ICM C07D277-56
ICS C07D263-34; C07D257-04; C07C225-18

INCL 544320000; 544408000; 546304000; 548194000; 548234000; 548254000; 548261000; 548309700; 548503000; 549434000

CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 25, 27, 63

IT Angiogenesis
Angiogenesis inhibitors
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Anticoagulants
Antimalarials
Antitumor agents
Antiviral agents
Human
Immunosuppressants
Solid phase synthesis
(preparation of 3,4-diaminobutene-1,2-diones as CXC chemokine receptor antagonists)

IT AIDS (disease)
Alzheimer's disease
Arthritis
Asthma
Atherosclerosis
Eye, disease
Malaria
Melanoma
Neoplasm
Psoriasis

Thrombosis
(treatment; preparation of 3,4-diaminobutene-1,2-diones as CXC chemokine receptor antagonists)

IT 50-35-1, Thalidomide 145-63-1, Suramin ***15866-90-7***, Col-3
33069-62-4, Taxol 37270-94-3, Platelet factor 4 38101-59-6, Im862
86090-08-6, Angiostatin 99519-84-3, CAI 114977-28-5, Taxotere
129298-91-5, Tnp-470 148717-90-2, Squalamine 154039-60-8, Marimastat
169799-04-6, Cgs27023a 187888-07-9, Endostatin 188968-51-6, Emd121974
192329-42-3, Ag3340 204005-46-9, Su-5416 212142-18-2, PTK 787
216974-75-3 252916-29-3, Su-6668 259188-38-0, Bms-275291
305838-77-1, Neovastat 324740-00-3, Vitaxin 386211-13-8, Zd-101
443913-73-3, Zd-6474
RL: ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(coadministration; preparation of 3,4-diaminobutene-1,2-diones as CXC chemokine receptor antagonists)

IT ***15866-90-7***, Col-3
RL: ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(coadministration; preparation of 3,4-diaminobutene-1,2-diones as CXC chemokine receptor antagonists)

RN 15866-90-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:551500 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 139:117431
TITLE: 4,5-Diamino-1,2,3,4-tetrahydro-3,6-pyridazinediones as CXC chemokine receptor antagonists for treatment of inflammatory disorders and cancer
INVENTOR(S): Taveras, Arthur G.; Dwyer, Michael; Chao, Jianping; Baldwin, John J.; Merritt, Robert J.; Li, Ge; Chao, Jianhua; Yu, Younong
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057676	A1	20030717	WO 2003-US299	20030103

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,

ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK,
SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004063709	A1	20040401	US 2003-335789		20030102
US 6878709	B2	20050412			
CA 2472165	AA	20030717	CA 2003-2472165		20030103
AU 2003207460	A1	20030724	AU 2003-207460		20030103
EP 1461321	A1	20040929	EP 2003-705667		20030103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1582280	A	20050216	CN 2003-801923		20030103
JP 2005516029	T2	20050602	JP 2003-557993		20030103
PRIORITY APPLN. INFO.:			US 2002-346248P	P	20020104
			US 2003-335789	A	20030102
			WO 2003-US299	W	20030103

OTHER SOURCE(S): MARPAT 139:117431
GI



I

AB Prepns. for title compds. I [wherein R1 and R15 = independently H or (un)substituted (hetero)aryl, alkyl, (hetero)cycloalkyl(alkyl), or (hetero)arylalkyl; A = (un)substituted thiazolyl(alkyl), thienyl(alkyl), oxazolyl(alkyl), pyridinyl(alkyl), piperazinyl(alkyl), piperidinyl(alkyl), imidazolyl(alkyl), indolyl(alkyl), benzotriazolyl(alkyl), phenyl(alkyl), naphthyl(alkyl), carbamoylalkyl, etc.; B = (un)substituted Ph, benzotriazolyl, benzimidazolyl, indolyl, indazolyl, pyridinyl, pyrazolyl, thienyl, pyrrolyl, or pyrimidinyl; or pharmaceutically acceptable salts or solvates thereof] and their intermediates are disclosed (no data). In addition, CXCR1 SPA, CXCR2 SPA, calcium fluorescence, chemotaxis, and cytotoxicity assays are described. For example, 5-methylsalicylic acid was coupled with dimethylamine in the presence of DCC in EtOAc to give 2-hydroxy-N,N,5-trimethylbenzamide, which was nitrated (44%) and reduced using 10% Pd/C to give 3-amino-2-hydroxy-N,N,5-trimethylbenzamide (99%). The amine may be coupled with 1,2,3,4-tetrahydro-3,6-pyridazinediones to provide compds. of the invention (no data). I may exhibit a range of CXCR2 receptor binding activities from about 1 nM to about 10,100 nM. Thus, I and pharmaceutical compns. comprising I may be useful for the treatment of acute and chronic inflammatory disorders and cancer (no data).

IC ICM C07D237-22
ICS C07D409-12; C07D405-12; C07D417-12; C07D403-12; A61K031-501;

A61P035-00
CC 28-15 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT AIDS (disease)
Alzheimer's disease
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Anticoagulants
Antimalarials
Antitumor agents
Antiviral agents
Arthritis
Asthma
Atherosclerosis
Drug delivery systems
Hepatitis virus
Human
Human herpesvirus
Malaria
Melanoma
Neoplasm
Psoriasis
Thrombosis
(preparation of pyridazinediones as CXC chemokine receptor antagonists for treatment of inflammatory disorders and cancer)
IT 50-35-1, Thalidomide 145-63-1, Suramin ***15866-90-7***, Col-3
33069-62-4, Paclitaxel 37270-94-3, Platelet Factor-4 38101-59-6, IM862
86090-08-6, Angiostatin 99519-84-3, CAI 114977-28-5, Docetaxel
129298-91-5, TNP-470 148717-90-2, Squalamine 154039-60-8, Marimastat
169799-04-6, CGS27023A 179545-77-8, Bay 12-9566 187888-07-9,
Endostatin 188968-51-6, EMD121974 192329-42-3, AG3340 204005-46-9,
SU-5416 212142-18-2, PTK-787 252916-29-3, SU-6668 259188-38-0,
BMS-275291 305838-77-1, Neovastat 324740-00-3, Vitaxin 386211-13-8,
ZD-101 443913-73-3, ZD 6474
RL: ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(combination therapy; preparation of pyridazinediones as CXC chemokine receptor antagonists for treatment of inflammatory disorders and cancer)
IT ***15866-90-7***, Col-3
RL: ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(combination therapy; preparation of pyridazinediones as CXC chemokine receptor antagonists for treatment of inflammatory disorders and cancer)
RN 15866-90-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:334375 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 138:343878
TITLE: Buccal sprays or capsules containing drugs for treating an infectious disease or cancer
INVENTOR(S): Dugger, Harry A., III
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 537,118.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003082107	A1	20030501	US 2002-230080	20020829
WO 9916417	A1	19990408	WO 1997-US17899	19971001
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 1029536	A1	20000823	EP 2000-109347	19971001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1036561	A1	20000920	EP 2000-109357	19971001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2497136	AA	20040311	CA 2003-2497136	20030827
WO 2004019912	A2	20040311	WO 2003-US26860	20030827
WO 2004019912	A3	20040819		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003262917 A1 20040319 AU 2003-262917 20030827
EP 1545458 A2 20050629 EP 2003-791859 20030827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006502150 T2 20060119 JP 2004-531575 20030827
US 2005142069 A1 20050630 US 2004-929001 20040827
PRIORITY APPLN. INFO.: WO 1997-US17899 A2 19971001
US 2000-537118 A2 20000329
EP 1997-911621 A3 19971001
US 2002-230080 A 20020829
WO 2003-US26860 W 20030827

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aqueous polar solvent, active compound, and optional flavoring agent; formulation B: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compound, and optional flavoring agent; and formulation D: non-polar solvent, active compound, optional flavoring agent, and propellant. Thus, a polar lingual spray contained albuterol sulfate 0.1-10, water 5-90, ethanol 1-10, sorbitol 0.1-5, aspartame 0.01-0.5, and flavors 0.1-5%.

IC ICM A61K009-00
ICS A61L009-04; A61K039-00
INCL 424043000; X42-418.41
CC 63-6 (Pharmaceuticals)

IT 5-HT antagonists
Antibacterial agents
Antidotes
Antimalarials
Antitumor agents
Cytoprotective agents
Flavoring materials
Fungicides
Parasiticides
Polar solvents
Propellants (sprays and foams)
Sweetening agents
Vaccines
Vasodilators
(buccal sprays or capsules containing drugs for treating an infectious disease or cancer)

IT 50-65-7, Niclosamide 51-30-9, Isoproterenol hydrochloride 51-34-3, Scopolamine 51-55-8, Atropine 54-05-7, Chloroquine 55-56-1, Chlorhexidine 57-41-0, Phenytoin 58-05-9, Leucovorin 58-14-0, Pyrimethamine 58-55-9, Theophylline, biological studies 58-61-7, Adenosine, biological studies 60-54-8, Tetracycline 60-87-7, Promethazine 61-33-6, biological studies 64-17-5, Ethanol, biological studies 67-45-8, Furazolidone 68-35-9, Sulfadiazine 70-51-9, Deferoxamine 72-14-0, Sulfathiazole 80-08-0, Dapsone 83-73-8, Iodoquinol 83-89-6, Quinacrine 90-34-6, Primaquine 100-33-4, Pentamidine 114-07-8, Erythromycin 126-07-8, Griseofulvin 127-71-9, Sulfabenzamide 130-26-7, Clioquinol 130-95-0, Quinine 144-80-9, Sulfacetamide 147-24-0, Diphenhydramine hydrochloride 148-79-8, Thiabendazole 155-97-5, Pyridostigmine 303-53-7, Cyclobenzaprine 306-44-5, Monoisonitrosoacetone 443-48-1, Metronidazole 465-65-6, Naloxone 483-18-1, Emetine 500-92-5, Chloroguanide 523-87-5, Dimenhydrinate 564-25-0, Doxycycline 569-65-3, Meclizine 630-93-3,

Phenytoin sodium 638-23-3 738-70-5, Trimethoprim 745-65-3, PGE1 1002-16-0, Amyl nitrate 2447-57-6, Sulfadoxine 3239-45-0, Dexfenfluramine hydrochloride 3576-64-5, Clefamide 3736-81-0, Diloxanide furoate 4914-30-1, Dehydroemetine 5560-78-1, Teclozan 5786-21-0, Clozapine 6735-59-7, Pralidoxime 7542-37-2, Paromomycin 7720-78-7, Ferrous sulphate 10238-21-8, Glyburide 11111-12-9, Cephalosporin 20537-88-6, Amifostine 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 25287-60-9, Etofamide 25322-68-3, Polyethylene glycol 30516-87-1, Zidovudine 30751-05-4, Troxipide 31431-39-7, Mebendazole 35700-23-3, Carboprost 36499-65-7, Dicobalt edetate 47931-85-1, Salmon calcitonin 51022-70-9, Albuterol sulfate 53230-10-7, Mefloquine 54965-21-8, Albendazole 55268-74-1, Praziquantel 58551-69-2, Carboprost tromethamine 59865-13-3, Cyclosporine 60205-81-4, Ipratropium 61036-62-2, Teicoplanin 61379-65-5, Rifapentine 69756-53-2, Halofantrine 70059-30-2, Cimetidine hydrochloride 70288-86-7, Ivermectin 76824-35-6, Famotidine 78755-81-4, Flumazenil 79517-01-4, Octreotide acetate 93107-08-5, Ciprofloxacin hydrochloride 98319-26-7, Finasteride 98530-76-8, Blood-coagulation factor XIV (human protein moiety) 99614-01-4, Ondansetron hydrochloride 103628-48-4, Sumatriptan succinate 113189-02-9, Antihemophilic factor 127045-41-4, Pazufloxacin 133107-64-9, Insulin lispro 137234-62-9, Voriconazole 164656-23-9, GI 198745 188039-54-5, Palivizumab 191114-48-4, Telithromycin 220349-64-4, biological studies ***220620-09-7***, GAR-936 516482-86-3, Sermorelin acetate
RL: ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(buccal sprays or capsules containing drugs for treating an infectious disease or cancer)

IT ***220620-09-7***, GAR-936
RL: ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(buccal sprays or capsules containing drugs for treating an infectious disease or cancer)

RN 220620-09-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:301081 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 138:321127
TITLE: Preparation of 3,4-disubstituted maleimide compounds as CXC-chemokine receptor antagonists
INVENTOR(S): Taveras, Arthur G.; Dwyer, Michael; Ferreira, Johan

A.; Girijavallabhan, Viyyoor M.; Chao, Jianping; Baldwin, John J.; Merritt, J. Robert; Li, Ge

PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE: PCT Int. Appl., 229 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003031440	A1	20030417	WO 2002-US32628		20021011
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2462862	AA	20030417	CA 2002-2462862		20021011
US 2004034229	A1	20040219	US 2002-269775		20021011
US 6903131	B2	20050607			
EP 1434775	A1	20040707	EP 2002-786395		20021011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005505595	T2	20050224	JP 2003-534423		20021011
CN 1599734	A	20050323	CN 2002-824052		20021011
PRIORITY APPLN. INFO.:			US 2001-329005P	P	20011012
			WO 2002-US32628	W	20021011

OTHER SOURCE(S): MARPAT 138:321127
GI



I

AB Disclosed are 3,4-disubstituted maleimides (shown as I; variables defined below; e.g. 3-[[3-(dimethylcarbamoyl)-2-hydroxyphenyl]amino]-4-((tert-butyl)amino)maleimide) or pharmaceutically acceptable salts or solvates thereof. The compds. are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer. CXCR1 and CXCR2 SPA, calcium fluorescence, chemotaxis (for 293-CXCR2), cytotoxicity and soft agar receptor binding assay methods are described but no test results are reported. Although the methods of preparation are not claimed, 1 example preparation of I and a large number of example prepns. of intermediates are included; also >200 specific I are claimed. For I: R1 =

H or (un)substituted aryl, heteroaryl, alkyl, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, and heterocycloalkylalkyl; A is selected from a very large group of possibilities, e.g. CR7R8Z (Z = (un)substituted pyridinyl, 1-oxopyridinyl, thiazolyl, furyl, oxazolyl, imidazolyl); B is selected from a very large group of possibilities, e.g. (un)substituted Ph, benzotriazol-7-yl, thienyl; addnl. details are given in the claims.

IC ICM C07D409-12
ICS C07D405-12; C07D207-44; C07D401-08; C07D403-12; C07D401-12; C07D409-14; C07D417-12; A61K031-4015; A61K031-4025; A61P035-00

CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

IT AIDS (disease)
Acne
Allergy inhibitors
Alzheimer's disease
Angiogenesis
Angiogenesis inhibitors
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antimalarials
Antitumor agents
Antiulcer agents
Arthritis
Asthma
Atherosclerosis
Celiac disease
Common cold
Cough
Cystic fibrosis
Emphysema
Encephalitis
Gout
Hepatitis virus
Herpesviridae
Human
Human herpesvirus
Hypercapnia
Hypoxia
Inflammation
Lupus erythematosus
Malaria
Melanoma
Meningitis
Multiple organ failure
Multiple sclerosis
Neoplasm
Osteoarthritis
Osteoporosis
Pruritus
Psoriasis
Sarcoidosis
(preparation of 3,4-disubstituted maleimides as CXC-chemokine receptor antagonists)

IT 50-35-1, Thalidomide 145-63-1, Suramin ***15866-90-7***, Col-3
33069-62-4, Taxol 37270-94-3, Platelet Factor-4 38101-59-6, IM862

86090-08-6, Angiostatin 99519-84-3, CAI 114977-28-5, Taxotere 129298-91-5, TNP-470 148717-90-2, Squalamine 154039-60-8, Marimastat 169799-04-6, CGS27023A 179545-77-8, Bay 12-9566 187888-07-9, Endostatin 188968-51-6, EMD121974 192329-42-3, AG3340 204005-46-9, SU-5416 212142-18-2, PTK-787 252916-29-3, SU-6668 259188-38-0, BMS-275291 305838-77-1, Neovastat 324740-00-3, Vitaxin 386211-13-8, ZD-101 443913-73-3, ZD-6474
RL: ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(combined with 3,4-disubstituted maleimide CXC-chemokine receptor antagonists useful against angiogenesis)

IT ***15866-90-7***, Col-3
RL: ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(combined with 3,4-disubstituted maleimide CXC-chemokine receptor antagonists useful against angiogenesis)

RN 15866-90-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:57866 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 138:117673
TITLE: Tetracycline compounds having target therapeutic activities
INVENTOR(S): Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003005971	A2	20030123	WO 2002-US22451	20020715
WO 2003005971	A3	20031127		
WO 2003005971	C1	20040506		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002318238	A1	20030129	AU 2002-318238		20020715
US 2004063674	A1	20040401	US 2002-196010		20020715
EP 1408987	A2	20040421	EP 2002-748169		20020715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2004537544	T2	20041216	JP 2003-511780		20020715
PRIORITY APPLN. INFO.:			US 2001-305546P	P	20010713
			US 2002-395741P	P	20020712
			WO 2002-US22451	W	20020715

OTHER SOURCE(S): MARPAT 138:117673

AB Methods and compds. for treating a variety of diseases with tetracycline compds. having a target therapeutic activity are described, as is compound preparation

IC ICM A61K

CC 1-12 (Pharmacology)
Section cross-reference(s): 26

IT Aging, animal
Alzheimer's disease
Amnesia
Aneurysm
Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiarteriosclerotics
Antiarthritics
Antiasthmatics
Antibacterial agents
Anticonvulsants
Antidepressants
Antidiabetic agents
Antihypertensives
Antimalarials
Antimigraine agents
Antipsychotics
Antirheumatic agents
Antitumor agents
Antiviral agents
Anxiety
Anxiolytics
Arteriosclerosis
Asthma
Atherosclerosis
Autoimmune disease
Carcinoma
Cardiovascular agents
Cognition enhancers
Cystic fibrosis
Diabetes mellitus
Drug delivery systems
Emphysema
Epilepsy
Escherichia coli

Eye, disease
Fungicides
Gastrointestinal agents
Hepatitis
Human
Hypertension
Inflammation
Ischemia
Learning disorders
Lung, disease
Macrophage
Malaria
Mental and behavioral disorders
Multiple sclerosis
Neoplasm
Nervous system, disease
Nervous system agents
Osteoarthritis
Osteomyelitis
Osteoporosis
Parasiticides
Psychotropics
Rheumatoid arthritis
Sarcoma
Schizophrenia
Skin, disease
Sleep disorders
Staphylococcus aureus
Wernicke-Korsakoff syndrome
Wound healing promoters
(tetracycline compds. with target therapeutic activities)

IT ***389624-49-1P 488820-35-5P 488820-36-6P***
488820-38-8P 488820-39-9P
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT 60-54-8 60-54-8D, Tetracycline, derivs. 127-33-3 564-25-0
914-00-1 2444-65-7 3242-03-3 4497-07-8
5874-95-3 5995-55-1 10118-89-5
16145-05-4 24290-70-8 31642-30-5
35689-63-5 35689-65-7 53108-41-1
53173-80-1 59046-79-6 77901-56-5 115207-75-5
120793-45-5 146253-71-6 146253-75-0
146278-01-5 146278-02-6 146278-03-7
149934-16-7 149934-19-0 151922-17-7
153621-68-2 161320-33-8 161321-34-2
161452-36-4 186759-47-7 186759-49-9
186759-51-3 186759-53-5 186759-55-7
186759-61-5 220620-09-7 233585-94-9
233585-95-0 233585-96-1 233585-97-2
233586-02-2 233586-03-3 233586-04-4
233586-06-6 233586-07-7 233586-08-8
233586-09-9 233586-10-2 233586-11-3
233586-12-4 233586-16-8 263760-96-9
263760-98-1 263761-01-9 263761-02-0
263761-08-6 295356-11-5 295356-12-6
295356-13-7 295356-16-0 295356-17-1
330627-21-9 330627-22-0 330627-23-1

330627-24-2 330627-26-4 330627-27-5
330627-32-2 344771-54-6 351336-92-0
351336-94-2 365276-98-8 365276-99-9
365277-00-5 365277-01-6 365277-02-7
365277-03-8 365277-04-9 365277-05-0
365277-06-1 365277-08-3 365277-11-8
365277-12-9 365277-13-0 365277-14-1
365277-16-3 365277-19-6 365277-20-9
365277-21-0 365277-22-1 365277-23-2
365277-24-3 365277-26-5 365277-28-7
365277-29-8 365277-34-5 365277-35-6
365277-36-7 365277-37-8 365277-38-9
365277-39-0 365277-40-3 365277-41-4
365277-42-5 365277-43-6 365277-44-7
365277-45-8 365277-46-9 365277-47-0
365277-48-1 365277-49-2 365277-50-5
365277-51-6 365277-52-7 365277-53-8
365277-54-9 365277-55-0 365277-56-1
365277-57-2 365277-58-3 365277-59-4
365277-60-7 365277-61-8 365277-62-9
365277-63-0 365277-64-1 365277-65-2
365277-66-3 365277-88-9 374748-06-8
380435-62-1 380435-63-2 380435-65-4
380435-76-7 380435-88-1 389081-55-4
389081-56-5 389081-58-7 389081-60-1
389081-61-2 389081-62-3 389081-63-4
389081-64-5 389081-65-6 389081-66-7
389081-67-8 389081-68-9 389081-69-0
389081-71-4 389081-72-5 389081-73-6
389081-74-7 389081-75-8 389081-76-9
389081-77-0 389081-78-1 389081-79-2
389081-80-5 389081-85-0 389139-10-0
389139-12-2 389139-15-5 389139-16-6
389139-17-7 389139-18-8 389139-19-9
389139-20-2 389139-21-3 389139-22-4
389139-23-5 389139-24-6 389139-25-7
389139-26-8 389139-27-9 389139-28-0
389139-29-1 389139-31-5 389139-32-6
389139-33-7 389139-34-8 389139-35-9
389139-36-0 389139-37-1 389139-38-2
389139-39-3 389139-40-6 389139-41-7
389139-42-8 389139-43-9 389139-44-0
389139-45-1 389139-46-2 389139-47-3
389139-48-4 389139-49-5 389139-51-9
389139-52-0 389139-53-1 389139-54-2
389139-55-3 389139-56-4 389139-57-5
389139-58-6 389139-59-7 389139-60-0
389139-61-1 389139-62-2 389139-63-3
389139-64-4 389139-65-5 389139-66-6
389139-67-7 389139-68-8 389139-69-9
389139-70-2 389139-71-3 389139-72-4
389139-73-5 389139-74-6 389139-75-7
389139-78-0 389139-79-1 389139-80-4
389139-81-5 389139-82-6 389139-83-7
389139-85-9 389139-86-0 389139-87-1
389139-88-2 389139-89-3
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT *389139-90-6 389139-91-7 389139-92-8*
389139-93-9 389139-94-0 389139-95-1
389139-96-2 389139-97-3 389139-98-4
389139-99-5 389140-00-5 389140-01-6
389140-02-7 389140-03-8 389140-04-9
389140-06-1 389570-43-8 389570-46-1
389570-49-4 389570-50-7 389570-51-8
389570-52-9 389570-53-0 389570-54-1
389623-72-7 389623-77-2 389623-80-7
389623-82-9 389623-86-3 389623-88-5
389623-89-6 389623-91-0 389623-93-2
389623-95-4 389623-96-5 389623-97-6
389623-98-7 389623-99-8 389624-01-5
389624-02-6 389624-03-7 389624-04-8
389624-05-9 389624-08-2 389624-09-3
389624-12-8 389624-13-9 389624-14-0
389624-15-1 389624-18-4 389624-20-8
389624-21-9 389624-22-0 389624-23-1
389624-24-2 389624-26-4 389624-27-5
389624-28-6 389624-29-7 389624-30-0
389624-31-1 389624-32-2 389624-33-3
389624-34-4 389624-35-5 389624-36-6
389624-37-7 389624-38-8 389624-39-9
389624-40-2 389624-41-3 389624-43-5
389624-44-6 389624-45-7 389624-46-8
389624-51-5 389624-52-6 389624-54-8
389624-55-9 389624-56-0 389624-57-1
389624-59-3 389624-62-8 389624-63-9
389624-66-2 389624-67-3 389624-68-4
389624-69-5 389624-70-8 389624-71-9
389624-72-0 389624-73-1 389624-75-3
389624-76-4 389624-77-5 389624-78-6
389624-79-7 389624-80-0 389624-81-1
389624-82-2 389624-83-3 389624-84-4
389624-85-5 389624-86-6 389624-87-7
389624-88-8 389624-89-9 389624-90-2
389624-91-3 389624-92-4 389624-93-5
389624-94-6 389624-95-7 389624-97-9
389624-98-0 389624-99-1 389625-00-7
389625-01-8 389625-02-9 389625-03-0
389625-04-1 389625-05-2 389625-06-3
389625-07-4 389625-07-4 389625-09-6
389625-09-6 389625-10-9 389625-11-0
389625-12-1 439217-57-9 439217-59-1
459425-79-7 459425-80-0 459425-96-8
459426-11-0 459809-42-8 459809-43-9
459809-44-0 459809-45-1 459809-46-2
459809-47-3 459809-48-4 459809-49-5
459809-50-8 459809-51-9 459809-52-0
459809-53-1 459809-54-2 459809-55-3
459809-56-4 459809-57-5 459809-58-6
459809-59-7 459809-61-1 459809-63-3
459809-65-5 459809-66-6 459809-67-7
459809-68-8 459809-70-2 459809-72-4
459809-74-6 459809-76-8 459809-77-9
459809-79-1 459809-81-5 459809-82-6
459809-86-0 459809-88-2 459809-91-7
459809-92-8 459809-93-9 459809-94-0
459809-95-1 459809-96-2 459809-97-3

459809-98-4 459810-00-5 459810-01-6
459810-02-7 459810-03-8 459810-04-9
459810-06-1 459810-07-2 459810-09-4
460068-26-2 460068-27-3 460068-29-5
460068-30-8 460068-31-9 460068-33-1
460068-34-2 460068-35-3 460068-36-4
460068-38-6 460068-39-7 460068-40-0
460068-41-1 460068-43-3 460068-44-4
460068-45-5 460068-46-6 460068-47-7 46006
8-48-8 460068-49-9 460068-50-2
460068-51-3 460068-52-4 460068-53-5
460068-54-6 460068-55-7 460068-57-9
460068-58-0 460068-59-1 460068-60-4
460068-63-7 460068-64-8 460068-65-9
460068-66-0 460068-67-1 460068-68-2
460068-69-3 460068-70-6 460068-71-7
460068-72-8 460068-73-9 460068-74-0
460068-75-1 460068-76-2 460068-77-3
460068-78-4 460068-79-5 460068-80-8
460068-81-9 460068-82-0
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT 460068-83-1 460068-84-2 460068-85-3
460068-86-4 460068-87-5 460068-88-6
460068-90-0 460068-92-2 460068-93-3
460068-94-4 460068-95-5 460068-96-6
460068-97-7 460068-99-9 460069-34-5
460069-38-9 460069-65-2 460069-70-9
460069-89-0 460069-96-9 460070-02-4
460070-03-5 460070-53-5 460070-61-5
460070-66-0 460070-73-9 460070-76-2
460070-79-5 460070-92-2 460070-95-5
460071-02-7 460071-04-9 460071-06-1
460071-09-4 460071-12-9 460071-14-1
460071-17-4 460071-19-6 460071-29-8
460071-31-2 460071-33-4 460071-37-8
460071-66-3 460071-69-6 460071-80-1
460071-83-4 460071-83-4 460071-87-8
460071-89-0 460071-91-4 460071-93-6
460071-97-0 460071-99-2 460072-01-9
460072-03-1 460072-05-3 460072-07-5
460072-09-7 460072-10-0 460072-12-2
460072-15-5 460072-17-7 460072-19-9
460072-21-3 460072-25-7 460072-28-0
460072-29-1 460072-30-4 460072-31-5
460072-33-7 460072-36-0 460072-38-2
460072-40-6 460072-43-9 460072-45-1
460072-47-3 460072-49-5 460072-61-1
460072-63-3 460072-65-5 460072-70-2
460072-73-5 460072-75-7 460072-78-0
460072-82-6 460072-86-0 460072-89-3
460072-91-7 460072-93-9 460072-99-5
460073-01-2 460073-03-4 460073-05-6
460073-07-8 460073-09-0 460073-11-4
460073-15-8 460073-17-0 460073-21-6
460073-22-7 460073-23-8 460073-25-0
460073-27-2 460073-29-4 460073-31-8
460073-33-0 460073-35-2 460073-37-4

460073-40-9 460073-41-0 460073-43-2
460073-45-4 460073-47-6 460073-49-8
460073-51-2 460073-55-6 460073-58-9
460073-60-3 460073-62-5 460073-64-7
460073-68-1 460073-70-5 460073-72-7
460073-74-9 460073-76-1 460073-78-3
460073-80-7 460073-82-9 460073-84-1
460073-86-3 460073-88-5 460073-90-9
460073-92-1 460073-94-3 460073-96-5
460074-00-4 460074-02-6 460074-04-8
460074-06-0 460074-09-3 460074-11-7
460074-13-9 460074-17-3 460074-19-5
460074-21-9 460074-23-1 460074-26-4
460074-28-6 460074-30-0 460074-32-2
460074-34-4 460074-36-6 460074-38-8
460074-40-2 460074-42-4 460074-44-6
460074-46-8 460074-48-0 460074-50-4
460074-52-6 460074-54-8 460074-56-0
460074-58-2 460074-60-6 460074-62-8
460074-64-0 460074-66-2 460074-68-4
460074-69-5 460074-71-9 460074-73-1
460074-75-3 460074-77-5 460074-79-7
460074-81-1 460074-85-5 460074-87-7
460074-89-9 460074-91-3 460074-93-5
460074-95-7 460074-97-9 460074-99-1 46007
5-04-1 460075-06-3 460075-08-5
460075-12-1 460075-14-3 460075-62-1
460076-23-7 460082-87-5 460082-89-7
460082-90-0 473973-13-6 473973-20-5
473973-34-1 473973-37-4 473973-41-0
473973-62-5 473973-64-7 473973-86-3
473973-96-5 473974-12-8 473974-75-3
473974-76-4 473974-77-5 473974-79-7
473974-80-0 473974-81-1 473974-82-2
473974-83-3 473974-84-4 473974-85-5
488815-44-7 488815-45-8 488815-46-9
488815-47-0 488815-48-1 488815-49-2
488815-52-7 488815-53-8 488815-54-9
488815-55-0 488815-56-1 488815-57-2
488815-58-3 488815-59-4 488815-60-7
488815-61-8 488815-62-9 488815-63-0
488815-64-1 488815-65-2 488815-66-3
488815-67-4 488815-68-5
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT 488815-69-6 488815-70-9 488815-71-0
488815-72-1 488815-73-2 488815-74-3
488815-75-4 488815-76-5 488815-77-6
488815-78-7 488815-79-8 488815-80-1
488815-82-3 488815-89-0 488815-93-6
488815-98-1 488816-00-8 488816-09-7
488816-13-3 488816-16-6 488816-18-8
488816-19-9 488816-26-8 488816-37-1
488816-39-3 488816-42-8 488816-54-2
488816-55-3 488816-58-6 488816-59-7
488816-64-4 488816-65-5 488816-70-2
488816-71-3 488816-73-5 488816-75-7
488816-82-6 488816-86-0 488816-88-2

488816-92-8 488816-93-9 488816-98-4
488817-01-2 488817-06-7 488817-11-4
488817-13-6 488817-14-7 488817-15-8
488817-16-9 488817-17-0 488817-18-1 488817-19-2
488817-20-5 488817-21-6 488817-22-7 488817-23-8
488817-24-9 488817-25-0 488817-26-1
488817-27-2 488817-28-3 488817-29-4
488817-30-7 488817-31-8 488817-32-9
488817-33-0 488817-34-1 488817-35-2
488817-36-3 488817-37-4 488817-38-5
488817-39-6 488817-40-9 488817-41-0
488817-42-1 488817-43-2 488817-44-3
488817-45-4 488817-46-5 488817-47-6
488817-48-7 488817-49-8 488817-50-1
488817-51-2 488817-52-3 488817-53-4
488817-54-5 488817-55-6 488817-56-7
488817-57-8 488817-58-9 488817-59-0
488817-60-3 488817-61-4 488817-62-5
488817-63-6 488817-64-7 488817-65-8
488817-66-9 488817-67-0 488817-68-1
488817-69-2 488817-70-5 488817-71-6
488817-72-7 488817-73-8 488817-74-9
488817-75-0 488817-76-1 488817-77-2
488817-78-3 488817-79-4 488817-80-7
488817-81-8 488817-82-9 488817-89-6
488817-91-0 488817-92-1 488817-93-2
488817-94-3 488817-95-4 488817-96-5
488817-97-6 488817-98-7 488817-99-8
488818-00-4 488818-01-5 488818-02-6
488818-03-7 488818-04-8 488818-05-9
488818-06-0 488818-07-1 488818-08-2
488818-09-3 488818-10-6 488818-11-7
488818-12-8 488818-13-9 488818-14-0
488818-15-1 488818-16-2 488818-17-3
488818-18-4 488818-19-5 488818-20-8
488818-21-9 488818-22-0 488818-23-1
488818-24-2 488818-25-3 488818-26-4
488818-27-5 488818-28-6 488818-29-7
488818-30-0 488818-31-1 488818-32-2
488818-33-3 488818-34-4 488818-35-5
488818-36-6 488818-37-7 488818-38-8
488818-39-9 488818-40-2 488818-41-3
488818-42-4 488818-43-5 488818-44-6
488818-45-7 488818-46-8 488818-47-9
488818-48-0 488818-49-1 488818-50-4
488818-51-5 488818-52-6 488818-53-7
488818-54-8 488818-55-9 488818-56-0
488818-57-1 488818-58-2 488818-59-3
488818-60-6 488818-61-7 488818-63-9
488818-64-0 488818-65-1 488818-66-2
488818-67-3 488818-68-4 488818-69-5
488818-70-8 488818-71-9 488818-72-0
488818-73-1 488818-74-2 488818-75-3
488818-76-4 488818-77-5 488818-78-6
488818-79-7 488818-80-0 488818-81-1
488818-82-2 488818-83-3 488818-84-4
488818-85-5 488818-86-6 488818-87-7
488818-88-8 488818-89-9 488818-90-2
488818-91-3 488818-92-4 488818-93-5

488818-94-6 488818-95-7 488818-96-8
488818-97-9 488818-98-0 488818-99-1
488819-00-7 488819-01-8 488819-02-9
488819-03-0 488819-04-1 488819-05-2
488819-06-3 488819-07-4 488819-08-5
488819-14-3 488819-15-4 488819-16-5
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT ***488819-17-6 488819-18-7 488819-19-8***
488819-20-1 488819-21-2 488819-22-3
488819-23-4 488819-24-5 488819-25-6
488819-26-7 488819-27-8 488819-28-9
488819-29-0 488819-30-3 488819-31-4
488819-32-5 488819-33-6 488819-34-7
488819-35-8 488819-36-9 488819-37-0
488819-38-1 488819-39-2 488819-40-5
488819-41-6 488819-42-7 488819-43-8
488819-44-9 488819-45-0 488819-46-1
488819-47-2 488819-48-3 488819-49-4
488819-50-7 488819-51-8 488819-52-9
488819-53-0 488819-54-1 488819-55-2
488819-56-3 488819-57-4 488819-58-5
488819-59-6 488819-60-9 488819-61-0
488819-62-1 488819-63-2 488819-64-3
488819-65-4 488819-66-5 488819-67-6
488819-68-7 488819-69-8 488819-70-1
488819-71-2 488819-72-3 488819-73-4
488819-74-5 488819-75-6 488819-76-7
488819-77-8 488819-78-9 488819-79-0
488819-80-3 488819-81-4 488819-82-5
488819-83-6 488819-84-7 488819-85-8
488819-86-9 488819-87-0 488819-88-1
488819-89-2 488819-90-5 488819-91-6
488819-92-7 488819-93-8 488819-94-9
488819-95-0 ***488819-96-1 488819-97-2***
488819-98-3 488819-99-4 488820-00-4
488820-01-5 488820-02-6 488820-03-7
488820-04-8 488820-05-9 488820-06-0 488820-07-1
488820-08-2 ***488820-09-3 488820-10-6***
488820-11-7 488820-12-8 488820-13-9
488820-14-0 488820-15-1 488820-16-2
488820-17-3 488820-18-4 488820-19-5
488820-20-8 488820-21-9 488820-22-0
488820-23-1 488820-24-2 488820-25-3
488820-26-4 488820-27-5 488820-28-6
488820-29-7 488820-30-0 488820-31-1
488820-32-2 488820-33-3 488820-34-4
488820-42-4 488820-43-5 488820-45-7
488820-46-8 488820-47-9 488820-48-0
488820-49-1 488820-50-4 488821-84-7
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT ***389624-49-1P 488820-35-5P 488820-36-6P***
488820-38-8P 488820-39-9P
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)

(tetracycline compds. with target therapeutic activities)

RN 389624-49-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[2-(4-methylphenyl)ethyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 488820-35-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-(3,4-dimethoxyphenyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 488820-36-6 HCAPLUS

CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[[(phenylmethyl)amino]carbonyl]amino]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 488820-38-8 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-10-(1,1-dimethylethoxy)-1,4,4a,5,5a,6,11,12a-octahydro-3,12,12a-trihydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 488820-39-9 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-10,12,12a-trihydroxy-1,11-dioxo-3-(phenylmethoxy)-7-[3-(trifluoromethyl)phenyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

RN 460072-10-0 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[4-[(dipropylamino)methyl]-1-naphthalenyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460072-12-2 HCAPLUS
CN Glycine, N-[[4-[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]-1-naphthalenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460072-15-5 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-[3-(aminomethyl)-4-ethoxyphenyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460072-17-7 HCAPLUS
CN Glycine, N-[[4-[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

[Remaining compounds are deleted to save paper]

L61 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:832571 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 137:333118
TITLE: Substituted tetracycline compounds for the treatment of ***malaria***
INVENTOR(S): Draper, Michael; Nelson, Mark L.; Frechette, Roger
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085303	A2	20021031	WO 2002-US12935	20020424
WO 2002085303	A3	20030515		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2444899	AA	20021031	CA 2002-2444899	20020424

EP 1399414 A2 20040324 EP 2002-723955 20020424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004529927 T2 20040930 JP 2002-582879 20020424
PRIORITY APPLN. INFO.: US 2001-286193P P 20010424
WO 2002-US12935 W 20020424
OTHER SOURCE(S): MARPAT 137:333118

AB The invention provides a method for treating or preventing ***malaria*** in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound, such that ***malaria*** is treated or prevented. In one aspect, the invention provides pharmaceutical compns. which include an effective amount of a tetracycline compound to treat ***malaria*** in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used in combination with one or more ***antimalarial*** compds. or can be used to treat or prevent ***malaria*** which is resistant to one or more other ***antimalarial*** compds. Compound preparation is described.

IC ICM A61K
CC 1-5 (Pharmacology)
Section cross-reference(s): 25, 63
ST tetracycline deriv prepn ***antimalarial***; ***malaria*** treatment tetracycline deriv
IT ***Antimalarials***
Drug resistance
Malaria
Plasmodium falciparum
Plasmodium ***malariae***
Plasmodium ovale
Plasmodium vivax
(Substituted tetracycline compds. for the treatment of ***malaria***)
IT Sulfonamides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Substituted tetracycline compds. for the treatment of ***malaria***)
IT Headache
(and malaise, supplementary compound for treatment of; Substituted tetracycline compds. for the treatment of ***malaria***)
IT Antimicrobial agents
(antimicrobial Gram-pos. activity; Substituted tetracycline compds. for the treatment of ***malaria***)
IT Drug delivery systems
(prodrugs; Substituted tetracycline compds. for the treatment of ***malaria***)
IT Spleen, disease
(splenomegaly, supplementary compound for treatment of; Substituted tetracycline compds. for the treatment of ***malaria***)
IT Anemia (disease)
Fever and Hyperthermia
(supplementary compound for treatment of; Substituted tetracycline compds. for the treatment of ***malaria***)
IT Antipyretics
(supplementary compound; Substituted tetracycline compds. for the treatment of ***malaria***)
IT Drug delivery systems
(tetracycline derivs. for ***malaria*** treatment)
IT 58-14-0, Pyrimethamine
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Substituted tetracycline compds. for the treatment of ***malaria***
)

IT 54-05-7, Chloroquine 56-54-2, Quinidine 86-42-0, Amodiaquine
90-34-6, Primaquine 130-95-0, Quinine 500-92-5, Proguanil 537-21-3,
Chlorproguanil 550-81-2, Amopyroquine 738-70-5, Trimethoprim
37338-39-9 37357-69-0 53230-10-7, Mefloquine 63968-64-9, Artemisinin
69756-53-2, Halofantrine 71963-77-4, Artemether 74847-35-1,
Pyronaridine 82186-77-4, Lumefantrine 88495-63-0, Artesunate
95233-18-4, Atovaquone 123407-36-3, Arteflene
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Substituted tetracycline compds. for the treatment of ***malaria***
)

IT ***389139-31-5P***
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(Substituted tetracycline compds. for the treatment of ***malaria***
)

IT 60-54-8 60-54-8D, Tetracycline, derivs. 79-57-2 127-33-3 564-25-0
808-26-4 914-00-1 10118-90-8 ***31642-30-5***
35689-65-7 146253-75-0 146278-03-7
151922-17-7 186759-47-7 186759-51-3
186759-53-5 201849-42-5 ***233585-95-0***
233586-04-4 233586-06-6 233586-09-9
263760-98-1 263761-02-0 263761-08-6
330627-24-2 344771-54-6 351336-94-2
365277-01-6 365277-22-1 365277-23-2
365277-28-7 365277-29-8 365277-38-9
365277-45-8 365277-47-0 365277-51-6
365277-55-0 365277-56-1 365277-57-2
365277-59-4 365277-60-7 365277-63-0
365277-66-3 374748-06-8 380435-62-1
380435-63-2 380435-65-4 380435-76-7
389081-56-5 389081-58-7 389081-61-2
389081-62-3 389081-64-5 389081-77-0
389081-85-0 389139-10-0 389139-12-2
389139-16-6 389139-19-9 389139-20-2
389139-21-3 389139-22-4 389139-23-5
389139-24-6 389139-27-9 389139-28-0
389139-30-4 389139-33-7 389139-41-7
389139-43-9 389139-44-0 389139-45-1
389139-46-2 389139-48-4 389139-49-5
389139-50-8 389139-51-9 389139-52-0
389139-53-1 389139-54-2 389139-55-3
389139-58-6 389139-62-2 389139-63-3
389139-64-4 389139-65-5 389139-67-7
389139-68-8 389139-78-0 389139-81-5
389139-86-0 389139-91-7 389139-93-9
389140-00-5 389623-72-7 389623-77-2
389623-80-7 389623-82-9 389623-88-5
389623-89-6 389623-90-9 389623-91-0
389623-93-2 389623-95-4 389623-96-5
389623-97-6 389623-99-8 389624-00-4
389624-01-5 389624-02-6 389624-03-7
389624-04-8 389624-05-9 389624-06-0
389624-07-1 389624-08-2 389624-09-3
389624-10-6 389624-11-7 389624-12-8
389624-14-0 389624-15-1 389624-16-2

389624-18-4 389624-19-5 389624-20-8
389624-21-9 389624-22-0 389624-23-1
389624-24-2 389624-26-4 389624-27-5
389624-28-6 389624-30-0 389624-32-2
389624-33-3 389624-35-5 389624-36-6
389624-37-7 389624-38-8 389624-39-9
389624-40-2 389624-41-3 389624-42-4
389624-43-5 389624-51-5 389624-55-9
389624-62-8 389624-73-1 389624-74-2
389624-75-3 389624-81-1 389624-83-3
389624-85-5 389624-95-7 389624-96-8
389624-97-9 389624-99-1 459809-44-0
459809-46-2 459809-53-1 459809-67-7
459809-72-4 459809-99-5 459810-00-5
459810-03-8 459810-06-1 460068-29-5
460068-31-9 460068-32-0 460068-33-1
460068-36-4 460068-38-6 460068-42-2
460068-44-4 460068-45-5 460068-48-8 46006
8-51-3 460068-55-7 460068-57-9
460068-58-0 460068-59-1 460068-60-4
460068-62-6 460068-65-9 460068-66-0
460068-68-2 460068-76-2 460068-77-3
460068-78-4 460068-80-8 460068-86-4
460068-87-5 460068-93-3 460068-95-5
460068-96-6 460068-97-7 460069-34-5
460069-38-9 460069-65-2 460069-70-9
460069-96-9 460070-02-4 460070-03-5
460070-61-5 460070-66-0 460070-73-9
460070-95-5 460071-09-4 460071-12-9
460071-14-1 460071-33-4 460072-33-7
460072-47-3 460072-59-7 460072-65-5
460073-05-6 460073-17-0 460073-22-7
460074-06-0 460074-13-9 460074-19-5
460074-21-9 460075-62-1 460082-77-3
460082-89-7 473972-91-7 473973-13-6
473973-20-5 473973-34-1 473973-37-4
473973-41-0 473973-62-5 *473973-64-7*
473973-69-2 473973-86-3
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(Substituted tetracycline compds. for the treatment of ***malaria***
)

IT *473973-96-5 473974-12-8 473974-75-3*
473974-76-4 473974-77-5 473974-79-7
473974-80-0 473974-81-1 473974-82-2
473974-83-3 473974-84-4 473974-85-5
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(Substituted tetracycline compds. for the treatment of ***malaria***
)

IT *263760-96-9P*, 7-Phenylsancycline *263760-99-2P*
389140-02-7P 389623-67-0P
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetracycline derivs. for ***malaria*** treatment)

IT 98-80-6, Phenylboronic acid 1679-18-1, 4-Chlorophenylboronic acid 1765-93-1, 4-Fluorophenylboronic acid 14047-29-1, p-Carboxyphenylboronic acid 35037-73-1, 4-Trifluoromethoxyphenylisocyanate 59046-78-5

263761-01-9 389140-05-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(tetracycline derivs. for ***malaria*** treatment)

IT 113164-67-3P, 7-Iodosancycline 389140-04-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tetracycline derivs. for ***malaria*** treatment)

IT ***389139-31-5P***
RL: ***PAC (Pharmacological activity)***; SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(Substituted tetracycline compds. for the treatment of ***malaria***)

RN 389139-31-5 HCAPLUS

CN Benzoic acid, 4-[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT ***808-26-4 914-00-1 31642-30-5***
35689-65-7 146253-75-0 146278-03-7
151922-17-7 186759-47-7 186759-51-3
186759-53-5 233585-95-0 233586-04-4
233586-06-6 233586-09-9 263760-98-1
263761-02-0 263761-08-6 330627-24-2
344771-54-6 351336-94-2 365277-01-6
365277-22-1 365277-23-2 365277-28-7
365277-29-8 365277-38-9 365277-45-8
365277-47-0 365277-51-6 365277-55-0
365277-56-1 365277-57-2 365277-59-4
365277-60-7 365277-63-0 365277-66-3
374748-06-8 380435-62-1 380435-63-2
380435-65-4 380435-76-7 389081-56-5
389081-58-7 389081-61-2 389081-62-3
389081-64-5 389081-77-0 389081-85-0
389139-10-0 389139-12-2 389139-16-6
389139-19-9 389139-20-2 389139-21-3
389139-22-4 389139-23-5 389139-24-6
389139-27-9 389139-28-0 389139-30-4
389139-33-7 389139-41-7 389139-43-9
389139-44-0 389139-45-1 389139-46-2
389139-48-4 389139-49-5 389139-50-8
389139-51-9 389139-52-0 389139-53-1
389139-54-2 389139-55-3 389139-58-6
389139-62-2 389139-63-3 389139-64-4

389139-65-5 389139-67-7 389139-68-8
389139-78-0 389139-81-5 389139-86-0
389139-91-7 389139-93-9 389140-00-5
389623-72-7 389623-77-2 389623-80-7
389623-82-9 389623-88-5 389623-89-6
389623-90-9 389623-91-0 389623-93-2
389623-95-4 389623-96-5 389623-97-6
389623-99-8 389624-00-4 389624-01-5
389624-02-6 389624-03-7 389624-04-8
389624-05-9 389624-06-0 389624-07-1
389624-08-2 389624-09-3 389624-10-6
389624-11-7 389624-12-8 389624-14-0
389624-15-1 389624-16-2 389624-18-4
389624-19-5 389624-20-8 389624-21-9
389624-22-0 389624-23-1 389624-24-2
389624-26-4 389624-27-5 389624-28-6
389624-30-0 389624-32-2 389624-33-3
389624-35-5 389624-36-6 389624-37-7
389624-38-8 389624-39-9 389624-40-2
389624-41-3 389624-42-4 389624-43-5
389624-51-5 389624-55-9 389624-62-8
389624-73-1 389624-74-2 389624-75-3
389624-81-1 389624-83-3 389624-85-5
389624-95-7 389624-96-8 389624-97-9
389624-99-1 459809-44-0 459809-46-2
459809-53-1 459809-67-7 459809-72-4
459809-99-5 459810-00-5 459810-03-8
459810-06-1 460068-29-5 460068-31-9
460068-32-0 460068-33-1 460068-36-4
460068-38-6 460068-42-2 460068-44-4
460068-45-5 460068-48-8 460068-51-3
460068-55-7 460068-57-9 460068-58-0
460068-59-1 460068-60-4 460068-62-6
460068-65-9 460068-66-0 460068-68-2
460068-76-2 460068-77-3 460068-78-4
460068-80-8 460068-86-4 460068-87-5
460068-93-3 460068-95-5 460068-96-6
460068-97-7 460069-34-5 460069-38-9
460069-65-2 460069-70-9 460069-96-9
460070-02-4 460070-03-5 460070-61-5
460070-66-0 460070-73-9 460070-95-5
460071-09-4 460071-12-9 460071-14-1
460071-33-4 460072-33-7 460072-47-3
460072-59-7 460072-65-5 460073-05-6
460073-17-0 460073-22-7 460074-06-0
460074-13-9 460074-19-5 460074-21-9
460075-62-1 460082-77-3 460082-89-7
473972-91-7 473973-13-6 473973-20-5
473973-34-1 473973-37-4 473973-41-0 47397
3-64-7 473973-69-2 473973-86-3
473973-96-5 473974-12-8 473974-75-3
473974-76-4 473974-77-5 473974-79-7
473974-80-0 473974-81-1
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(Substituted tetracycline compds. for the treatment of ***malaria***
)
RN 808-26-4 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-

3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 914-00-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S,4aR,5S,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 31642-30-5 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-bromo-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 35689-65-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 5-(acetyloxy)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 146253-75-0 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-1,11-dioxo-6-[[(phenylmethyl)thio]methyl]-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 146278-03-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 6-[(cyclopentylthio)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

[Remaining compounds were deleted to save paper]

L61 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:754340 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 137:279205
TITLE: Preparation of 3,4-diaminocyclobutene-1,2-diones as CXC chemokine receptor antagonists
INVENTOR(S): Taveras, Arthur G.; Aki, Cynthia J.; Bond, Richard W.; Chao, Jianping; Dwyer, Michael; Ferreira, Johan A.; Pachter, Jonathan; Baldwin, John J.; Kaiser, Bernd; Li, Ge; Merritt, J. Robert; Nelson, Kingsley H., Jr.; Rokosz, Laura L.
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002076926	A1	20021003	WO 2002-US2888		20020201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2436351	AA	20021003	CA 2002-2436351		20020201
EP 1355875	A1	20031029	EP 2002-731085		20020201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002006968	A	20040309	BR 2002-6968		20020201
JP 2004529911	T2	20040930	JP 2002-576189		20020201
CN 1575273	A	20050202	CN 2002-804517		20020201
NZ 527947	A	20051028	NZ 2002-527947		20020201
ZA 2003005881	A	20041101	ZA 2003-5881		20030730
NO 2003003424	A	20030930	NO 2003-3424		20030731
PRIORITY APPLN. INFO.:			US 2001-265951P	P	20010202
			WO 2002-US2888	W	20020201

OTHER SOURCE(S): MARPAT 137:279205
GI



AB Title compds. I; [A = (substituted) aryl, heteroaryl; B = (substituted) Ph, benzotriazolyl, benzimidazolyl, hydroxyimidazolyl, hydroxythienyl, hydroxypyrrolyl, etc.], were prepared Thus, 1-ethoxy-2-phenylamino-1-cyclobutene-3,4-dione (preparation given) and 2-OH-3-[2-(morpholinoethyl)aminocarbonyl]aniline (preparation given) were refluxed overnight in EtOH to give 34% title compound (II). I showed CXCR2 receptor binding activity in the range of 1-10000 nM.

IC ICM C07C225-20
ICS C07C229-42; C07C229-64; C07C237-36; C07C237-44; C07C255-58; C07C255-59; C07C271-20; C07C311-08; C07C311-21; C07D205-04; C07D207-08; C07D207-16; C07D211-60; C07D213-89; C07D231-38; C07D235-06; C07D239-42; C07D249-18; C07D277-28

CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 25, 27

IT Anti-AIDS agents
Anti-Alzheimer's agents
Antiarthritics
Antiasthmatics
Anticoagulants
Antimalarials
Antitumor agents
Antiviral agents
Human
Solid phase synthesis
(preparation of 3,4-diaminobutene-1,2-diones as CXC chemokine receptor antagonists)

IT AIDS (disease)
Alzheimer's disease
Arthritis
Asthma
Atherosclerosis
Eye, disease
Malaria
Melanoma
Neoplasm
Psoriasis
Thrombosis
(treatment; preparation of 3,4-diaminobutene-1,2-diones as CXC chemokine receptor antagonists)

IT 50-35-1, Thalidomide 145-63-1, Suramin ***15866-90-7***, Col-3
33069-62-4, Taxol 37270-94-3, Platelet factor 4 38101-59-6, Im862
86090-08-6, Angiostatin 99519-84-3, CAI 114977-28-5, Taxotere
129298-91-5, Tnp-470 148717-90-2, Squalamine 154039-60-8, Marimastat
169799-04-6, Cgs27023a 187888-07-9, Endostatin 188968-51-6, Emd121974
192329-42-3, Ag3340 204005-46-9, Su-5416 212142-18-2, PTK 787
216974-75-3 252916-29-3, Su-6668 259188-38-0, Bms-275291
305838-77-1, Neovastat 324740-00-3, Vitaxin 386211-13-8, Zd-101
443913-73-3, Zd-6474
RL: ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(coadministration; preparation of 3,4-diaminobutene-1,2-diones as CXC chemokine receptor antagonists)

IT ***15866-90-7***, Col-3
RL: ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(coadministration; preparation of 3,4-diaminobutene-1,2-diones as CXC chemokine receptor antagonists)

RN 15866-90-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:71906 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 136:123678
TITLE: Enhancement of the action of anti-infective agents using an administration medium containing nitrous oxide
INVENTOR(S): Meyer, Petrus Johannes
PATENT ASSIGNEE(S): Pitmy International N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002005850	A2	20020124	WO 2001-ZA98		20010719
WO 2002005850	A3	20030109			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2416512	AA	20020124	CA 2001-2416512		20010719
ZA 2003000366	A	20040629	ZA 2003-366		20030114
PRIORITY APPLN. INFO.:			ZA 2000-3644	A	20000719
			WO 2001-ZA98	W	20010719

AB The invention provides a method of enhancing the action of anti-infective agents, i.e., antimicrobial agents, anthelmintics, and anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, characterized in that the agent is formulated with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas. The administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5ω3], docosahexaenoic acid [C22: 6ω3], ricinoleic acid and derivs. thereof selected from the group consisting of the C1-6 alkyl esters, the glycerol-polyethylene glycol esters and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid-based oils, such as castor oil with ethylene oxide. For example, an aqueous emulsion was prepared by mixing 30 g vitamin F Et ester with 10 g Cremophor RH40, 2.2 g Me paraben, 0.08 g Bu hydroxyanisole, and 0.23 g Bu hydroxytoluene. Into 942.5 g of the stock nitrous oxide aqueous solution, 2.5 g sodium Pr paraben and 2.5 g Germall 115 were added with stirring at room temperature The oily composition was then emulsified into the aqueous solution to obtain a nanolipid vesicle formulation. A non-aqueous solution of nitrous oxide in carrier formulation was also prepared
Polyoxyl hydrogenated castor oil (1.15 kg) was mixed with 2.35 kg vitamin F Et ester, 150.0 g α-tocopherol, and 1.295 kg PEG 400 at 40°. The oily mixture was gassed with nitrous oxide for 3 h at 2 bar

and then heated at 70°. To the heated gas-oil mixture, 50.0 g Me paraben and 5.0 g butylated hydroxytoluene were added and the mixture was allowed to cool down. When the mixture was cooled down to approx. 40°, 5.00 kg pyrazinamide (particle size <40 μm) was added while continuously mixing and the mixture was addnl. gassed with nitrous oxide at 20 kPa for 30 min. After the mixture was cooled down to reach room temperature,
it was encapsulated in soft gel capsules. Encapsulation of pyrazinamide in lipid vesicles led to a 65-70% decrease in BCG (bacillus Calmette-Guerin) viability within a 2-h incubation with no moving BCG observed, while the incubation with free pyrazinamide resulted in the appearance of single live bacteria with a few granuloma-type clumps, which gradually secreted single live bacteria.

IC ICM A61K047-00

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 10, 15

IT Anthelmintics
Anti-AIDS agents
Anti-infective agents
Antibacterial agents
Antibacterial agents
Antibiotics
Antimalarials
Antimicrobial agents
Antiviral agents
Drug bioavailability
Encapsulation
Fungicides
Parasiticides
Tuberculostatics
(lipid vehicles containing nitrous oxide for enhancement of activity of anti-infective agents)

IT 50-59-9, Cephaloridine 54-42-2, Idoxuridine 54-85-3 56-75-7, Chloramphenicol 57-62-5, Chlortetracycline 57-67-0, Sulfaguanidine 57-68-1, Sulfadimidine 57-92-1, Streptomycin, biological studies 60-54-8, Tetracycline 61-32-5, Methicillin 61-33-6, Penicillin G, biological studies 61-72-3, Cloxacillin 64-75-5, Tetracycline Hydrochloride 65-85-0, Benzoic Acid, biological studies 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 68-35-9, Sulfadiazine 68-41-7, Cycloserine 69-53-4, Ampicillin 69-72-7, Salicylic acid, biological studies 70-00-8, Trifluridine 74-55-5, Ethambutol 79-09-4, Propionic Acid, biological studies 79-57-2, Oxytetracycline 80-08-0, Dapsone 80-35-3, Sulfamethoxypyridazine 85-73-4, Phthalylsulfathiazole 87-08-1, Penicillin V 98-96-4, Pyrazinamide 98-97-5, Pyrazinoic acid 100-97-0, Methenamin, biological studies 112-38-9, Undecylenic Acid 114-07-8, Erythromycin 116-43-8, Succinylsulfathiazole 122-11-2, Sulfadimethoxine 124-07-2, Caprylic Acid, biological studies 126-07-8, Griseofulvin 127-33-3, Demeclocycline 127-56-0, Sulfacetamide sodium 127-69-5, Sulfafurazole 144-80-9, Sulfacetamide 144-83-2, Sulfapyridine 147-52-4, Nafcillin 152-47-6, Sulfametopyrazine 288-32-4D, Imidazole, derivs. 389-08-2, Nalidixic Acid 536-33-4, Ethionamide 564-25-0, Doxycycline 599-79-1, Sulfasalazine 651-06-9, Sulfamethoxydiazine 723-46-6, Sulfamethoxazole 768-94-5, Amantadine 777-11-7, Haloprogin ***914-00-1***, Methacycline 1066-17-7, Colistin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1403-66-3, Gentamicin 1404-04-2, Neomycin 1404-26-8, Polymyxin B 1404-90-6, Vancomycin 1405-20-5, Polymyxin B Sulfate 1405-41-0, Gentamicin Sulfate 1405-87-4, Bacitracin 1405-89-6, Bacitracin Zinc 1695-77-8, Spectinomycin 2022-85-7, Flucytosine 2030-63-9, Clofazimine

2398-96-1, Tolnaftate 2447-57-6, Sulfadoxine 3056-17-5, Stavudine 3116-76-5, Dicloxacillin 3511-16-8, Hetacillin 4299-60-9, Sulfisoxazole diolamine 4428-95-9, Foscarnet 4697-36-3, Carbenicillin 5250-39-5, Flucloxacillin 5536-17-4, Vidarabine 6489-97-0, Metampicillin 7481-89-2, Zalcitabine 7681-11-0, Potassium Iodide, biological studies 7681-93-8, Natamycin 8063-07-8, Kanamycin 8064-90-2, Co-Trimoxazole 10118-90-8, Minocycline 11003-38-6, Capreomycin 13009-99-9, Mafenide Acetate 13292-46-1, Rifampicin 13392-28-4, Rimantadine 13721-01-2D, derivs. 13838-08-9, Azidamphenicol 14698-29-4, Oxolinic Acid 15318-45-3, Thiamphenicol 15686-71-2, Cefalexin 18323-44-9, Clindamycin 19562-30-2, Piromidic Acid 20461-54-5, Iodide, biological studies 22199-08-2, Silver sulfadiazine 22832-87-7, Miconazole nitrate 22916-47-8, Miconazole 23593-75-1, Clotrimazole 25953-19-9, Cephazolin 26787-78-0, Amoxicillin 27025-49-6, Carfecillin 27220-47-9, Econazole 27726-31-4, Pivcephalexin 28088-64-4, Aminosalicylic acid 28657-80-9, Cinoxacin 29342-05-0, Ciclopirox 30516-87-1, Zidovudine 32886-97-8, Pivmecillinam 32986-56-4, Tobramycin 33817-20-8, Pivampicillin 34444-01-4, Cephamandole 34787-01-4, Ticarcillin 35531-88-5, Carindacillin 35607-66-0, Cefoxitin 36791-04-5, Ribavirin 37091-66-0, Azlocillin 37517-28-5, Amicacin 38821-53-3, Cephradine 39809-25-1, Penciclovir 40034-42-2, Acrosoxacin 41621-49-2, Ciclopirox olamine 47747-56-8, Talampicillin 49842-07-1, Tobramycin sulfate 50370-12-2, Cefadroxil 50972-17-3, Bacampicillin 51481-65-3, Mezlocillin 51627-14-6, Cefatrizine 51940-44-4, Pipemidic Acid 53994-73-3, Cefaclor 55268-75-2, Cefuroxim 56391-56-1, Netilmicin 58001-44-8, Clavulanic Acid 59277-89-3, Acyclovir 60925-61-3, Ceforanide 61036-62-2, Teicoplanin 61270-58-4, Cefonicid 61318-90-9, Sulconazole 61477-96-1, Piperacillin 61622-34-2, Cefotiam 62587-73-9, Cefsulodin 62893-19-0, Cefoperazone 63469-19-2, Apalcillin 63527-52-6, Cefotaxime 63744-80-9, Cephamycin 64211-45-6, Oxiconazole 64221-86-9, Imipenem 64544-07-6, Cefuroxime axetil 64872-76-0, Butoconazole 64952-97-2, Latamoxef 65085-01-0, Cefmenoxime 65243-33-6, Cefetamet Pivoxil 65277-42-1, Ketoconazole 65472-88-0, Naftifine 65899-73-2, Tioconazole 66148-78-5, Temocillin 67915-31-5, Terconazole 68373-14-8, Sulbactam 68401-81-0, Ceftizoxime 69655-05-6, Didanosine 69712-56-7, Cefotetan 69739-16-8, Cefodizime 70458-92-3, Pefloxacin 70458-96-7, Norfloxacin 70797-11-4, Cefpiramide 72558-82-8, Ceftazidime 72559-06-9, Rifabutin 73384-59-5, Ceftriaxone 74011-58-8, Enoxacin 76168-82-6, Ramoplanin 76470-66-1, Loracarbef 77181-69-2, Sorivudine 78110-38-0, Aztreonam 79350-37-1, Cefixime 79660-72-3, Fleroxacin 80214-83-1, Roxithromycin 81103-11-9, Clarithromycin 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 83905-01-5, Azithromycin 84625-61-6, Itraconazole 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86393-37-5, Amifloxacin 88040-23-7, Cefepime 89786-04-9, Tazobactam 91161-71-6, Terbinafine 91832-40-5, Cefdinir 92665-29-7, Cefprozil 93106-60-6, Enrofloxacin 96036-03-2, Meropenem 97519-39-6, Ceftibuten 98079-51-7, Lomefloxacin 100490-36-6, Tosufloxacin 100986-85-4, Levofloxacin 101363-10-4, Rufloxacin 104227-87-4, Famciclovir 110871-86-8, Sparfloxacin 124832-26-4, Valacyclovir 124858-35-1, Nadifloxacin 126602-89-9, RP 59500 134678-17-4, Lamivudine

RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)

(lipid vehicles containing nitrous oxide for enhancement of activity of anti-infective agents)

IT ***914-00-1***, Methacycline

RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)

(lipid vehicles containing nitrous oxide for enhancement of activity of anti-infective agents)
RN 914-00-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S,4aR,5S,5aR,12aS)-(9CI) (CA INDEX NAME)

[Remaining compounds were deleted to save paper]

L61 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:378922 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 135:89745
TITLE: In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron
AUTHOR(S): Pradines, Bruno; Rogier, Christophe; Fusai, Thierry; Mosnier, Joel; Daries, William; Barret, Eric; Parzy, Daniel
CORPORATE SOURCE: Unite de Parasitologie, Institut de Medecine Tropicale du Service de Sante des Armees, Marseille, 13998, Fr.
SOURCE: Antimicrobial Agents and Chemotherapy (2001), 45(6), 1746-1750
CODEN: AMACCQ; ISSN: 0066-4804
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The in vitro activities of cyclines (tetracycline, doxycycline, minocycline, oxytetracycline, and rolitetracycline), macrolides (erythromycin, spiramycin, roxithromycin, and lincomycin), quinolones (norfloxacin and ofloxacin), rifampin, thiamphenicol, tobramycin, metronidazole, vancomycin, phosphomycin, and cephalosporins (cephalexin, cefactor, cefamandole, cefuroxime, ceftriaxone, cefotaxime, and cefoxitin) were evaluated on Plasmodium falciparum clones, using an isotopic, micro-drug susceptibility test. Only tetracyclines, macrolides, quinolones, and rifampin demonstrated in vitro activity against P. falciparum, which increased after a prolonged exposure (96 or 144 h). In the presence of iron (FeCl3), only the activities of tetracyclines and norfloxacin were decreased. Their in vitro activity against intraerythrocytic stages of multidrug-resistant P. falciparum and their efficacy in vivo favor the use of antibiotics as ***antimalarial*** drugs. However, due to their slow ***antimalarial*** action and to the fact that they act better after prolonged contact, they probably need to be administered in conjunction with a rapidly acting ***antimalarial*** drug, such as a short course of chloroquine or quinine.
CC 10-5 (Microbial, Algal, and Fungal Biochemistry)
ST antibiotic resistance ***antimalarial*** iron Plasmodium
IT Antibiotic resistance
Antibiotics
Antimalarials
Plasmodium falciparum
(in vitro activities of antibiotics against Plasmodium falciparum inhibited by iron)
IT 60-54-8, Tetracycline 79-57-2, Oxytetracycline 114-07-8, Erythromycin

564-25-0, Doxycycline ***751-97-3***, Rolitetracycline 7439-89-6, Iron, biological studies 8025-81-8, Spiramycin 10118-90-8, Minocycline 13292-46-1, Rifampin 70458-96-7, Norfloxacin 80214-83-1, Roxithromycin 82419-36-1, Ofloxacin
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); BIOL (Biological study)
(in vitro activities of antibiotics against Plasmodium falciparum inhibited by iron)

IT ***751-97-3***, Rolitetracycline
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); BIOL (Biological study)
(in vitro activities of antibiotics against Plasmodium falciparum inhibited by iron)

RN 751-97-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-, (4S,4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:366042 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 133:785
TITLE: Use of phosphonformic acid derivatives for the prevention and treatment of infections and for fungicides, bactericides, and herbicides in plants
INVENTOR(S): Jomaa, Hassan
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 10 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19854402	A1	20000531	DE 1998-19854402	19981125
CA 2352549	AA	20000602	CA 1999-2352549	19991120
WO 2000030625	A2	20000602	WO 1999-EP8965	19991120
WO 2000030625	A3	20001005		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 9915639	A	20010807	BR 1999-15639		19991120
EP 1131075	A2	20010912	EP 1999-958099		19991120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200101433	T2	20011022	TR 2001-200101433		19991120
JP 2002530326	T2	20020917	JP 2000-583508		19991120
NO 2001002541	A	20010724	NO 2001-2541		20010523
PRIORITY APPLN. INFO.:			DE 1998-19854402	A	19981125
			WO 1999-EP8965	W	19991120

OTHER SOURCE(S): MARPAT 133:785

AB Phosphonformic acid derivs. (Markush included) are used for the prevention and treatment of infectious conditions in humans and animals which are caused by bacteria, fungi, or parasites, as well as for fungicides, bactericides, and herbicides in plants.

IC ICM A61K031-66
ICS C07H015-04; C07F009-48

CC 1-5 (Pharmacology)
Section cross-reference(s): 5, 63

IT Actinobacillus
Actinomyces
Actinomycetaceae
Aeromonas
Aeromonas salmonicida
Amebicides
Anti-infective agents
Antibacterial agents
Antimalarials
Antiulcer agents
Bacillaceae
Bacillus (bacterium genus)
Bartonellaceae
Bordetella
Borrelia
Borrelia burgdorferi
Brucella
Campylobacter
Campylobacter coli
Campylobacter fetus
Campylobacter jejuni
Chlamydia psittaci
Chlamydia trachomatis
Chlamydiaceae
Clostridium
Coccidiosis
Corynebacterium
Corynebacterium diphtheriae
Corynebacterium pseudotuberculosis
Dermatophilus
Drug delivery systems
Enterobacteriaceae
Enterococcus
Erysipelothrix rhusiopathiae
Escherichia
Fungicides

Haemophilus
Helicobacter
Helicobacter pylori
Herbicides
Klebsiella
Legionella
Legionellaceae
Leptospira
Leptospiraceae
Listeria
Listeria monocytogenes
Listonella anguillarum
Micrococcaceae
Micrococcus
Moraxella
Moraxella bovis
Mycobacteriaceae
Mycobacterium
Mycobacterium avium
Mycobacterium bovis
Mycobacterium leprae
Mycobacterium tuberculosis
Mycoplasma
Mycoplasma pneumoniae
Mycoplasmataceae
Neisseria
Neisseria gonorrhoeae
Neisseria meningitidis
Neisseriaceae
Nocardia
Parasiticides
Pasteurellaceae
Photobacterium
Plesiomonas
Propionibacteriaceae
Propionibacterium
Propionibacterium acnes
Proteus (bacterium)
Providencia
Pseudomonadaceae
Pseudomonas
Rhodococcus
Rickettsiaceae
Salmonella
Serratia
Shigella
Spirochaetaceae
Staphylococcus
Streptococcaceae
Streptococcus
Treponema
Trichomonacides
Ureaplasma
Vibrio
Vibrio cholerae
Vibrionaceae
Xanthomonas
Yersinia
Yersinia enterocolitica

Yersinia pestis
Yersinia pseudotuberculosis
Yersinia ruckeri
(phosphonformic acid derivs. for prevention and treatment of infections and for fungicides, bactericides, and herbicides in plants)

IT 50-65-7, Niclosamide 52-68-6, Metrifonate 54-05-7, Chloroquine 54-42-2, Idoxuridine 54-85-3, Isoniazid 56-54-2, Quinidine 56-75-7, Chloramphenicol 57-92-1, Streptomycin, biological studies 58-14-0, Pyrimethamine 59-87-0, Nitrofurazone 60-54-8, Tetracycline 60-54-8D, Tetracycline, derivs. 61-33-6, Benzylpenicillin, biological studies 67-20-9, Nitrofurantoin 69-53-4, Ampicillin 70-00-8, Trifluridine 74-55-5, Ethambutol 79-57-2, Oxytetracycline 80-08-0, Dapson 83-89-6, Mepacrine 84-65-1, Anthraquinone 86-42-0, Amodiaquin 90-34-6, Primaquin 90-44-8, 9(10H)-Anthracenone 90-47-1, Xanthone 90-89-1, Diethylcarbamazine 97-18-7, Bithionol 98-96-4, Pyrazinamide 100-33-4, Pentamidine 110-85-0, Piperazine, biological studies 114-07-8, Erythromycin 118-42-3, Hydroxychloroquine 126-07-8, Griseofulvin 130-15-4, 1,4-Naphthalenedione 130-26-7, Clioquinol 130-85-8 130-95-0, Quinine 145-63-1, Suramin 148-79-8, Tiabendazole 152-47-6, Sulfalene 260-94-6, Acridine 443-48-1, Metronidazole 472-15-1, Betulinic acid 494-79-1, Melarsoprol 500-92-5, Proguanil 537-21-3, Chlorproguanil 564-25-0, Doxycycline 738-70-5, Trimethoprim ***751-97-3***, Rolitetracycline 768-94-5, Amantadine 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1403-66-3, Gentamicin 1404-04-2, Neomycin 1404-88-2, Tyrothricin 1404-90-6, Vancomycin 1405-87-4, Bacitracin 1406-11-7, Polymyxin 1695-77-8, Spectinomycin 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2398-96-1, Tolnaftate 2447-57-6, Sulfadoxin 3056-17-5, Stavudine 4428-95-9, Foscarnet 6990-06-3, Fusidic acid 7187-62-4, Pyrvinium 7481-89-2, Zalcitabine 7542-37-2, Paromomycin 7681-93-8, Natamycin 8025-81-8, Spiramycin 8063-07-8, Kanamycin 8064-90-2, Co-trimoxazole 10118-90-8, Minocycline 11003-38-6, Capreomycin 11111-12-9, Cephalosporin 11111-12-9D, Cephalosporin, derivs. 12650-69-0, Mupirocin 13239-97-9 13292-46-1, Rifampicin 14222-60-7, Prothionamide 15686-71-2, Cefalexin 15686-71-2D, Cefalexin, derivs. 15686-83-6, Pyrantel 16037-91-5, Sodium stibogluconate 16846-24-5, Josamycin 18323-44-9, Clindamycin 21738-42-1, Oxamniquine 22916-47-8, Miconazole 23155-02-4, Fosfomycin 23256-30-6, Nifurtimox 23593-75-1, Clotrimazole 25683-71-0, Terizidon 25953-19-9, Cefazoline 25953-19-9D, Cefazoline, derivs. 26787-78-0, Amoxicillin 27194-24-7, Nitrofuran 27220-47-9, Econazole 27523-40-6, Isoconazole 30516-87-1, Azidothymidine 31135-62-3, Aminoquinoline 31431-39-7, Mebendazole 32887-01-7, Mecillinam 32986-56-4, Tobramycin 34787-01-4, Ticarcillin 35607-66-0, Cefoxitin 35607-66-0D, Cefoxitin, derivs. 36791-04-5, Ribavirin 36877-68-6, Nitroimidazole 37091-66-0, Azlocillin 37517-28-5, Amikacin 41138-58-3, Isoxazolylpenicillin 41621-49-2, Ciclopiroxolamine 41929-27-5, Armexin 50972-17-3, Bacampicillin 51481-65-3, Mezlocillin 52152-93-9 53230-10-7, Mefloquin 55268-74-1, Praziquantel 55268-75-2, Cefuroxime 55268-75-2D, Cefuroxime, derivs. 56391-56-1, Netilmicin 56796-20-4, Cefmetazole 59277-89-3, Acyclovir 60628-96-8, Bifonazole 61036-62-2, Teicoplanin 61477-96-1, Piperacillin 62013-04-1, Dirithromycin 62893-19-0, Cefoperazone 63019-62-5 63469-19-2, Apalcillin 63527-52-6, Cefotaxime 63527-52-6D, Cefotaxime, derivs. 63968-64-9, Artemisinin 64211-45-6, Oxiconazole 64544-07-6, Cefuroxime-Axetil 64952-97-2, Latamoxef 65052-63-3, Cefetamet 65277-42-1, Ketoconazole 65472-88-0, Naftifine 66148-78-5, Temocillin 69655-05-6, Didanosine 69712-56-7, Cefotetan 69756-53-2, Halofantrine 70288-86-7, Ivermectin 70458-92-3, Pefloxacin 70458-96-7, Norfloxacin 71939-50-9, Dihydroartemisinin 71963-77-4, Artemether 72558-82-8, Ceftazidime

72558-82-8D, Ceftazidime, derivs. 72559-06-9, Rifabutin 74011-58-8, Enoxacin 74847-35-1, Pyronaridine 75887-54-6, Arteether 76470-66-1, Loracarbef 78110-38-0, Aztreonam 78613-35-1, Amorolfine 79198-29-1, Clavulanic acid-amoxicillin mixture 79350-37-1, Cefixime 79660-72-3, Fleroxacin 80214-83-1, Roxithromycin 80738-43-8, Lincosamide 81103-11-9, Clarithromycin 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 83200-96-8, Carbapenem 83905-01-5, Azithromycin 84625-61-6, Itraconazole 84957-29-9, Cefpirome 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86482-18-0, Clavulanic acid-ticarcillin 87118-81-8 87239-81-4, Cefpodoxime-Proxetil 88040-23-7, Cefepime 88495-63-0, Artesunate 91161-71-6, Terbinafine 91832-40-5, Cefdinir 92309-29-0, Imipenem-cilastatin mixture 92665-29-7, Cefprozil 94935-63-4, Sulbactam-ampicillin mixture 95233-18-4, Atovaquone 95761-91-4, Cefotiam-Hexetil 96036-03-2, Meropenem 97519-39-6, Ceftibuten 98079-51-7 99665-00-6, Flomoxef 106635-80-7, WR 238605 110871-86-8, Sparfloxacin 114632-31-4, Pyrimidinediamine 114632-31-4D, Pyrimidinediamine, derivs., mixts. with sulfonamides 120410-24-4, Biapenem 123683-33-0, Piperacillin-Tazobactam mixture 137234-62-9, UK-109496 144194-96-7, BAY Y3118 270076-60-3, Pristinamycin 270913-38-7
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(phosphonformic acid derivs. for prevention and treatment of infections and for fungicides, bactericides, and herbicides in plants, and use with other agents)

IT ***751-97-3***, Rolitetracycline
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(phosphonformic acid derivs. for prevention and treatment of infections and for fungicides, bactericides, and herbicides in plants, and use with other agents)

RN 751-97-3 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-, (4S,4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:201117 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 132:246352
TITLE: Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
INVENTOR(S): Pruzanski, Waldemar; Golub, Lorne M.; Vadas, Peter;

Greenwald, Robert A.; Ramamurthy, Nangavarum S.; Mcnamara, Thomas F.
PATENT ASSIGNEE(S): The Research Foundation of State Univ. of New York, USA
SOURCE: U.S., 10 pp., Cont.-in-part of U.S. Ser. No. 25,035, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6043231	A	20000328	US 1993-115158	19930831
US 5523297	A	19960604	US 1995-426899	19950421
PRIORITY APPLN. INFO.:			US 1993-25035	B2 19930302
			US 1993-115158	A2 19930831

AB A method for treating mammals suffering from inflammation associated with excess phospholipase A2 (PLA2) activity and/or production comprises administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit an ability of PLA2 to bind to its substrate. Inflammation associated with excess PLA2 activity and/or production is present in rheumatoid arthritis, osteoarthritis, and other tissue-destructive conditions, sepsis, septic shock, pancreatitis, ***malaria***, psoriasis, inflammatory bowel disease and multisystem organ failure. A pharmaceutical composition containing tetracyclines is also disclosed. For example, a chemical-modified tetracycline, CMT-10, at a concentration of 5 and 10 μg/mL did not exhibit substantial inhibition of PLA2 activity. However, at concns. of ≥ 25 μg/mL, CMT-10 exhibited significant PLA2-inhibitory activity. The IC50 of CMT-10 was 30 μg/mL.

IC ICM A61K031-65
INCL 514152000
CC 1-7 (Pharmacology)

IT Anti-inflammatory agents
Antiarthritics
Antimalarials
Antirheumatic agents
Multiple organ failure
Psoriasis
Sepsis
(non-antimicrobial tetracyclines for inhibition of excessive phospholipase A2 activity and/or production)

IT ***2444-65-7***, CMT 1 4199-33-1, CMT 2 ***4632-89-7***, CMT 4 ***15866-90-7***, CMT 3 ***27720-34-9***, CMT 6 145031-44-3, CMT 5 ***180002-76-0***, CMT 10
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(non-antimicrobial tetracyclines for inhibition of excessive phospholipase A2 activity and/or production)

IT ***2444-65-7***, CMT 1 ***4632-89-7***, CMT 4 ***15866-90-7***, CMT 3 ***27720-34-9***, CMT 6 ***180002-76-0***, CMT 10
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(non-antimicrobial tetracyclines for inhibition of excessive phospholipase A2 activity and/or production)

RN 2444-65-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4632-89-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-chloro-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15866-90-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 27720-34-9 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,4,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 180002-76-0 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:404850 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 131:39735
TITLE: Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha with modified tetracyclines
INVENTOR(S): Amin, Ashok; Abramson, Steven
PATENT ASSIGNEE(S): New York University, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9930720	A1	19990624	WO 1998-US26870	19981217
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2316972	AA	19990624	CA 1998-2316972	19981217
AU 9920015	A1	19990705	AU 1999-20015	19981217
EP 1041991	A1	20001011	EP 1998-964764	19981217

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

US 6319910	B1	20011120	US 1998-213149	19981217
JP 2002508327	T2	20020319	JP 2000-538702	19981217
PRIORITY APPLN. INFO.:			US 1997-68268P	P 19971219
			WO 1998-US26870	W 19981217

AB Chemical modified tetracyclines are a new class of non-steroidal anti-inflammatory drugs which inhibit cyclooxygenase-2 and tumor necrosis factor alpha. These chemical modified tetracyclines are used in a method for inhibiting COX-2, which in turn inhibits PGE2, and/or inhibiting TNFα. They are also used in a method for treating a disease or disorder associated with elevated activities of COX-2 (i.e., increased production of PGE2) and/or TNFα. The inventors evaluated the action of chemical modified tetracyclines on the spontaneous release of PGE2 from osteoarthritis-affected human cartilage in ex vivo conditions and on COX-2 in LPS-stimulated murine macrophages and found that the chemical modified tetracycline, 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3), which was previously shown to inhibit nitric oxide synthetase activity, also inhibits COX-2 activity independent of intracellular NO concns. CMT-3 inhibited COX-2 expression and PGE2 production as well.

IC ICM A61K031-65

CC 1-7 (Pharmacology)

IT ***Malaria***
Malaria
(cerebral, treatment of; inhibiting cyclooxygenase-2 and TNFα with modified tetracyclines)

IT Brain, disease
Brain, disease
(***malaria***, treatment of; inhibiting cyclooxygenase-2 and TNFα with modified tetracyclines)

IT ***2444-65-7***, CMT-1 ***15866-90-7***, CMT-3 ***88828-25-5***, CMT-8
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(inhibiting cyclooxygenase-2 and TNFα with modified tetracyclines)

IT ***2444-65-7***, CMT-1 ***15866-90-7***, CMT-3 ***88828-25-5***, CMT-8
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(inhibiting cyclooxygenase-2 and TNFα with modified tetracyclines)

RN 2444-65-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15866-90-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 88828-25-5 HCAPLUS
CN 2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1978:83985 HCAPLUS <<LOGINID::20060801>>
DOCUMENT NUMBER: 88:83985
TITLE: In vitro studies on drug-antibiotic interactions. I: Analgesics, antipyretics, ***antimalarials***, and tranquilizers
AUTHOR(S): Toama, Mohamed A.; El Fatatry, Hamed M.; El Falaha, Bahgat

CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Journal of Pharmaceutical Sciences (1978), 67(1), 23-6
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The antimicrobial effects of some analgesics, antipyretics, ***antimalarials***, and tranquilizers were determined The phenothiazines were the most active group. The effect of the chosen drugs when combined with a selected number of antibiotics was studied on Staphylococcus aureus and Escherichia coli to determine the type of interaction. Most analgesics, antipyretics, and ***antimalarials*** showed either no effect or a synergistic action. However, some exhibited antagonistic effects. All tested tranquilizers were synergistic. Preliminary studies, using electronic absorption spectrometry, indicated that the antagonistic action may be attributed to a phys. interaction.

CC 3-2 (Biochemical Interactions)
Section cross-reference(s): 1

ST antibiotic drug interaction; analgesic antibiotic interaction; antipyretic antibiotic interaction; ***antimalarial*** antibiotic interaction; tranquilizer antibiotic interaction

IT Analgesics
Antimalarials
Antipyretics
Tranquilizers and Neuroleptics
(bactericidal activity of antibiotics and)

IT 56-75-7 64-72-2 64-73-3 64-75-5 69-52-3 69-57-8 114-07-8 132-98-9 985-16-0 1173-88-2 1404-93-9 1405-10-3 1405-20-5 1405-97-6 1476-53-5 2058-46-0 3810-74-0 ***3963-95-9*** 5490-27-7 7060-74-4 25389-94-0
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, drugs effect on)

IT ***3963-95-9***
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, drugs effect on)

RN 3963-95-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, monohydrochloride, (4S,4aR,5S,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl